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SUMMARY
Platelet adenylate cyclase is a complex system composed of 
a catalytic unit coupled to stimulatory and inhibitory (R.)
receptors through the guanine nucleotide regulatory proteins G
s
and G. respectively.
Treatment of human platelet membranes with concentrations 
of benzyl alcohol up to 50mM augmented adenylate cyclase activity 
when it was assayed in the basal state. Stimulation of enzymatic 
activity at Rg by PGE^ and isoprenaline, and at Gg by NaF, was 
similarly enhanced. The stimulatory effect of the diterpene 
forskolin on the catalytic unit of adenylate cyclase was antagonised 
by benzyl alcohol. This inhibition was shown to occur via a 
non-competitive mechanism.
Benzyl alcohol did not modify the magnitude of the 
inhibitory response when the catalytic unit of adenylate cyclase was 
inhibited using low concentrations of GppNHp which acts selectively 
on the inhibitory G-protein, G.. Neither was the potent 
inhibitory action of the alpha^-adrenoceptor on the catalytic unit 
altered by the presence of benzyl alcohol. However, the ability of 
adrenaline (4- propranolol) to inhibit PGE^-stimulated adenylate 
cyclase was attenuated by benzyl alcohol in a dose-dependent fashion 
(IC,-q = 12.5mM). Some residual inhibitory action remained even 
at concentrations of benzyl alcohol as high as 50mM, thus 
identifying an inhibitory component which was apparently insensitive 
to blockade by action of benzyl alcohol. The effect of benzyl 
alcohol on adrenaline (+ propranolol) inhibition of 
PGE^-stimulated adenylate cyclase could not be mimicked by 
increasing temperature which will enhance membrane fluidity. 
Treatment of platelet membranes with benzyl alcohol did not lead to 
the release of either the alpha-subunit of G^ or G-protein beta
-K.VJ_.LJL
subunits. The alpha^-adrenoceptor-mediated inhibition of
adenylate cyclase was abolished when assays were performed in the
24- 24-presence of Hn rather than Mg and, under such conditions,
dose-effect curves for the action of benzyl alcohol on
PGE^-stimulated adenylate cyclase activity were similar whether or
not adrenaline (+ propranolol) was present. It is suggested that
(i) alpha^-adrenoceptor- and G.-mediated inhibition of
PGE^-stimulated adenylate cyclase may have two components, one of
which is sensitive to inhibition by benzyl alcohol and (ii) the
G^-mediated inhibition of forskolin-stimulated adenylate cyclase
exhibits predominantly the benzyl alcohol-insensitive component.
It is proposed that the benzyl alcohol- insensitive component may
reflect the direct inhibitory action of alpha-G. on the catalytic
unit of adenylate cyclase, whilst the benzyl alcohol-sensitive
component may reflect an action on the beta/gamma-subunit-mediated
inhibitory effect of G. on G dissociation. These actions ofi s
benzyl alcohol we suggest to occur due to direct effects upon
protein components rather than due to changes in membrane fluidity.
G.-mediated inhibition of the catalytic unit of adenylate
cyclase was shown to be attenuated (45% decrease) by the presence of
the anionic drug pentobarbital. Positively charged prilocaine
augmented the ability of G.-alpha to interact with the catalytic
unit (87% increase). It is suggested that a positive charge may be
required for the efficient interaction of the alpha-subunit of G^
with the catalytic unit of platelet adenylate cyclase.
Adenylate cyclase activity is also shown to be attenuated
by the presence of acidic phospholipids. Inhibition occurs by a
24-mechanism which does not require GTP and is not Mn sensitive.
It is proposed that acidic phospholipids directly attenuate the 
activity of the catalytic unit and, under normal circumstances, may 
be excluded from the lipid annulus.
xix
Inhibition of adenylate cyclase activity is also observed 
in the presence of insulin. It is shown that attenuation arises by 
a mechanism which differs from that mediating either 
alpha^-adrenoceptor- or GppNHp-mediated inhibition. The ability 
of insulin to activate a GTPase activity in platelets suggests the 
mechanism of inhibition to involve a G-protein, but not G^.
The hysteretic nature of GppNHp-mediated stimulation of
2-j-platelet adenylate cyclase was shown to be a time, Mg and 
guanine-nucleotide, dependent process. The rate limiting step 
being suggested to reflect the conversion of Gg from an inactive 
to an active form, due to the dissociation of the heterotrimer as:
_ , ,, , . GppNHp _ _ , GppNHp , , .
G alpha/beta/gamma z— z.--- ^ G alpha 4- beta/gamma
s ' s
It is proposed that the ability to modulate the efficiency 
of cAMP production in platelets may be of importance in determining 
the aggregatory properties of these cells.
CHAPTER 1
INTRODUCTION
Regulation of G-Protein Coupled Adenylate Cycl 
in Human Platelets
1. INTRODUCTION
1.1 Membrane Structure
Because adenylate cyclase is primarily located in plasma 
membranes (Davoren & Sutherland, 1963) it was decided to study the 
effect of manipulating membrane integrity on the activity of this 
enzyme in human platelet plasma membranes. It is thought that the 
structure of biological membranes, and more importantly, the 
maintenance of these structures, is vital to the functioning of 
integral proteins such as adenylate cyclase.
(i) Structure and composition of bioloRical membranes
Membranes are basically organised assemblies of lipid and 
protein, with some carbohydrate present in the form of glycolipids 
and glycoproteins. Whilst the proportions of lipid and protein 
vary from membrane to membrane, they are all based on the same 
general structure; an asymmetric bilayer. The most abundant 
lipids in these bilayers are the phospholipids i.e. 
phosphoglycerides and sphingomyelins, although cholesterol and 
glycolipids also exist. It is therefore apparent that lipids are 
numerous and quite variable. However, they are mostly amphipathic 
molecules of similar overall dimensions, allowing them to pack 
closely in a lipid bilayer. It is this amphipathic structure of 
the polar membrane lipids that directly determines the bilayer 
structure as it is the repulsion of lipid hydrocarbon chains by the 
water structure that drives these chains into an environment 
sequestered from water (Yeagle, 1989). Hence the bilayers are 
arranged so that polar or charged groups are positioned on the 
surface of the bilayer creating a hydrophobic interior of two layers 
of hydrocarbon moieties positioned tail-to-tail. The polar 
head-groups lie parallel to, rather than perpendicular with, the 
plane of the bilayer (Storch & Kleinfeld, 1985) (see Fig.l).
Figure 1 Diagrammatic representation of phospholipid bilaver 
structure
Polar 
Headgroups
Hydrocarbon
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Associated with these lipid bilayers are to be found 
proteins. Membrane proteins can generally be categorised as being 
either intrinsic, or extrinsic, depending on their ease of removal 
from the membrane. Extrinsic proteins are loosely associated 
proteins, and may only partially penetrate the bilayer, or be held 
in place by electrostatic forces. These proteins are easily 
dissociated from the bilayer by mild treatment such as changes in 
ionic strength. Intrinsic proteins on the other hand, penetrate 
the bilayer to varying degrees, and may span the bilayer, or be 
situated in one leaflet. Disruption of the bilayer by detergents 
or chaotropic agents is required to release intrinsic proteins.
Integral membrane proteins are amphipathic molecules, with 
the apolar regions of their structure being buried in the bilayer, 
whilst extrinsic proteins have a micellar structure, i.e. 
charged/polar sidechains are near the surface of the protein, and 
hydrophobic residues are buried in the apolar core.
The model of membrane structure most widely accepted is the 
Fluid-Mosaic model of Singer and Nicholson (1972) where the lipids 
provide the structural backbone of the membrane and proteins are 
‘suspended* in this lipid bilayer. Both lipids and proteins are 
mobile in the plane of the bilayer; this permits the short range 
ordering of these components, and the formation of regions, or 
’domains* of distinctive character. This mobility exists due to 
the fact that biological membranes are held together by non-covalent 
forces, which allows a high degree of flexibility and fluidity.
Integral membrane proteins exhibit two distinct types of 
mobility within the bilayer; (a) fast lateral diffusion in the 
bilayer, and (b) fast rotational diffusion about the vertical axis 
(Fig.2)
FiRure 2 Membrane proteins and lipids: permitted modes of
mobility
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Rotation through the plane of the bilayer is a prohibited 
event due to the thermodynamic difficulties that would have to be 
overcome in transferring hydrophilic constituents through the apolar 
core of the bilayer. By the same argument, ’flip-flop* of 
phospholipids is also a rare event, although it is one of four 
permitted modes of mobility.
(a) Fast lateral diffusion
(b) Fast axial rotation
(c) Flip-flop
(d) Intra-chain motion (Fig.2)
Not all phospholipids are able to undergo these movements 
at the same rate i.e. a ’shell* of lipids surrounds integral 
proteins, which, by virtue of their interaction with the proteins 
they solvate, appear to exchange with their neighbours in the bulk 
lipid pool at rates at least one order of magnitude slower. This 
ring of lipid which provides the interface between the protein and 
the bulk lipid pool has been termed the annular lipid domain. The 
composition of lipids in this annular domain need not reflect that 
of the bulk lipid pool, as a protein may exhibit segregation for, or 
even against, particular lipid species (Houslay & Stanley, 1982).
As stated previously, biological membranes are asymmetric 
structures, i.e. with respect to both protein and lipid 
distribution. In general, neutral and positively charged 
phospholipids are concentrated in the outer leaflet of the bilayer, 
whilst negatively charged phospholipids are predominantly found in 
the inner leaflet. This distribution of membrane components, and 
the maintenance of the structure which they form is important with 
respect to determining the activity of associated proteins, such as 
adenylate cyclase, as will be discussed later.
(ii) Methods of manipulating membrane structure
The physical properties of a bilayer, in particular its 
fluidity or rigidity, can influence not only the lateral migration 
of any integral proteins, but also the internal motions of groups or 
peptide chains within the protein connected with its function 
(Houslay & Stanley, 1982). Hence, the membrane structure may 
determine the activity of integral proteins such as adenylate 
cyclase. The ability to manipulate this lipid bilayer is therefore 
of interest, and forms the basis of the following discussion.
The lipid bilayer can be perturbed in a number of ways.
One of the simplest means of achieving this is to alter the 
temperature, where increased temperature relates directly to 
increase fluidity. This has been determined in a number of 
membrane systems, including human platelet plasma membranes (Gordon 
et al., 1983), by the use of spin-labelling techniques such as 
e.s.r. In platelets, it has been shown from Arrhenius-type plots 
of order-parameter vs temperature, that a lipid phase separation 
occurs between 37°C and 22°C. The fact that the platelet 
plasma membrane, like all biological membranes, contains a mixture 
of lipids, means that it does not undergo a clear-cut lipid phase 
separation as do pure lipids. With pure lipid species, the 
transition from liquid to solid state occurs at a well-defined 
temperature, whereas in biological membranes, a lipid 
phase-separation rather than transition occurs (Houslay & Gordon, 
1983).
Here, lowering the temperature causes lipids in the fluid 
state to form ’quasi-crystalline clusters' (QCC) which co-exist with 
fluid lipid. These domains consist of lipid which is more ordered 
than the fluid state, but less so than the solid state. Further
decreases in temperature result in the lipids of these
quasi-crystalline clusters attaining the solid state. Hence, the 
bulk phase lipid will be transformed from liquid, to 
quasi-crystalline clusters, to solid state by a lowering of 
temperature. As integral membrane proteins are excluded from 
ordered lipid domains, such alterations in the composition and size 
of the fluid lipid environment may affect protein activities.
Indeed, break-points occur in Arrhenius plots of the activities of 
many integral membrane proteins, and these usually coincide with a 
lipid phase separation, indicating that the altered lipid 
environment affects the activity of the biological process (see 
Section 1.3(vi)).
It is possible to alter membrane fluidity at more 
physiologically relevant temperatures in in vitro experiments using 
a wide variety of agents, such as local and general anaesthetics 
(Houslay & Gordon, 1983). Much of the work in this area has 
entailed studies of rat liver plasma membranes, where a lipid phase 
separation has been observed as occurring at 28°C (Dipple &
Houslay, 1978). This is proposed as being confined to the external 
leaflet of the bilayer, i.e. no such phase separation occurs in the 
inner leaflet over a temperature range of 0-42°C.
Examining the effect of local anaesthetics on this system 
(Houslay & Gordon, 1983; Friedlander et al., 1987; De Foresta et 
al,« 1987; Cherenkevich et al.,, 1982; Dipple & Houslay, 1978; 
Houslay et al., 1981; Houslay et al.., 1980(b)) showed that the 
temperature at which this phase separation occurred could be 
manipulated, and indeed other phase separations could be induced. 
Hence, the use of such anaesthetics is proposed as a method by which 
membrane fluidity can be altered.
The neutral, local anaesthetics are particularly useful, as 
their neutrality precludes any electrostatic interactions with
either the asymmetically dispersed phospholipids, or proteins, in 
the membrane. Benzyl alcohol (see Appendix I for structure) is one 
such anaesthetic which is commonly used in manipulating membrane 
fluidity in both model, and biological membranes (Friedlander et 
al., 1987; De Foresta et al., 1987; Cherenkevich et al,., 1982; 
Dipple & Houslay, 1978). In examining the effects of such neutral 
anaesthetics it was found that benzyl alcohol lowers the lipid phase 
separation temperature by around 6°C (Dipple & Houslay, 1978), as 
the result of a classical depression-of-freezing-point mechanism.
This arises because small lipophilic molecules like benzyl alcohol 
can readily partition into the fluid-lipid from aqueous solution, 
but are excluded from the crystalline-phase lipid which forms on 
cooling. As benzyl alcohol molecules disrupt the ordered packing 
of the hydrocarbon chains, a lower temperature is required before 
chain interactions are strong enough to expel the alcohol from this 
region, and allow crystallisation to ensue (Houslay et al., 1980(b)).
Such disruption to the ordered packing of the hydrocarbon 
chains is a result of the way in which benzyl alcohol orientates
itself in the membrane. From n.m.r. studies (Colley & Metcalfe,
1972) it was deduced that benzyl alcohol was positioned in the 
bilayer such that its hydroxyl group aligned with the polar head
groups of the phospholipids, and the aromatic residue pointed
towards the interior of the bilayer. Not only does benzyl alcohol 
penetrate the bulk phase lipid, but it will also enter the 
annulus. Such penetration leads to an increase in fluidity of this 
shell of lipids, and may affect enzyme activity (see Section 
1.3(vi)>.
Due to the asymmetric distribution of proteins and 
phospholipids, it is possible to exert selective manipulations on 
membrane fluidity. Such selective manipulation can be brought
about by the use of charged local anaesthetics. Due to the 
asymmetric distribution of lipids in the membrane these compounds 
are proposed to preferentially interact at one or other sides of the 
bilayer. As the external leaflet of the membrane is believed to 
contain a high proportion of positive/neutral lipids, it would be 
expected that anionic drugs would undergo preferential interactions 
here. In fact, studies on rat liver plasma membranes have shown 
the negatively charged drug phenobarbital (Houslay et al., 1981) to 
selectively fluidise the external leaflet (see Appendix I for 
structure). The lipid phase separation temperature of 28°C is 
depressed in accordance with this (to 16°C), whilst there is no 
detectable effect on the inner leaflet.
Cationic drugs such as prilocaine (Houslay et al.., 1980(b)) 
are suggested to undergo selective interactions with the negative 
phospholipids of the inner leaflet (see Appendix I for structure). 
Indeed, the use of such positively charged anaesthetics has been 
shown to induce a lipid phase separation at 11°C in the inner half 
of the bilayer, whilst having no detectable effect on the phase 
separation occurring at 28°C in the external leaflet.
It is also possible to manipulate membrane fluidity by
other methods, such as manipulation of fatty acids. For example,
incorporation of fatty acids of various chain lengths, and degrees
of unsaturation into the bilayer will alter the ability of lipids to
pack together, and hence will modulate membrane fluidity (Houslay &
Gordon, 1983). Similarly, the incorporation of perturbants such as 
2+ 2+ ,
the cations Ca and La will modulate membrane fluidity, as 
reflected by an elevation of phase separation temperature 
(Sauerheber et al., 1980). It is proposed that these ions 
manipulate fluidity in an asymmetric manner, binding to the 
cytosolic half of the bilayer (Houslay & Gordon, 1983),
Finally, one of the more widely employed methods of 
selectively modulating membrane fluidity, is to modify membrane 
composition by the incorporation of specific types of phospholipid 
into the bilayer. In fact, incorporation of phosphatidic acid into 
rat liver plasma membranes has been found to induce a lipid phase 
separation (at 16°C) in the inner leaflet of the bilayer, i.e. 
where such acidic phospholipids would be expected to reside (Houslay 
et al., 1986(a)).
A number of these methods of manipulating membrane fluidity 
will be examined in this study with respect to their effect on the 
adenylate cyclase activity in human platelets. It was decided to 
examine such parameters in platelets as these elements provide an 
easily available system of functional significance for looking not 
only at signal transduction events, but at membrane perturbations.
It should be noted that most of the results presented here centre on 
the effects of the local anaesthetic benzyl alcohol with respect to 
adenylate cyclase activity,
1,2 Platelets
(i) Morphology and functions
Platelets are the smallest of the formed elements of human 
blood, appearing as anucleate, granular bodies, 2-4uM in diameter. 
These disc-shaped elements arise by the cytoplasmic fragmentation of 
mature megakaryocytes in the bone-marrow, and typically have a 
life-span of 7-10 days. Each platelet has an intact plasma 
membrane about 7-9nm in thickness, and a complement of intracellular 
organelles.
These organelles include mitochondria, lysosomal-like 
organelles, glycogen-containing granules (from which they derive 
most of their energy by glycolysis) and two types of organelles that 
are specific for platelets; dense granules and alpha-granules.
Dense granules contain serotonin, calcium, ADP, and ATP, whilst 
alpha-granules contain proteins that are (a) also found in the 
plasma (e.g. fibrinogen) or (b) specific for alpha-granules (e.g. 
beta-thrombglobulin) (Crawford & Taylor, 1977).
Platelets also possess a complex canalicular network which 
connects with the surface membrane, and a circumferential band of 
microtubules which seem to be concerned in maintaining the discoid 
shape. A system of microfilaments also exists within platelets, 
which are believed to be components of a contractile system.
Physiologically, the platelet helps maintain the integrity 
of the vascular system by interacting with the vessel wall and other 
elements of the blood. The platelet also fulfils a number of other
important roles, such as the storage and secretion of vasoactive 
compounds, and the transport of various materials. It also 
participates in the body's defence mechanism, by undergoing 
phagocytosis and chemotaxis as well as by releasing bacteriocidal 
substances (Crawford & Taylor, 1977; Page, 1988).
In order to fulfil any of these roles, a platelet must 
become activated; this entails a complex series of events, the 
trigger to which is the modulation of the level of some key
regulatory elements within the platelet (namely cyclic AMP and/or
^ 2-k  Ca ),
(ii) Signal transduction in platelets
Because platelets are electrically non-excitable, there 
must exist transduction processes which link events at the cell 
surface, to the key intracellular reactions which control cellular 
responsiveness. These signal-transduction processes are centred 
around the production of cyclic AMP and inositol-phosphates, i.e. 
these compounds act as second-messengers conveying information from 
the cell surface to effectors within the platelet.
Inhibition of platelet responsiveness is associated with
agonist-induced elevation of the intracellular concentration of
cyclic AMP, whilst stimulation is associated with agonist-induced
elevations in the intracellular concentraions of diacylglycerol,
2+inositol triphosphate and Ca (from inositol phosphate signalling 
pathway). How these two systems interact in platelets is quite 
complex and an attempt to illustrate this interaction is made in 
Figure 3.
Obviously there appears to be several mutual interactions 
between these two signal-generating systems. On the one hand, 
increases in cyclic AMP levels inhibit the formation of inositol 
phosphates and diacylglycerol. Is is unclear whether this 
inhibition is due to a direct effect of cyclic AMP on the 
phospholipase C itself, or to an indirect mechanism. On the other 
hand, protein kinase C, which is activated by diacylglycerol, 
largely interferes with the adenylate cyclase system. This 
kinase, when activated by diacylglycerol, apparently phosphorylates 
the guanine-nucleotide binding alpha-subunit of G. (see Section 
1.3(iv) for G^), which results in an impairment or loss of the 
inhibitory hormonal signal transduction to the adenylate cyclase 
(Jakobs et al., 1986).
Here we are looking at the adenylate cyclase system of 
platelets, with emphasis on the inhibitory arm of regulation in this 
dual controlled system.
(iii) The role of cyclic AMP in platelets
Cyclic AMP is one of the major intracellular modulators of 
biochemical reactions involved in the stimulation of platelets (the 
other being the calcium ion). This stimulatory response of 
platelets involves adhesion to sub-endothelial tissues, the 
formation of platelet aggregates, the secretion of secretory granule
IN
H
IB
IT
O
R
Y
 
S
T
IM
U
L
A
T
O
R
Y
H
O
R
M
O
N
E
 
H
O
R
M
O
N
E
13.
FiRure 3 SiRflal transduction pathways in platelets
Q.I-
<tn
< w j=
_J CO >
U1UH
cr.
I §
L> c 5:
a
li
sp
h
o
sp
lu
it
o
components, the rapid synthesis of oxidative metabolites of
arachidonic acid, increased glycogenolysis, and the consumption of
substantial amounts of ATP. All of these reactions depend in one
2+way or another, on intracellular and/or extracellular Ca
However, agents which increase cyclic AMP levels antagonise these
24-
responses by regulating the free Ca level in the platelet, or by
2+
controlling the Ca -dependent reactions that are essential for 
the responses. Cyclic AMP therefore represents the most important 
intracellular regulator which prevents cellular activation 
(Feinstein et al., 1981).
However, it is not possible to directly relate cyclic AMP 
levels to functional changes in platelets, as the level of cyclic 
AMP represents a parameter distal to the functions which are 
affected. Cyclic AMP actually activates protein kinases to 
catalyse phosphorylation reactions, which in turn affect various 
enzymes or regulator proteins. It is therefore the steady-state 
level, or rate and direction of change of these phosphoproteins 
which is more directly related to cellular responses (Booyse et al., 
1976). This series of reactions, which is initiated by the 
production of cyclic AMP, constitutes a cascade-mechanism, whereby 
the production of a small amount of cyclic nucleotide can regulate a 
wide variety of cellular reactions. The effects of cyclic AMP are 
therefore mediated by protein phosphorylations catalysed by cyclic 
AMP-dependent proteins kinases (Fig.4).
Both soluble and membrane-bound cyclic AMP-dependent 
protein kinase activity has been identified in platelets. These 
two forms have been termed type I (membrane-bound) and type II 
(cytosolic) on the basis of their elution from DEAB cellulose, i.e. 
two principal classes of isoenzymes exist in platelets. In fact, 
cyclic AMP-dependent protein kinase is, thus far, the only receptor
Figure 4 Cascade mechanism for cyclic AMP action
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protein defined for cyclic AMP in eukaryotic cells (Krebs, 1985).
Bach cyclic AHP-dependent protein kinase has two parts, a catalytic
subunit and a regulatory subunit. Cyclic AMP binds to the
regulatory subunit, thereby liberating the catalytic unit, which is
then free to phosphorylate proteins (Berridge, 1985).
i.e. R +■ 4 cAMP — ^ R0 « (cAMP), + 2C
2 2 * 2 4
It has been suggested that protein phosphorylation is
involved in the platelet release reaction rather than in primary
2+
aggregation. In fact it is proposed that Ca -mediated 
phosphorylation occurs prior to secretion and places the platelet in 
a state where secretion can occur (Feinstein, 1981),
Modulation of this phosphorylation, and therefore of 
platelet activation, is possible via the production of cyclic AMP by 
adenylate cyclase in the plasma membrane.
1.3 The Adenylate Cyclase System
(i) General introduction
The formation of cyclic AMP is platelets is therefore 
dependent upon the regulation of the enzyme adenylate cyclase [E.C. 
4.6.1.1; ATP pyrophosphate-lyase (cyclising)]. The reaction 
catalysed by this enzyme can be represented by:-
Mg2*ATP -------- > 3*5* cyclic AMP + 2P1
(see Fig.5)
The platelet enzyme, like the adenylate cyclase in the 
membranes of other eukaryotic cells, is a multicomponent system. 
Here, the activity of the catalytic unit (C) is regulated by 
stimulatory (Rg)~ and inhibitory (IO-receptors whose actions 
are mediated by the guanine nucleotide-binding proteins Gg and 
Gj respectively. The system is therefore composed of at least 
five elements, the arrangement of which is shown in Figure 6.
Figure 5
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(ii) Association of receptor, G-protein and catalytic unit in 
the membrane
Here the association of adenylate cyclase components refers
largely to R , G and C interactions, as most analysis has been 
s s
on the mammalian beta-adrenergic system, i.e. a stimulatory 
system. However, the interaction of components of the inhibitory 
arm of regulation will be discussed later (see section 1.3(iv)).
Although detailed kinetic studies have taken place 
(Levitzki, 1986; Hanski et al., 1979) the precise mechanism by 
which these components interact is still a matter of controversy. 
However, three main contenders exist with respect to a plausible 
model for component interaction (Arad et al., 1984).
(a) The collision coupling model
The main tenets of this hypothesis are that the G-protein
and the catalytic unit are always associated with each other, and
that the hormone-receptor complex only makes a transient encounter
with G C. 
s
R + G (GDP)• C 
s , s
V
H • R • G * (GTP) • C* Active state 
s
HR + G (GDP) C s
Inactivation occurs by hydrolysis of GTP to yield inactive
G (GDP) C. 
s
(b) The precoupled model
Here is it assumed that all three components involved in 
stimulatory regulation of adenylate cyclase are associated at all 
times.
R • G (GDP) • C
S I?
HR • G * (GTP)• C» Active state
s jS
HR • G (GDP) • C
s s
(c) The shuttle model
R + G (GDP)— >H.R • G ’ (GTP)— >HR + G * (GTP)
S S  7 S S 7 3 3
then,
G » (GTP) + C-*G * (GTP) • C*— ^G (GDP) + C s s s
Active state
Here all three components are separate, and interactions 
occur only in an ordered sequence, the ‘cycle* being terminated by 
hydrolysis of GTP to yield free Gg.
Evidence exists to both support and disfavour each of these 
three models. For example, the precoupled model is not favoured
mainly due to the fact that the beta-adrenergic receptor, in the
2+ , .
absence of Mg and GTP, exhibits an altered affinity for agonist
binding, i.e. this may result from R • G dissociation. Others s
evidence which tends to disfavour this model of component
interaction is the fact that receptor down regulation has been
observed without concomitant movement of G . In other words,
s
different lines of evidence exist for the R and G unassociated
s s
state, which is in major disagreement with the basis of the 
•precoupled model*.
This last piece of evidence would not, however, be in 
disagreement with the tenets of the collision-coupling model. This 
theory could accommodate R and G being unassociated at times,
S 3
as it assumes only a transient R -G -C complex formation. The
S 3
major proposal of this theory is that a persistently activated Gg- 
C complex exists and in support of this suggestion is the fact that 
alpha-G^ has been copurified with the catalytic unit. In fact, 
high salt concentrations are required to separate these two 
components (Levitzki, 1986).
The final model to be considered, i.e. the shuttle model,
again has conflicting evidence for and against it. In favour of
this model is the fact that it would allow the activation of G ins
the absence of the catalytic unit (as has been found with 
non-hydrolysable GTP analogues); a condition which would not be 
thought to exist under the constraints of the other two models. 
However, the observation that R and G can form a complex in
3 3
the presence of agonists and the absence of GTP, goes against the 
’shuttle* model (Levitzki, 1986).
The conclusion to be drawn is therefore that the 
interaction of components within the membrane occurs by a mechanism 
which is, as yet, undefined, although kinetic analysis does tend to 
favour a collision-coupling type model.
(iii) Receptors
Platelets have receptors for a large number of agents which 
are either synthesised/secreted by the platelets themselves, or 
which are normally present in the circulation, e.g. adrenaline, ADP, 
thromboxane A^, vasopressin, PGD^, adenosine etc. A number of 
these agents act at receptors which are coupled to guanine 
nucleotide-regulatory proteins(G-proteins) and it is these receptors 
which are of interest in discussing regulation of adenylate cyclase 
activity (see Table 1).
Prostanoid receptors
Classification of prostanoid receptors is limited due to 
the lack of specificity of available antagonists. However, it is 
believed that receptors exist for each of the natural prostanoids. 
Human platelet membranes are thought to contain distinct receptors 
for PGD2 and PGI2 . PGE^ effects parallel those of PGI^ and 
it is believed these prostaglandins share a receptor-type, although 
PGI2 is in fact the endogenous ligand. Both the PGD^ and the
z.'.
Table 1 G-protein-coupled receptors which modulate adenylate
cyclase activity in platelets
Stimulatory receptors and their aRonists
PGE1
PGD_ R linked to G2 s s
p g i2
Adenosine
Catecholamines (beta2>
Inhibitory receptors and their agonists
Catecholamines (alpha2> 
ADP
R. linked to G. 
1  l
PGI2/PGE^ receptor types are linked to activation of platelet 
adenylate cyclase via the stimulatory G-protein, Gg (MacIntyre, 
1981).
Purine receptors
Purine receptors fall into two general classes as regards 
their sensitivity to the purine agonists adenosine, AMP, ADP, and 
ATP;
(a) P^-purinoceptors also known as the adenosine receptor
as this is the most potent agonist 
here.
(b) P^-purinoceptors also known are the ATP receptor as
this is the most potent purine 
agonist here.
Whilst the exact role of the P^-receptor is unclear, the
P^-receptor is known to be linked to adenylate cyclase
regulation. In human platelets, adenosine exhibits a biphasic
effect on cyclase activity; low concentrations (2-25uM) causing
stimulation and high concentrations (>100uM) causing inhibition
(Schwabe, 1982). On this basis it has therefore been proposed that
two subtypes of P^-purinoceptor exist:
A^ inhibition of adenylate cyclase (R.)
A n stimulation of adenylate cyclase (R /R )
2 a s
(see Satchell, 1984)
Both A^- and A^-subtypes are located in the plasma 
membrane, and are linked to adenylate cyclase via the appropriate 
G-protein. Studies do however indicate that the predominant 
P^-receptor in platelets is the Rg subtype (Schwabe, 1982).
Another adenosine regulatory site exists in platelets; 
this is an intracellular P-site, which inhibits adenylate cyclase 
(see Section 1.3(v)).
Catecholamine receptors
Platelet receptors can be grouped into two classes with
respect to their effect on adenylate cyclase activity upon agonist
binding, stimulatory receptors (R ), and inhibitory receptorss
(R. ).
1
Catecholamine receptors exist in platelets which fall into 
each of these classes, i.e. adrenoceptor-mediated stimulation and 
inhibition of adenylate cyclase has been demonstrated in human 
platelet lysates (Jakobs et al., 1978).
Adrenoceptors can be subdivided into alpha- and 
beta-adrenoceptors on the basis of their pharmacological 
characteristics. Whilst both these classes can be further 
sub-divided, it has not been shown that these subtypes are all 
linked to regulation of adenylate cyclase activity. The classical 
subdivision of adrenoceptors is as shown in Figure 7.
However, from studies of pharmacological characteristics, 
mechanisms of signal transduction, and the molecular cloning of the 
cDNA encoding the receptors, it has been proposed that adrenoceptors 
can be subdivided as shown in Figure 7. Three major subtypes 
exist; beta, alpha2 » and alpha^, and each can be further 
divided into two or more additional secondary subtypes.
It is assumed that both beta^ and beta2 are linked to 
adenylate cyclase activation as there is no convincing evidence to 
suggest differences in their stimulus-response coupling mechanism. 
However, the spectrum of compounds capable of exhibiting intrinsic 
activity through these receptors in human platelets is very narrow, 
suggesting that the human platelet beta-adrenoceptor differs from 
those found in other cell types (Jakobs et al., 1978). Radioligand 
binding analyses have in fact led to the proposal that the platelet 
beta-adrenoceptor is of the beta^-subtype, and that they are
Figure 7 Classification of adrenoceptors
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present in very small numbers, being approximately 1/10-1/20 of the 
alpha^-adrenoceptor number.
Although not suggested as occurring in human platelets, a 
third species of beta-adrenoceptor has recently been reported 
(Zaagsma & Nahorski, 1990). Functional studies on adipocytes 
indicate the presence of this atypical receptor, i.e. in addition to 
the known beta^- and beta^-adrenoceptor subtypes. This 
polypeptide is thought to be encoded by a recently isolated gene 
whose expression product has approximately 50% homologies with the 
beta^- and beta2~adrenoceptors (Emorine et al., 1989). The 
occurrence of such 'beta^-adrenoceptors* is reported in an 
increasing number of tissues, and in several tissues, including 
atrial and ventricular heart tissues, the three separate 
beta-adrenoceptor subtypes may mediate the same function, depending 
upon the stimulation conditions used.
Studies using various catecholamine agonists and 
antagonists have shown platelets to possess alpha-adrenoceptors, 
with numbers in the region of 100-460 per platelet. It has been 
suggested that this receptor is exclusively of the 
alpha^-subtype. However, whilst this is indeed the predominant 
platelet receptor for adrenaline, alpha^-receptors have been found 
to exist, although they account for only a small percentage of the 
total alpha-adrenoceptor population (Scrutton & Wallis, 1981).
Although the alpha^-receptor has been shown to exist in 
platelets, its exact physiological role is unclear; current 
evidence suggests they are coupled to regulation of calcium flux 
through phosphatidylinositol turnover (Limbird, 1984). On the 
other hand, alpha-adrenoceptors are known to be linked to 
inhibition of adenylate cyclase. The alpha^-adrenoceptors 
themselves have been found to be a heterogenous population with
respect to their pharmacological characteristics. It has actually 
been proposed that subdivisions exist, the adrenoceptor found in 
human platelets being a typical alpha^ A subtype. The prototype 
tissue for the alpha^ B receptor is neonatal rat lung, whilst a 
third subtype, alpha^C, may exist, although so far it has been 
found in only one (kidney-derived) cell line.
The gene encoding the platelet alpha^-adrenoceptor has 
been localised to chromosome 10, and from its DNA sequence, is 
predicted to have a unique, but similar, primary amino acid sequence 
to the receptor from human kidneys. This receptor is encoded by a 
gene on chromosome 4, and may represent a fourth subtype of 
alpha^adrenoceptor (Bylund, 1988). More recently, a human 
alpha2~adrenoceptor has been cloned which represents the product 
of a gene located on chromosome 2, i.e. alpha2C2 (Lomasney et al,. 
1990). This receptor is alpha^-like in that it is 
non-glycosylated, but it is distinct from alpha , and representsZ j&
a previously unidfentified alpha^ adrenoceptor subtype. Indeed, 
other reports exist describing the cloning of alpha^ adrenoceptors 
which are suggested to be different again from alpha^ CIO, 
alpha2 C4 and alpha2C2.
The platelet alpha^-adrenoceptor is linked to inhibition 
of adenylate cyclase. However, inhibition was found to occur only 
upon binding of the natural catecholamines, L-adrenaline and 
L-noradrenaline. This would therefore suggest that the 
alpha-adrenoceptors of platelets, like the beta-adrenoceptors, are 
indeed somewhat different from those found in other cells (Jakobs et 
al., 1978).
So far, all G-protein coupled receptors which have been 
isolated and sequenced, have been found to be glycoproteins which 
are characterised by a common topology of seven transmembrane
regions, and by varying degrees of primary sequence similarity 
(Schofield & Abbott, 1989; Brooker et al., 1983; Dohlman et al., 
1987). Much of the work on G-protein-coupled receptors has been 
performed on beta-adrenergic receptors. Using this system it was 
found, from primary sequence analysis, that seven hydrophobic 
stretches of approximately 20-25 amino acid residues existed, 
surrounded by eight hydrophilic stretches of variable length. It 
is thought that each hydrophobic domain forms a transmembrane alpha 
helix, with the intervening (less conserved) hydrophilic loops being 
alternatively exposed intra- and extra-cellularly (Strader et al., 
1989). Genetic analysis of the beta-adrenergic receptor revealed 
the ligand binding domain to involve residues within the hydrophobic 
core of the protein, i.e. it is possible by deletion mutagenesis 
(and by proteolytic cleavage) to remove most of the connecting 
hydrophilic regions without affecting ligand binding to the 
receptor. On the other hand, lesions within the transmembrane 
domains interfere with ligand binding (Strader et aJ., 1988).
From mutagenesis experiments, it was found that aspartate 
113 in helix 3 is involved in agonist/antagonist binding, amino 
groups of the ligand forming an ion-pair with the carboxylate side 
chain of this residue (Strader et al., 1989). Other interactions 
between specific residues of the receptor and functional groups on 
ligands have also been proposed e.g. photolabelling suggests 
tryptophan in transmembrane domain 7 forms part of the ligand 
binding site. A suggestion which is supported by studies involving 
chimeric receptors (Schofield & Abbott, 1989). However, it should 
be remembered that transmembrane domains all have a potential role 
in ligand binding.
Results therefore indicate that transmembrane (TM) domains 
fold around to make a pocket into which the ligands bind. It is
also thought that the cytoplasmic side of this structure has a 
number of contact points for G-proteins, thus providing a means of 
signal transduction, i.e. positive residues on the cytoplasmic side 
are thought to constitute the putative G-protein binding domain.
This is thought to involve three domains on the cytoplasmic side of 
TM5, TM6 and TM7, and palmitilation of cysteine 341 of TM7 is 
thought to be particularly important. This post-translational 
modification is conserved between various members of the 
G-protein-coupled receptor family, and if palmitoylation cannot 
occur, receptor affinity for G-proteins is reduced (Schofield & 
Abbott, 1989).
As stated previously, these receptors have been found to be 
glycoproteins (1-3 consensus sites for N-linked glycosylation near 
the amino terminus of the protein). However, glycosylation appears 
to play no role in either ligand binding or functional coupling to 
G-proteins. It would appear that glycosylation serves a role only 
in trafficking the receptor through the cell, and in expression of 
the protein at the cell surface (Benovic et al., 1987),
The orientation of G-protein-coupled receptors in the 
membrane is therefore as shown in Figure 8.
(iv) Guanine nucleotide regulatory proteins
(a) Structure and mode of activation
Guanine nucleotide regulatory proteins (G-proteins) play an 
important role in the regulation of adenylate cyclase activity.
These proteins serve to transduce information between the catalytic 
unit of adenylate cyclase and the receptors in the membrane.
JU.
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In platelets, where the activity of the catalytic unit may 
be dually regulated, two forms of G-protein are especially important
(1) G which mediates stimulatory effects, ands
(2) G^ which mediates inhibitory effects.
Gg and G^ are part of a larger 'family' of G-proteins
which are all believed to be structurally similar heterotrimers,
consisting of a large alpha-subunit (M^ 41-45,000), and two
smaller subunits, beta, M =approximately 35,000 and gamma, Mr r
approximately 10,000 (Gilman, 1984).
It has been proposed that upon hormone receptor interaction
with the G-protein, the latter dissociates into free alpha subunits
and beta-gamma complexes (Gilman, 1984). This is believed to
involve a change in conformation at the receptor upon agonist
binding being transmitted to the G-protein, probably via receptor
interaction at the C-terminal domain of the alpha-chain. This
results in the guanine-nucleotide binding site attaining an open
conformation, such that bound GDP is released, whilst GTP can enter
to cause yet another change in conformation. The end result is
that the G-protein alpha-subunit*s affinity for binding beta-gamma
is reduced, whilst its affinity for the catalytic unit increases
(Bourne et al., 1987). This, therefore, constitutes the
*on-reaction*, and in the case of G alpha would mean thats
adenylate cyclase would be activated, resulting in increased
formation of cyclic AMP (see page 41 , for d iscussion of G^
activation). In fact, it has recently been suggested that
GTPactivation by GTP is sequential; alpha -beta-gamma heterotrimer
GTP
dissociating from the receptor before alpha and beta-gamma 
separate, and subsequently interact with the catalytic unit (Miller 
et al.« 1988). The *off-reaction* results from the fact that 
G-protein alpha-subunits exhibit an intrinsic GTPase activity, which
allows them to hydrolyse GTP to GDP (Bourne et al., 1987), This 
slow hydrolysis of GTP (4 min *) is followed by the reassociation 
of alpha GDP with beta-gamma to reform the inactive heterotrimer 
(Weiss et al_., 1988); see Diagram 9.
The change in conformation of G-proteins, notably Gs#
resulting from GTP-binding, are reflected in agonist binding
affinities of R ; GTP-G binding generally resulting in a s s
decrease in agonist high-affinity binding at Rg. The same is 
also true for R^ with respect to GTP binding to G. .
As well as containing the site of guanine nucleotide 
binding, the alpha subunits, which are unique gene products (Weiss 
et al,, 1988), are therefore responsible for regulating the 
effector, and also confer on each G-protein its specificity for 
interacting with particular receptors (Bourne et al., 1987). These 
alpha-chains are 300-400 residues long, and from comparison of 
sequences from different G-proteins, an 'average* structure for the 
alpha-chain has been proposed, in which aspartate residues bind 
guanine nucleotides to a guanine-nucleotide binding domain. Other 
domains are thought to exist, including a short hydrophilic domain 
at the amino terminus which may be involved in controlling 
interactions of the alpha-chains with the beta-gamma complex.
Contact sites for G-protein alpha-chain interaction with effector 
molecules also exist, whilst a carboxy-terminal domain is thought to 
form at least part of the contact site for receptors coupled to 
G-proteins (Bourne, 1988).
Whilst the alpha-subunits are distinctive from, and 
non-identical to each other, the beta-subunits appear to be 
identical in each member of the G-protein family. These subunits 
are functionally and structurally indistinguishable by biochemical 
and immunological methods (Sternweis, 1986), although molecular
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cloning of cDNA shows at least two forms of the beta chain exist
(Fong et al,, 1987), These proteins have approximately 90%
homology and are denoted beta, (36,000 M ) and beta. (35,000l r i.
Hr>: they are encoded by distinct genes located on chromosomes 1
and 7 respectively. It would appear that a third form of the 
beta-subunit (beta^), may exist: restriction mapping having shown
it to be distinct from the other two forms. This species is 
encoded by a gene localised on chromosome 12. However, its precise 
molecular weight as well as its functional significance, are as yet 
unidentified (Levine et al., 1989).
The third subunit species present in G-proteins is the 
gamma-subunit, which has a low molecular weight of approximately 
10kDa. This was first identified as being a component of Gg and 
Gj by Hildebrandt et al., 1984(b), who proposed the gamma-subunits 
of Gg and G^ as being indistinguishable. Recently however, 
studies have suggested that multiple forms of the gamma-subunit also 
exist (Robishaw et , 1989). Although the total number of 
gamma-subunits is not yet known, immunoblotting studies have 
suggested the existence of at least four different types of 
gamma-subunit. These are the y<. and y^ subunits of brain Gg,
G. and G ; the y. subunit of retinal G, , and the
1 O 6 t
gamma-subunit of placental G.. Whilst all of these 
gamma-subunits are structurally distinct, they are all proposed as 
exhibiting a conserved C-terminal cysteine residue. This residue 
may be subject to covalent modification (palmitilation or 
isoprenylation) as part of the process leading to 
membrane-associated forms of these proteins.
Given that there are at least two beta-subunits, and at 
least four gamma-subunits, the possible number of combinations of 
these subunits is relatively large. However, whether a specific
beta-gamma complex is required to interact with a particular
alpha-subunit to modify its function, is not yet known. These
three components, i.e. alpha, beta and gamma, therefore combine to
form what is termed a G-protein, with the alpha-subunit apparently
being the more active species. In fact, the alpha-subunits are
soluble in aqueous solution (Sternweis, 1986) and will only interact
with phospholipid vesicles which have beta-gamma already present.
On the other hand, beta-gamma subunits will associate totally with
phospholipid vesicles, thereby implying that the function of the
beta-gamma complex is to attach the G-protein to the membrane.
Alpha-subunit association with beta-gamma-containing vesicles
actually occurs in a saturable fashion, indicating a stoichiometric
association between the subunits. However, whether beta-gamma*s
serve only to function as ‘anchors' for alpha subunits is debatable,
beta-gamma subunits being proposed as having other functions, as
will be discussed later.
Gg and G. are actually part of an ever-expanding family
of G-proteins, which includes, amongst others, transducin, Gq,
G , G , and the putative G. . Other GTP-binding proteins do p z ins
exist in platelets. However, these are unrelated to the G /G.
s i
family, having no beta-gamma subunits, and are termed 'small
molecular weight GTP-binding proteins*. Binding studies using
35radioactively-labelled guanine nucleotides such as [ SjGTPy'S
(Ohmori et al., 1989), and [<XT^P)GTP (Bhullar & Haslam. 1987)
have revealed the presence of a family of such monomeric GTP-binding
proteins, with molecular weights in the range 20-30kDa (Nagata et
al., 1989 : and see Table 2). Whilst it is noted that such species
exist, these low molecular weight G-proteins will not be discussed
here. Instead we will focus on the roles of G and G. with
s 1
respect to adenylate cyclase regulation.
Table 2 Low molecular weight GTP-binding. proteins
Name
ARF
rab 1 
rab 2 
rab 3 
rab 4 
rab 3
ral
rap 1A 
rap IB 
rap 2
BRL-ras
Ha-ras
Ki-ras
N-ras
R-ras
rho A 
rho B 
rho C
Comments
ADP-riblsylation factor
Expressed in most cells 
Expressed in most cells 
Expressed in brain 
Expressed in most cells
Expressed in most cells
Expressed in most cells 
Reverts ras-transformed cells
Expressed in most cells
) Involved in growth control
) Expressed in most cells
)
)
) Botulinum toxin substrate
)--------- Expressed in most cells
) Botulinum toxin substrate
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(b) Gs
This G-protein stimulates the activity of adenylate
cyclase, resulting in an increase in the formation of cyclic AMP.
The alpha-subunit of exists as two species in most cells, with
M 45,000 and 52,000 (Robishaw et al., 1986). The relative r -----
amounts of these two species is tissue-specific, although the reason
for the differences is not known. Both these products are encoded
by a single 13-exon gene spanning 21Kb (Ishikawa et al., 1990) and
it has been shown that alternative splicing of precursor RNA can
give rise to at least four types of alpha mRNA, which are almosts
identical in sequence (Bray et al,., 1986). All four forms of G
s
2+activate adenylate cyclase (and Ca channels) with similar
potencies (Carty et al., 1990).
It is probable that other forms of Gg alpha may exist;
for example by the use of an alternative promoter, a 38kDa form of
G alpha has been recorded (Ishikawa et al., 1990). whilst other 
s
groups have reported a unique alpha mRNA to exist in haploid germs
cells (Haugen et al., 1990).
The Gg alpha subunit can undergo ADP-ribosylation by
cholera toxin in the presence of a membrane-bound protein factor,
termed ARF (Morgan, 1989) the result being that GTP is bound and the
alpha-subunit remains in this activated state due to the inhibition
of GTPase activity.
Activation of G by agonist-occupied receptors (H*R ) s s
requires a number of factors in order to occur efficiently. One
such factor is the presence of Mg^* (Iyengar & Birnbaumer, 1981a;
2 +Iyengar & Birnbaumer, 1981b), with the K for Mg beingm
5-10mM. However, it has been postulated that receptor activation
of G decreases this K (Iyengar & Birnbaumer, 1982), i.e. 
s m
2+activation is primarily by decreasing the Mg requirement such
that physiological concentrations of free Mg (0.5mM) are
sufficient to saturate the system.
The other factor required for G activation is thes
presence of guanine nucleotides. Here, physiological
concentrations of GTP (approx, O.lmM) are such that saturating
levels of the nucleotide are always present; the K of G alpha
m s
for GTP being approximately luM.
The activation of Gg can be brought about directly at the
level of the G-protein rather than via the stimulatory receptor
i.e. H • Re
i s 
v'
Direct Gs alpha/beta/gamma >GS alpha + beta/gamma
Interaction
This can be attained in a number of ways:
1. The use of GTP analogues such as GTP-y’-S and p[NH]ppG.
These non-hydrolysable molecules activate G following a
s
definite ’lag* period which is not observed with GTP.
This lag reflects a distinct activation process which, once 
completed, leads to a steady-state of activation 
(Birnbaumer et al,, 1980).
2. Ggalpha can also be activated by sodium fluoride. This
requires the presence of Al**+, the active species being 
AIF^, This appears to promote persistent subunit 
dissociation, the AIF^ being thought to resemble the 
terminal gamma-phosphate of guanine nucleotides, i.e. it is 
suggested that AIF^ associates with the beta-phosphate 
of GDP and mimics the effect of non-hydrolysable GTP 
analogues (Chabre, 1989).
Activation of G by any of these routes is thought to 
s
result in dissociation of the alpha-beta-gamma heterotrimer to yield
the active G -alpha species. G -alpha is then thought to 
s s
directly modulate the activity of the catalytic unit. The basis of
GTP
this model being the fact that the species alphag -‘y'-S is 
sufficient to activate the purified catalytic subunit of adenylate 
cyclase (Levitzki, 1987).
(c) G.
—l
G. is a class of G-protein that not only inhibit
adenylate cyclase but regulate other enzymes and ion channels. The
existence of such an inhibitory G-protein in the adenylate cyclase
system was first postulated when GTP was found to be able to inhibit
the enzyme’s activity in rat adipocyte membranes. As discussed
previously, this protein is an alpha-beta-gamma heterotrimer, which
undergoes dissociation following GTP binding. The alpha-subunit
has in the region 40-41,000, with cDNA studies identifying at
least three forms of this polypeptide which are probably the
products of at least two separate genes (Kim et al., 1988). These
species termed G,alpha-1 (M 41,000), G. alpha-2 (H 40,000) l r l r
and G. alpha-3 (H^ 41,000), have greater than 80% sequence 
homology. However, distribution of these G. subtypes varies 
within tissues, the sequence for G, alpha-2 being the most common.
Studies using G^-specific antibodies have shown that 
platelets contain G.-2 and G.-3 but not apparently G.-l 
(Simonds et al., 1989). As would be expected from the earlier 
statement, G^~2 is the major G.-subtype present. In platelets, 
the use of G^-2-specific antibodies has led to the conclusion that 
this species is the dominant mediator of cyclase inhibition, at 
least in the pathway of alpha^-adrenoceptor-mediated inhibition.
This conclusion arose from observations that only antibodies 
specific for the C-terminal of G,-alpha-2 were able to block this 
inhibition. The function of G.-alpha-3 in platelets is therefore 
unclear. However, although these findings would rule out a 
predominant role for G^-3 in this inhibitory pathway, they do not 
exclude an ancillary role for G^-3 in cyclase inhibition, nor do 
they rule out the possibility that G.-3 mediates inhibition of 
adenylate cyclase by some other ligands. It may be that G.-3 is 
not actually linked to adenylate cyclase, and indeed attempts have 
been made to assign specific roles to each of the 
G^alpha-subtypes. For example, G^alpha-3 is proposed as a 
regulator of K+-channel function. However, studies have since 
shown that all three forms of G. are capable of this function 
(Yatani et al., 1988a). It may be that the differential expression 
of alpha, genes in different cell types will permit 
characterisation of distinct physiological roles for the G-proteins.
Recently it has been shown that whilst there is no apparent
difference in effector interactions, the three forms of G. do have
1
different kinetics of activation, i.e. the rates of GDP-release and 
GTP-binding may be independently regulated for these three 
proteins. Hence the relative proportions of these species may be a 
crucial factor in determining the kinetics of signal-transduction 
through G^-coupled effectors (Carty et al., 1990).
As regards G. involvement in adenylate cyclase
inhibition, G.alpha, like G alpha, binds GTP upon hormonal 
1 s
stimulation, i.e. H'R. interacts with G. alpha-beta-gamma 
resulting in the alpha chain binding GTP. The resultant change in 
conformation causes beta-gamma to dissociate from the holomeric 
complex. Once again GTP hydrolysis to GDP, via the inherent GTPase 
of the alpha-subunit, constitutes the 'off-reaction*.
Concentrations of guanine-nucleotides required to activate G. are 
lower than those required by Gg, i.e. G^ has a higher affinity 
for GTP and its analogues. Similarly, G^alpha requires lower
2-f-concentrations of Mg (uM) for activation than does G^alpha
(Jakobs et al., 1985).
G. , like G , can be ADP-ribosylated. Here, the
i s
bacterial toxin which mediates this ribosylation is pertussis toxin,
isolated from the bacterium Bordetella pertussis. This
ribosylation occurs at a cysteine residue in the C-terminal region
of the alpha-chain, and requires the presence of the
alpha-beta-gamma holomeric complex. Treatment with pertussis
toxin, also known as IAP (Islet Activating Protein), results in the 
GDPinactive (G alpha ]beta-garama complex being stabilised, with the 
net effect being that G. activation cannot occur (Morgan, 1989).
This toxin will also ADP-ribosylate the alpha-subunits of Gq and 
G^, i.e. it is not specific for G.alpha as had first been 
thought.
It has also been shown that G.alpha can be 
mono(ADP-ribosyl)ated at a cysteine residue (presumed to be the same 
as that ribosylated by pertussis toxin) (Tanuma et al., 1988), by an 
endogenous mono(ADP-ribosyl) transferase enzyme. The role of these 
enzymes is unclear, although it has been suggested they attenuate 
G^-mediated inhibition in platelets, i.e. they may have a role in 
regulation of adenylate cyclase activity (Tanuma & Endo, 1989).
42.
It is possible to selectively inactivate G. in platelets 
by various treatments:
1. Pretreatment of cells/membranes with low concentrations of
N-ethylmaleimide (NEM). This sulphydryl agent is thought
to specifically affect the receptor-G, interaction
(Garcia-Sevilla et al., 1988).
2+
2. Low concentrations of Mn (ImM) can similarly be used to 
preferentially uncouple G^-mediated inhibition. This is 
thought to interfere with G.-catalytic unit interactions 
(Hoffmann et al., 1981).
3. Treatment of platelets with phorbol esters which activate 
protein kinase C leads to attenuation of G,-function.
This is due to protein kinase C phosphorylating the 
alpha-chain of G^ to the impairment of its activity.
This is probably a result of an increase in hydrolysis of 
G.alpha-bound GTP to give inactive G.alpha-GDP; as 
hormonal/GTP-dependent inhibition is attenuated, whilst the 
action of stable GTP analogues is unaffected (Bauer & 
Jakobs, 1986).
Activation of G. either via agonist occupied receptors
(H'R.) or directly by guanine nucleotides, e.g. low
concentrations of p[NH3ppG (0.01-luM) (Seamon & Daly, 1982), is
analogous with the activation of G^; dissociation of the
GTP
heterotrimer to yield alpha and beta-gamma. However, beyond 
this point the two routes differ, for it is not clear which G. 
component interacts with the effector.
43.
It has been proposed (Gilman, 1984) that inhibition occurs
by either direct G.alpha interaction with the catalytic unit,
and/or by G. beta-gamma acting to *mop up* G alpha and so 
1 s
prevent activation of C.
i.e.
G alpha*beta*gamma v G alpha +- beta-gammas s
Reaction would be driven to the left by presence
of excess beta-gamma from G.; therefore
inhibition by mass action.
It is probable that G^alpha regulates the activity of the
catalytic unit, at least to some degree. This conclusion arises
from the fact that hormonally-mediated inhibition of C has been
demonstrated in eye S49 cell membranes, which lack functional
Ggalpha (Katada et al.., 1984a). This interaction of G. alpha
with C is thought to occur at a site distinct from that at which
G interacts, as G and G. affect catalytic unit activity in a 
s s i
non-competitive manner (Hildebrandt et al., 1984(a)),
However, because beta(gamma)*s are highly homologous, and 
functionally interchangeable, they do have the potential to modulate 
the activity of different signalling pathways within the same 
cell. The role of G^beta-gamma in attenuating stimulation of 
adenylate cyclase has been studied in a number of systems, including 
platelets and S49 lymphoma cells. Here beta-gamma was observed to 
cause a dose-dependent inhibition of G^-stimulated adenylate 
cyclase activity by reassociation with free alphag (Katada et al,. 
1984a,b). It has also been observed that hormone-independent
adenylate cyclase activity is inhibited to a greater extent by 
beta-gamma subunits than is the hormone-dependent activation (Im et 
al., 1987). This suggests that whilst beta-gamma probably does 
play an important role in inhibiting Gs~controlled adenylate
44.
cyclase, that this role cannot be directly extrapolated to hormonal 
inhibition (Birnbaumer, 1987), i.e. here alpha, will no doubt play 
a role (Katada et al., 1984a), whilst the extent of the contribution 
from beta-gamma is as yet, unclear. Evidence has also been put 
forward which implicates beta-gamma as having a role to play in 
directly inhibiting the catalytic unit i.e. direct beta-gamma-C 
interaction (Enomoto & Asakawa, 1986; Katada et al., 1986).
However, whilst its precise role remains unclear, it has 
been proposed that beta-gamma acts as a general attenuator of the 
actions of all G-proteins operating in the normal membrane 
environment i.e. it will lower the noise of systems coupled by 
G-proteins, and thereby improve the *signal-to-noise* ratio of 
hormonal effects (Cerione et al., 1985). It has even been 
suggested that some systems contain excess free beta-gamma which 
suppresses adenylate cyclase activity (Bokoch, 1987).
One function of beta-gamma which is agreed upon, is that 
its association with the alpha-subunit is essential for efficient 
receptor-catalysed guanine nucleotide exchange, i.e. the 
alpha-beta-gamma heterotrimer must be present. It is therefore 
possible that free beta-gamma might regulate the functioning of 
different G-proteins at two stages:
1. by binding free alpha-subunits and preventing activation of
C, and
2. by stabilising the interaction of the alpha-subunit with
the receptor, and stimulating guanine-nucleotide exchange 
(Weiss et al., 1988).
It has been proposed that these G-proteins, G^ and Gg, 
may be involved in the regulation of effector systems other than 
adenylate cyclase. There is evidence for a direct role of 
G.alpha^^ in potassium-channel regulation (Yatani et al.«
45.
1988b), with conflicting evidence for G. beta-gamma in the same
role (Kira et al., 1989). Other roles for beta-gamma include the
proposed inhibition of calmodulin-stimulated phosphodiesterase
activity (Asano et al., 1986), as well as involvement in the
regulation of phospholipase activity (Jelsema & Axelrod,
1987). G.alpha has also been proposed as having a role to play
in thrombin regulation of phospholipase C activity in platelets
(Crouch & Lapetina, 1988). Although not as many roles have been
implicated for G alpha, this too has been suggested as a regulator
2+
of other systems, such as Ca -channels (Yatani et al^ ., 1988a).
No doubt, other roles will be found in the near future.
Finally, it should be noted that the G-protein, G ,
z
exists in platelets. This protein is most closely related to the
G.alpha family, although it is distinct, having only 66-67%
homology with G^l-3 as regards amino acid sequence (Premont et
al., 1989). It has an M of 41,000 and whilst its function is,r
to date, unknown, it is presumed to be involved in mediating
transduction in signalling systems which are insensitive to
pertussis toxin, i.e. G^alpha cannot be ADP-ribosylated by
pertussis toxin presumably as it lacks the appropriate C-terminal
cysteine residue. In fact, a recent study has shown an isoleucine
residue to replace this cysteine residue (Casey et ai., 1990).
Preliminary work also suggests it is not ribosylated by any other
known bacterial toxin. As G^ is implicated as playing some role
in platelet signal transduction, it may yet materialise that G ,
z
or perhaps some other, as yet, unidentified, G-protein, is involved
in the regulation of platelet adenylate cyclase activity, i.e. in
addition to G and G. (Fig.10). 
s 1
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Figure 10 Scheme for interaction in regulation of
platelet adenylate cyclase activity
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(v) The catalytic unit
The catalytic unit of adenylate cyclase binds MgATP and 
converts this molecule to cyclic AMP. However, whilst the reaction 
catalysed by this component has been known about for many years, it 
is only quite recently that the catalytic unit itself has been 
identified and isolated.
Catalytic units isolated from a number of sources, 
including rabbit heart, bovine brain and rat synaptosomes, yield 
similar molecular weights, i.e. approximately 150kDa (Pfeuffer et 
al., 1985; Monneron et al., 1987; Bender & Neer, 1983). This is 
in agreement with the Mr estimation by target size theory of 
membrane-bound rat liver adenylate cyclase i.e. Mr=150,000 
(Schlegel et al., 1979), Also, the finding that adenylate cyclase 
specifically binds to wheat-germ lectin (Pfeuffer et al., 1985) 
suggests that the catalytic unit is a glycoprotein. This fact, 
coupled with the large Mr of the catalytic unit suggests that this 
component of the adenylate cyclase system may traverse the membrane.
Such an orientation of the catalytic unit in the bilayer 
has very recently been confirmed via cloning studies, i.e. the 
primary amino acid sequence of adenylate cyclase has finally been 
deduced (Schofield & Abbott, 1989). From this information it is 
believed that the protein has a pair of six membrane-spanning 
segments separated by a large (43kDa) cytoplasmic loop, and one 
major extra-celllular loop containing one of the four possible 
glycosylation sites in the sequence. There is also thought to be a 
long (36kDa) cytoplasmic tail, and a short cytoplasmic 
amino-terminal sequence. Thus, most of the protein is located on 
the cytoplasmic side of the membrane (Fig.11). This is in 
agreement with earlier studies on rat liver plasma membranes, which 
by the use of charged anaesthetics to selectively manipulate
Figure 11 Orientation of the catalytic unit in the membrane
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may specify nucleotide binding sites.
membrane fluidity, predicted that the bulk of the catalytic unit was
located in the cytoplasmic side of the membrane, i.e. adenylate
cyclase was sensitive to fluidity changes in the cytoplasmic half of
the bilayer only (Houslay & Gordon, 1983). Although the catalytic
unit is a very minor component of the plasma membrane, accounting
for less than 0.01% of its proteins (Honneron et a l ., 1987), it does
have very specific requirements for its activity.
The catalytic unit has an absolute requirement for 
2+magnesium: Mg -ATP being the true substrate for adenylate
2-i-
cyclase. However, Mg ions also fulfil a regulatory role, as a
second allosteric site exists on the catalytic unit. The existence
of this divalent cation binding site was deduced from the fact that
the catalytic unit is much more active in the presence of manganese
than magnesium, whilst the affinity of the catalytic unit for its
substrate, Me'ATP is the same with either cation. Also, free 
2+Mn activates the enzyme at concentrations greater than that
2+required to convert all the ATP to Mn .ATP. This is consistent 
2+with Mn being able to interact with the catalytic unit both at 
the active site (with ATP) and at a separate divalent cation site 
(Bender & Neer, 1983).
Not only is the activity of the catalytic unit regulated by 
divalent cations, but it is also subject to regulation by the 
calcium-binding protein calmodulin. This is true only in some 
tissues; in fact, in tissues other than the central nervous system, 
the stimulatory effect of calmodulin is weak or absent. Evidence 
actually suggests that in neuronal tissues there are distinct 
calmodulin-sensitive and insensitive forms of adenylate cyclase 
(Cooper & Caldwell, 1988). However, reports that platelet cyclase 
is stimulated by calmodulin (Resink et al., 1986) are actually 
believed to reflect calmodulin antagonising inhibition caused by low
50.
2+Ca concentrations, i.e. calmodulin does not mediate a direct 
stimulatory effect on the catalytic unit in platelets.
Direct interaction at the level of the catalytic unit is 
also one of the modes of action of adenosine. This compound
inhibits adenylate cyclase activity in detergent-solubilised cyclase 
preparations, indicating that it acts at an internal site, and not 
at an external receptor (Londos, 1977). It is believed that this 
GTP-independent inhibition is mediated by adenosine binding directly 
at the so-called 'P'-site on the catalytic unit.
However, probably the most widely used means of directly 
modulating catalytic unit activity is via the use of the diterpene 
forskolin. This compound was discovered in root extracts of the 
plant Coleus Forskohlii(Seamon & Daly, 1981b), and has been found to 
stimulate adenylate cyclase activity in intact cells and membrane 
preparations, including human platelets, where it is a potent 
inhibitor of aggregation (Siegl et al., 1982).
The precise mechanism of action of forskolin is unknown, 
although a number of lines of evidence suggest that it causes 
activation via an allosteric conformational change in the catalytic 
unit (Seamon & Daly, 1986). This direct interaction with the 
catalytic unit is consistent with the enhanced thermal stability of 
the enzyme in the presence of forskolin (Seamon & Daly, 1981b; Awad 
et al., 1983).
It has also been shown that activation by forskolin does 
not require guanine nucleotide regulatory proteins (Seamon & Daly, 
1981a) nor does it require adenylate cyclase to be associated with a 
lipid bilayer. This latter point is suggested by the fact that 
forskolin can activate solubilised adenylate cyclase in the presence 
of ionic and non-ionic detergents. This also suggests that this 
compound does not activate the enzyme by causing perturbations of
either membrane structure, or of the interactions between the 
catalytic unit and phospholipids (Seamon & Daly, 1986). In fact, 
forskolin only begins to have any effect on membrane fluidity at 
concentrations greater than those required to maximally activate 
adenylate cyclase (Whetton et al.., 1983).
As yet, C from eukaryotic tissues is the only enzyme which
has been demonstrated to be directly affected by forksolin (Seamon &
Daly, 1984), This activation is rapid and reversible, resulting in
an increased vmax» without significantly altering the enzyme’s
K for MgATP (Birnbaumer et al., 1983). This activation does not m
desensitise the enzyme with respect to subsequent activation by 
forskolin (Seamon & Daly, 1981a). Low concentrations of forskolin, 
which by themselves have little effect on cyclic AMP levels, 
markedly potentiate the effects of various hormones. However, the 
precise mechanism behind this is unclear (Seamon & Daly, 1984). It 
has been suggested that forskolin acts at two different sites in the 
cyclase system; a low affinity site which is responsible for 
activation of adenylate cyclase, and a high affinity site which is 
responsible for forskolin*s synergistic action with hormones (Nelson 
& Seamon, 1986). It is thought that the low affinity sites 
represent binding to C, and that these sites are numerous, i.e. low 
affinity/high capacity (Shi et al., 1986), whilst the high affinity 
sites are thought to reflect a ternary complex of C, , and 
forskolin. In fact, it is thought that forskolin may act to 
stabilise the complex between Gg and C. This is reflected by an 
increase in the sedimentation co-efficient of solubilised adenylate 
cyclase in the presence of forskolin (Bouhelal et al., 1985).
It has also been reported that low concentrations of 
forskolin have, in some cases, been found to inhibit adenylate 
cyclase (Watanabe & Jakobs, 1985), This inhibition is again 
suggested to be due to a direct interaction with the catalytic unit.
It should be emphasised again that forskolin may not bind
directly to C, and in fact recent evidence has shown forskolin can
modulate a number of membrane transport processes via a cyclic 
AMP-independent mechanism. For example, the diterpene has been 
shown to directly bind to the glucose transporter (Laurenza et al., 
1989). It may, therefore, come to light in the near future that 
forskolin interaction with adenylate cyclase is via a specific, as 
yet unidentified, binding protein (Brooker et al., 1983).
(vi) The effect of manipulating membrane fluidity on adenylate
cyclase activity
As stated previously (Section l.l(ii)), the fluidity of the
plasma membrane is important as regards the activity of integral
membrane proteins. In the case of adenylate cyclase, a number of 
studies have been undertaken (Gordon et al., 1980; Houslay &
Gordon, 1983; Friedlander et al., 1987; De Foresta et al., 1987; 
Cherenkevich et al., 1982; Dipple & Houslay, 1978; Houslay et al., 
1981; Houslay et al., 1980(b)) which show that enhanced membrane 
fluidity augments adenylate cyclase activity. Obviously the 
sensitivity of such penetrant proteins to modulations in fluidity, 
and the degree to which activity is subsequently altered, is a 
property peculiar to an individual protein and its particular 
conformation in the bilayer.
In studies where membrane fluidity is enhanced by the local 
anaesthetic benzyl alcohol (Gordon et al., 1980; Houslay & Gordon, 
1983; Friedlander et al., 1987; De Foresta et al., 1987; 
Cherenkevich et al,, 1982; Dipple & Houslay, 1978), it has been 
shown that the increase in lipid fluidity (both bulk phase and 
annular) effects an increase in adenylate cyclase activity. This 
activation applies to both the receptor-coupled and 
receptor-uncoupled states, and is presumed to result from the
increase in membrane fluidity removing some conformational 
constraint imposed on the enzyme by the membrane (Gordon et al,, 
1980).
However, it should be noted that enzymes such as adenylate 
cyclase, whose activity is augmented by low concentrations of benzyl 
alcohol (40-50mM), are also inhibited at higher concentrations of 
anaesthetic. This inhibition is not a direct result of the 
anaesthetic*s ability to manipulate fluidity, i.e. it is not due to 
the formation of a ’too fluid* lipid bilayer. Rather, such 
inhibition is believed to arise from alcohol competing for sites on 
the protein previously occupied by annular lipid. The displacement 
of such annular lipid would, by this hypothesis, give rise to 
inhibition of activity either because the displaced lipid species 
were essential for activity, or the alcohol when occupying these 
sites is itself inhibitory. This inhibition is characteristic of a 
number of neutral and charged anaesthetics, and is of a reversible 
nature. Clearly, the susceptibility of a protein to such 
inhibition depends upon the strength of lipid-protein interaction, 
and the affinity of the sites for anaesthetic (Houslay & Stanley, 
1982).
In examining the effects of selective perturbations in 
membrane fluidity by charged anaesthetics (Houslay & Gordon, 1983; 
Houslay et al., 1981; Houslay et al., 1980(b)), the coupling state 
of adenylate cyclase will determine whether or not the enzyme 
activity is enhanced by this manipulation of fluidity. In studies 
with rat liver plasma membranes (Dipple & Houslay, 1978), 
receptor-uncoupled activity (NaF-stimulated), was found to exhibit a 
linear Arrhenius plot. This is presumably because in this 
conformation adenylate cyclase experiences the environment of the 
inner half of the bilayer, where no lipid phase separation has been
found to occur (see Section l.l(ii)). This is because the 
functional, globular, domains of both the stimulatory guanine 
nucleotide regulatory protein, and the catalytic unit are postulated 
as residing within this leaflet. Indeed, this is consistent with 
structural predictions which show the active site of adenylate 
cyclase to exist on a loop at the cytoplasmic surface of the bilayer 
(Schofield & Abbott, 1989). In the presence of the appropriate 
hormone, in this case glucagon, the receptor couples, structurally 
and functionally, with the G-protein to form a transmembrane 
complex. As a result of this conformation, the activity of the 
catalytic unit of adenylate cyclase will be modulated by the lipid 
environment in both hemileaflets, Arrhenius plots of such 
receptor-coupled activity are therefore found to exhibit a break at 
28°C reflecting the lipid phase separation of the external leaflet 
(Dipple & Houslay, 1978).
The effects of selective modulations in fluidity can 
therefore be observed by examining hormone-stimulated 
(receptor-coupled) activity in comparison to basal, or 
fluoride-stimulated (receptor-uncoupled) activities (see Diagram 
12). It has been shown that this increased membrane fluidity will 
only amplify the stimulation caused by NaF, if the lipid environment 
of the inner leaflet is altered, i.e. as Gg and C are postulated 
as residing here. With receptor-coupled activity, the presence of 
the transmembrane complex means adenylate cyclase activity is 
regulated by the lipid environment of both halves of the bilayer. 
Amplifying the fluidity of only the external leaflet would have a 
selective effect here, as only the receptor-coupled state would 
experience such changes in the outer half of the bilayer, i.e. there 
would be no effect on basal, or fluoride-stimulated activities 
(Houslay & Gordon, 1983).
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Hence, perturbation of the external leaflet by the anionic 
drug phenobarbital, results in a reduction in the temperature at 
which a break occurs in Arrhenius plots of receptor-coupled 
activity, whilst having no effect on the linear Arrhenius plot of 
receptor-uncoupled activity (Houslay et al., 1981). Similarly, the 
cationic anaesthetic prilocaine selectively amplifies the fluidity 
of the inner leaflet of the bilayer. This preferential 
manipulation of fluidity is reflected in Arrhenius plots of 
adenylate cyclase activity. Here a break is observed in the 
activity plots of both the fluoride- and glucagon-stimulated states, 
reflecting the induction of a lipid phase separation at 16°C in 
the inner leaflet. The break at 28°C observed in Arrhenius plots 
of receptor-coupled (glucagon-stimulated) activity is unaltered, as 
would be expected of a phase separation of the external leaflet 
(Houslay et al., 1980(b)).
It is therefore apparent that adenylate cyclase activity is 
not only sensitive to the fluidity of its membrane environment, but 
that it is possible to selectively modulate this parameter and 
thereby to preferentially alter the activity of chosen adenylate 
cyclase states.
(vii) Insulin and its interaction with the adenylate cyclase
system
Insulin has been shown to reduce the levels of cyclic AMP 
in a number of tissues, including human platelets. This effect is 
mediated by insulins ability to stimulate phosphodiesterase 
activity, and attenuate adenylate cyclase activity. Insulin has no
effect on the rate of cyclic AMP efflux from cells. Exactly how
insulin alters the activity of these enzymes is unclear; the 
regulation of adenylate cyclase being more open to question, and of 
particular interest here.
D! .
The effects of insulin depend upon the recognition and
binding of the hormone by specific plasma membrane receptors.
These receptors have been shown to exist in human platelets at
levels similar to those exhibited by more conventional target
tissues such as liver and adipose tissue, i.e. in the region of 25 
2
sites/uM platelet surface area (Falcon et al., 1988).
Insulin receptors are heterologous molecules, consisting of 
two types of polypeptide chain (alpha and beta) cross-linked by 
disulphide bridges. The holomeric structure is actually a complex 
of around 450kD, consisting of two alpha-subunits of 135kD and two 
beta-subunits of 90kD (Fig.13). Both types of subunit are
glycosylated. However, whether or not the platelet 
insulin-receptor exhibits this characteristic structure is unclear, 
as some reports have suggested that although the beta-subunit is 
unaltered, a typical alpha-subunit may not exist (Falcon et al.,
1988).
In the classical model of receptor activation, the 
alpha-subunit exhibits insulin-binding properties, being exposed at 
the extracellular surface of the plasma membrane. The 
transmembranous beta-subunit exhibits no such activity, but anchors 
the alpha-subunit to the bilayer. However, as the beta-subunit has 
a cytosolic domain, it is involved in eliciting the intracellular 
signal(s) produced upon insulin binding. In fact, insulin binding 
activates an endogenous tyrosyl kinase activity, such that the 
beta-subunit undergoes autophosphorylation (Houslay, 1990).
Exactly how such tyrosine phosphorylation relates to the generation 
of intracellular effects of insulin in unclear. No endogenous 
cellular substrates have been identified, and indeed the bulk of 
cellular phosphorylations occur on serine and threonine residues, as 
opposed to tyrosine.
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It is therefore, apparent that the mechanism by which 
insulin elicits its effects subsequent to receptor-binding are 
unclear. Various methods have been proposed as to how the hormone 
is able to exert such varied effects, both with respect to time and 
variety of substrate (Fig.14).
Amongst these suggestions is the possibility that the 
insulin-receptor tyrosyl-kinase activity is capable of 
phosphorylating the components of the adenylate cyclase system. In 
fact, it has been demonstrated that the alpha and beta-subunits of 
holomeric G-proteins (G. and G^) are capable of being 
phosphorylated in this manner (O'Brien et al., 1987; Krupinski et 
al., 1988; Zick et al., 1986) as is transducin. However, the 
functional significance of this tyrosine phosphorylation is unclear, 
although if may alter the stability of the inactive, holomeric 
states. Insulin may therefore interact and modify signal 
transduction through the G-protein system.
It has also been proposed that insulin-interaction with the
G-protein system may occur via a novel G-protein, termed G^ng*
Indeed, it has been shown in human platelets that insulin actually
stimulates a high affinity GTPase (Gawler & Houslay, 1987). This
novel putative G-protein has an alpha-subunit of 25kD, and
exhibits sensitivity to cholera toxin, whilst it is unable to
undergo ADP-ribosylation by pertussis toxin. The actual
effector/signal generating mechanism which G *ns couples to is
unknown, although it has been postulated as mediating the
insulin-inhibition of adenylate cyclase activity. Such inhibition
could result from direct interaction of G. alpha with them s
catalytic unit of adenylate cyclase, or via the beta-subunit of 
G.^^ attenuating dissociation of Gs (Houslay, 1990: Houslay,
1986), i.e. analogous to G^-roediated inhibition. Alternatively,
Figure 14 A multipathwav mechanism for the action of insulin
phospholipase C
•production of a 
second messenger or 
media t o r •
internalisation of
activation of 
seryl kinase
an autophosphorylated, 
active receptor•
downregulation translocation of 
specific 
vesicule-associated 
proteins
p h o s p h o r y l a t i o n  of G - p r o t e i n s
Tyrosyl kinase activity
\l/
r e c e p t o r
a u t o p h o s p h o r y l a t i o n
Go others c.g 
Gins
T
a signal for interaction 
with other systems and 
for  internalisation ?
\]/
other Intracellular 
proteins which can 
act as targets for 
pho sp ho ry la tion
'A'
function?
central  metabolic  and growth promoting act ions
insulin may inhibit adenylate cyclase activity by more direct 
interaction with Gg, for example by phosphorylating one of its 
components.
Other propositions as to how insulin mediates its effects 
within the cell have included the suggestion that at least some of 
its effects, including the attenuation of adenylate cyclase 
activity, arise due to the production of a chemical 
mediator-substance(s) (Houslay, 1990), Such mediators were 
originally thought to be peptides, although it is now believed that 
they are inositol phosphate oligosaccharides (Mato, 1989). The 
precise composition of these small molecular weight (1-3K) mediators 
remains to be established, but it appears to contain glucosamine or 
galactosamine, galactose and further phosphate linked to the 
inositol phosphate moiety (Houslay & Siddle, 1989).
As these substances can be produced by insulin action on 
membrane fractions, as well as whole cells, this suggests all the 
necessary components are located in the plasma membrane. It is 
possible that the precursor from which these substances arise is a 
glycolipid analogous to the phosphatidylinositol phosphate anchor 
described for a number of membrane-associated proteins (Saltiel & 
Cautrecasas. 1986). Generation of the mediator from such a 
precursor is thought to involve the action of an insulin-stimulated 
phospholipase. How insulin would stimulate such a selective 
activity is again a matter of conjecture (Houslay & Siddle, 1989; 
Saltiel & Cuatrecasas, 1986), as is the mechanism by which such a 
mediator would attenuate adenylate cyclase activity. It has been 
proposed that the mediator could modulate the phosphorylation state 
of adenylate cyclase, as has been found for various other proteins, 
or that the mediator could interact with the G-proteins of the 
adenylate cyclase system (Shirong et al., 1988).
In conclusion, the method(s) by which insulin mediates its
effects is unclear, although various mechanisms have been
proposed. Amongst these suggestions are insulin stimulation of
phosphorylation, interaction with G-proteins, including the novel
G. , or the production of a chemical mediator substance. It may m s
be that insulin modulates adenylate cyclase activity by one or more 
of these methods, or by a method as yet unidentified.
CHAPTER 2
MATERIALS AND METHODS
2. MATERIALS AND METHODS
2.1 Solutions
Double-distilled deionised water was used in the 
preparation of all solutions. pH values were determined using a 
Horiba F.8L pH meter with temperature compensator.
2.2 Chemicals
Chemicals used, and their suppliers, are listed in 
Appendix II.
2.3 Source of human blood for platelet membrane preparations
Blood was obtained from volunteers not undergoing
medication for at least one month prior to donation. 500ml volumes 
were removed from the anticubital vein. Blood was obtained via the 
co-operation of the Blood Transfusion Service, St. Vincent Street, 
Glasgow and Law Hospital, Carluke, Lanarkshire, Scotland,
2.4 Preparation of crude membrane pellets from human platelets
Membrane pellets were prepared from platelets using the
method outlined by Jakobs et al. (1982).
This entailed collecting 10ml aliquots of fresh blood into 
lml of 3.8% (w/v) trisodium citrate and centrifuging at l,000gav
for 5 minutes at room temperature in a Centaur 2 bench centrifuge. 
The supernatant was aspirated and retained and this pooled liquid 
was then centrifuged at 30,000gav for 15 minutes using an MSE-21 
Hi-spin centrifuge and an 8x50ml rotor at 4°C.
The resulting pellet was resuspended in 15ml of lOmM 
Tris/lmM EDTA, pH7.4, using ten up/down strokes with a glass 
Potter-Elvejm homogeniser and teflon pestle and then recentrifuged 
at 30,000gav as before. A wash step was then carried out with 
the pellet being resuspended in 15ml of lOiriM Tris, pH7.4 and 
centrifuged once more. The final * crude membrane pellet* was 
resuspended in lOmM Tris; 2ml of buffer for every 100ml of fresh
o
blood used. This membrane suspension was stored frozen at -80 C 
until required.
2.5 Protein estimations
A modified-form of the method of Lowry et al. (1951) was 
used to determine protein concentrations of the platelet 
membranes. This procedure is as detailed by Peterson et al. (1977) 
and permits the removal of interfering substances from the assay.
This is done by the inclusion of a solubilisation/ precipitation 
step preceding the colourimetric estimation of protein concentration.
Standard solutions of bovine serum albumin were prepared 
covering the range 0-100ug protein ml These, and unknown
protein solutions, were made up to a 1ml volume using distilled 
water and 0.1ml of 0.15% (w/v) deoxycholate was then added to each 
tube. Samples were mixed and incubated at room temperature for 10 
minutes. 0.1ml of 72% (w/v) trichloroacetic acid was then added 
and samples were again mixed. This was followed by centrifugation 
at 3,000gav for 15 minutes at room temperature in a Centaur 2 
bench centrifuge. Supernatants were then decanted and discarded, 
with any excess liquid being removed by aspiration.
Each sample was then made up to a 1ml volume using
distilled water. A *Lowry C* solution consisting of 50ml of 4%
(w/v) Na^CO^ containing 0.4% (w/v) sodium dodecyl sulphate and
lml of 1% (w/v) CuSO. . 5H_0 in 2% (w/v) sodium citrate was then
4 2
prepared. lml of this solution was then added to each tube and 
samples were vortexed and left at room temperature for 10 minutes. 
0.5ml of Folin and Ciocalteu's reagent (diluted 1 to 5 with 
distilled water) was added. Samples were left at room temperature 
for 30 minutes to allow colour to develop and absorbance was read at 
750nm using an LKB spectrophotometer. Samples were measured in 
triplicate and protein concentration was determined using an LKB 
'Wavescan* linear regression curve-fit programme (LKB, Surrey, UK).
2.6 Preparation of cyclic AMP binding protein from bovine
cardiac muscle
The method employed here was essentially as detailed by 
Rubin et al. (1974) and can be considered as 3 distinct stages.
i ) HomoRen i s ati on
Fresh bovine heart was dissected into small cubes, which 
were then finely minced. The resultant •homogenate* was mixed with 
4 litres of 40mM KPO^ buffer, pH6.1, containing 2mM 
beta-mercaptoethanol and further homogenised in a Waring blender. 
This step was performed using small batches of the minced heart and 
homogenisation lasted for approximately 1 minute. The homogenate 
was then centrifuged at 4°C for 10 minutes at 10,000gav and the 
supernatant was filtered through Whatman No.54 filter paper using a 
Buchner funnel and flask under vacuum. The pellet was further 
washed with 1 litre of the KPO^ , buffer and the supernatant again 
filtered. This step was repeated once more and the resultant 
supernatants were combined.
ii) (NH.)^SO. precipitation 4“2— 4 ---- --------
Solid (NHa)„S0, was added to the combined 4 2 4
supernatants until 55% saturation was obtained. (320g
(NH^ , ^ SO^/L) pH was maintained at 7-8 by adding concentrated
(NH,)0H solution. After 2.5-3 hours at 4°C, protein 
4
precipitation had occurred and the precipitate was collected by 
centrifugation at 10,000gav for 10 minutes at 4°C. Having 
discarded the supernatant, the precipitate was dissolved in 500ml of 
50mM Tris/HCl, pH7.6, containing 4mM beta-mercaptoethanol and lOmM 
NaCl. This solution was dialysed overnight against 5 litres of 
Tris buffer (4°C) to remove the (NH.^SO,.
iii) DE-50 cellulose purification
a. Pre-treatment of DE-50 cellulose
50g of DE-50 cellulose (in place of DEAE-Sephadex in 
Rubin*s method) was added to 2 litres of 0.5M HC1 and left for 30 
minutes. This was then washed with distilled water until the pH 
rose to 4 units. The resin was then stirred into 2 litres of 0.5M 
NaOH and left for a further 30 minutes. Once again the DE-50 
cellulose was washed, this time until the eluate was neutral. The 
whole acid/alkali cycle was repeated once more and the resin was 
then equilibrated with 50mM Tris/HCl, pH7.6 containing lOmM NaCl and 
4mM beta-mercaptoethanol. A final slurry was prepared to give a 
wet settled volume: final volume ratio of 2:1.
b. Absorption of the binding protein
The dialysed preparation was mixed with 800ml of 
equilibrated DE-50 cellulose and stirred for 1 hour. Under these 
conditions cyclic AMP-dependent protein kinase activity should be 
absorbed. The mixture was filtered using Whatman No.54 filter 
paper and a Buchner funnel and flask under vacuum. The resin 
collected was then washed with 3 litres of Tris/HCl pH7.6 containing 
lOmM NaCl and 4mM beta-mercaptoethanol, until the filtrate was 
colourless. The resin was then mixed with 200ml of 50mM Tris-HCl 
pH7.6 containing 0.3mM NaCl and 4mM beta-mercaptoethanol for 45 
minutes. The DE-50 cellulose was collected by washing through 
filter paper using 50mM Tris/HCl buffer and a Buchner flask and 
funnel.
c. Isolation of the cyclic AMP bindinR protein
Filtrates from the previous step were combined and
(NH.)_S0. added to give 35% saturation. pH was maintained at 
4 2 4
7-8 units using NH^OH solution and after 60 minutes the mixture 
was centrifuged for 10 minutes at 10,000gav, 4°C. The
precipitate was discarded and the supernatant was brought to 75% 
saturation by adding 258g/litre (NH^^SO^. Again this 
mixture was left for 1 hour and the resultant precipitate was 
collected by centrifuging at 10,000g as before. This time the
8V
pellet was retained, and suspended in a minimal volume of 50mM 
KPO^ pH7 containing 4mM beta-mercaptoethanol. Following 
overnight dialysis at 4°C, against 2 litres of this KPOA buffer, 
the purified protein kinase was stored at -80°C in 250ul 
aliquots. Each preparation was found to be stable for at least 6 
months under these conditions.
2.7 Assay of adenylate cyclase activity
Adenylate cyclase (E.C. 4.6.1.1) was assayed by 2 methods 
as described:
i) Activity was measured as described by Houslay et al.
(1976). Here an assay cocktail was prepared consisting of an
ATP-regenerating system (1.5mMATP, 7.4mg/ml creatine phosphate,
0.2mg/ml creatine kinase and 0.8mg/ml BSA) in a buffer of 25mM
triethanolamine, 5mM MgSO,, lOmM theophylline, ImM EDTA and ImM
4
dithiothreitol, pH7.4. Drugs and membranes (20-100ug) were then 
added as appropriate to give a final assay volume of lOOul.
Samples were then incubated at 30°C for 10 minutes, and 
reactions terminated by boiling samples at 90°C for 3 minutes. 
Centrifugation at 14,000gav for 5 minutes caused the precipitated 
protein to pellet, and the supernatants were then removed for cyclic 
AMP determination (see Section 2.8).
ii) Here activity was measured using the method of Jakobs and
Aktories (1983), which is an adaptation of Salomon et al. (1974).
The reaction mixture consisted of 50uM ATP, 5mM creatine phosphate, 
0.4mg/ml creatine kinase, 2mg/ml BSA and O.lmM cyclic AMP in a 
buffer of 50mM triethanolamine, pH7.4, containing 2mM MgCl^t O.lmM
ethylene glycol bis(beta-amino ethyl ether) N,N*-tetracetic acid,
ImM isobutylmethylxanthine and ImM dithiothreitol.
Reactions were initiated by the addition of platelet
membranes (20-100ug protein) and continued for 15 minutes at 
o 32
25 C. P3ATP (2uCi/tube) was then added and reactions
continued for a further 10 minutes. Again final volumes were
lOOul, Incubations were terminated by the addition of a 'stopping*
solution containing 2% sodium dodecyl sulphate, 40mM ATP, and 1.4mM
cyclic AMP at pH7.5. Cyclic AMP was determined as described by
Salomon et al.. (1974).
2.8 Cyclic AMP determination
Again, 2 methods of determination were employed:
i) Determination of cyclic AMP content in samples assayed for
adenylate cyclase activity by the method of Houslay et al. (1976)
(Section 2.7(i>), was based on the saturation assay of Brown et al.
(1972), as described by Whetton et al^ . (1983).
This depends upon the specific binding of the cyclic AMP
nucleotide to a cyclic AMP-binding protein isolated and purified
from bovine heart, as described in Section 2.6. Samples and
binding protein are incubated together until equilibrium occurs and
bound cyclic AMP is then separated from unbound by the use of a
charcoal/BSA suspension. The. charcoal absorbs free nucleotides and
3therefore estimation of H-cyclic AMP bound to the protein can be 
made.
Using a range of known cyclic AMP concentrations, it is 
possible to construct a standard displacement curve from which 
estimations of cyclic AMP content can be made. This is done by 
incubating increasing amounts of unlabelled cyclic AMP with a fixed 
amount of the tritiated nucleotide, and binding protein. The 
portion of cyclic AMP can in this way be reduced, as the unlabelled
and tritiated species compete for a finite number of binding sites 
on the protein.
Total cyclic AMP binding to the protein is determined by 
incubating the tritiated cyclic AMP in the absence of the unlabelled 
species, whilst non-specific binding is estimated by the incubation 
of tritiated cyclic AMP in the absence of binding protein as well as 
unlabelled cyclic AMP.
For the assay, a series of unlabelled-cyclic AMP solutions
were prepared ranging from 0-320pmoles ml This was done by
dissolving cyclic AMP in a buffer containing 50mM Tris/SmM EDTA,
3
pH7.4. Tritiated-cyclic AMP (5.8- H-adenosine 3*5’ cyclic 
phosphate) in 50% ethanol was diluted in this Tris/EDTA buffer to 
give approximately 500,000cpm/ml. lOOul of this solution was added 
to tubes containing 50ul of assay buffer, and 50ul of standard 
cyclic AMP solution or 50ul of supernatant from samples with unknown 
cyclic AMP content was then added. After mixing, lOOul of binding 
protein, (see Section 2.6, diluted 1:70 with assay buffer) was added 
to the samples, which were mixed once again. Following incubation 
at 4°C for 2 hours, the binding reaction was terminated by 
addition of 0.25ml of a BSA/charcoal suspension. This solution 
consisted of 2% GSX-100 charcoal and 1% BSA suspended in ice-cold 
assay buffer. The charcoal was pelleted from the samples by 
centrifuging at 14,000gav for 5 minutes at a temperature of 
4°C. AOOul of supernatant was removed into *Ecoscint* 
scintillation fluid, and the samples counted in an LKB scintillation 
counter. This counter had an RIA curve fitting programme and hence 
cyclic AMP content was automatically calculated from the standard 
curve. The binding assay gave optimum sensitivity between 0.25 and 
8pmoles/sample.
ii) To determine cyclic AMP content in samples from the
adenylate cyclase assay of Jakobs and Aktories (1983) (Section
2.7(ii)), the cyclic AMP was isolated using the procedure detailed
by Salomon (1974).
Here, lOOul of tritiated cyclic AMP (approx. 20,000 cpm)
was added to samples in order to monitor cyclic AMP recovery.
Reaction tubes were then processed following the addition of 0.75ml
of distilled water. This entailed passing the samples over lml
Dowex-50 AGWX4 resin in 0.4 x 15cm columns. The eluate from this
and two successive lml water washes were discarded. Three
millilitres of water were then added to each column and the eluate
from these columns was then passed directly over 0,6g neutral
alumina (again in 0.4 x 15cm columns). After discarding the
subsequent eluate, these columns were then washed with 4rol of 0.1M
imidazole, pH7.5, and the eluate was collected directly into
scintillation vials. After the columns were completely drained,
12ml of ’Ecoscint* scintillation fluid was added to each vial, and
the samples were counted using an LKB scintillation counter. This
32 3
counter measured both P and H counts in all samples, results 
being expressed in cpm.
Dowex columns could be reused by regenerating with 2 x lml 
IN HCl and washing with 10ml of distilled water prior to use.
Alumina columns could also be reused if equilibrated with 0.1M 
imidazole (8ml) prior to use.
2.9 Lubrol-solubilisation of adenylate cyclase
Membrane protein was solubilised using the method of 
Swislocki and Tierney (1975), This entailed adding approximately 
30mg of protein to 4ml of a solubilising solution containing 
Lubrol-PX (40mM), 0.25M sucrose and ImM EDTA, in 50mM Tris/HCl, 
pH7.4. This suspension was then mixed by inversion and left on ice
for 10 minutes. The sample was then centrifuged for 1 hour at 
165,000gav at 5°C on a Beckman TL-100 benchtop ultra- 
centrifuge. Adenylate cyclase activity was present in the 
supernatant fraction produced. The supernatant was therefore 
retained and used in assays of adenylate cyclase activity. This 
fraction was prepared afresh for each experiment.
2.10 Phosphodiesterase assay
Phosphodiesterase activity in platelet membranes was
3
measured by the method of Rutten et al. (1973). Here H-cyclic
3
AMP (8- H-adenosine 3*5*-cyclic phosphate) was diluted in 20mM 
Tris/HCl, pH7.4, containing 5mM MgCl^ and luM cyclic AMP. 50ul 
of this solution (approx. 0,2uCi) was then added to tubes containing 
15-30ug membrane protein, and the volume made up to lOOul using 20mM 
Tris/HCl, pH7.4, containing 5mM MgCl^ and ImM cyclic AMP.
Samples were then incubated at 30°C for 10 minutes, and boiled for 
2 minutes to terminate the reaction.
After being allowed to cool, 25ug of snake venom 
(OphiphaRus hannah-cobra. lmg/ml in H^O) was added, and the 
samples were again incubated at 30°C for 10 minutes. 400ul of 
Dowex AG I-X2 in ethanol/water (1:1:1) was then added and following 
incubation on ice for 15 minutes, the samples were then spun at 
15,000gav for 2 minutes on a Beckman benchtop microcentrifuge.
150ul of supernatant was then removed into 4ml of *Ecoscint'
3
scintillation fluid. The amount of H-adenosine present was 
determined by counting on an LKB scintillation counter.
32
2.11 Preparation of gamma- P GTP
GTP was radioactively labelled at the gamma-phosphate 
position using the method detailed by Maxim and Gilbert (1980).
The principle here can be outlined as:
 ^ . . __  phosphoglvcerate kinaseva) Glycerate-3-phosphate +■ GTP 7 ;| ■
1,3 diphosphoglycerate ■+• GDP
b) 1,3 diphosphoglycerate Glyceraldehyde JLs QiyCera^(jej1yCje_3 _p
phosphate dehydrogenase +• P.
3-phosphoglycerate kinase [E.C. 2.7.2.3] catalyses the
reversible conversion of glycerate-3-phosphate to 1,3
diphosphoglycerate using GTP (or ATP) as the phosphate donor. The
1,3-diphosphoglycerate can be further converted to glyceraldehyde-3-
phosphate in the presence of the enzyme glyceraldehyde-3-phosphate
32dehydrogenase [E.C. 1.2.1.12). P-labelled inorganic phosphate
is also produced in this reaction, but under the conditions
employed, the position of equilibrium is shifted so far to the left 
32that this P. is incorporated into the 1,3 diphosphoglycerate
and subsequently into GTP at the gairana position. Theoretically, a
32 32
78% conversion of the P. to [ PjGTP is possible; 70-75%
conversion was actually obtained.
The method employed involves 4 major stages, which entail
washing commercially bought enzymes, incubation of the reaction
mixture, PEI-cellulose thin-layer chromatography to identify and
32quantify products, and finally purification of the gamma[ P]GTP 
by ion-exchange chromatography.
i) Removal of (NH^)^SO  ^ from commercial enzyme
preparations
This step is included in order to remove traces of
inorganic phosphate which would reduce the percentage conversion of 
32 32[ P]P. into gamma[ P)GTP, and also to remove residual 
(NH.)^SO. which would inhibit the reaction.
Here 12.5ul of yeast 3-phosphoglycerate kinase (specific 
activity approx. 4.5U/ul) was combined with 32.5ul of 
glyceraldehyde-3-phosphate dehydrogenase (rabbit muscle, SA approx. 
0.8U/ul) in a 1.5ml Eppendorf tube on ice. This was then 
sedimented by centrifugation at 14,000g for 5 minutes at 4°C, and 
the supernatant was removed and discarded. The sediment was very 
gently resuspended in 50ul of *wash buffer* i.e. lOOmM Tris/HCl, 
pH8, containing ImM EDTA (pH8), O.lmM NAD*, 3.2M ( N H ^ S O  
and lOmM beta-mercaptoethanol. This was then sedimented by 
centrifugation as before, and washed and recentrifuged again. The 
walls of the Eppendorf tube and the top of the pellet were then 
carefully washed with 12.Sul of distilled water, at all times trying 
not to disturb the pellet. Finally, the enzymes were centrifuged 
once more, and all supernatant was discarded. The pellet was very 
gently resuspended in 37.5ul of distilled water and placed on ice.
ii) Incubation of the reaction mixture
32
Before using { P]P., the inorganic phosphate
(specific activity lmCi/lOOul) was neutralised by adding lOul of
500mM NaOH and mixed using a heat-sealed glass capillary tube.
50ul of a 10 x concentrated solution of (final concentrations) 500mM
Tris/HCl (pH8), 50mM MgCl^t 20mM reduced glutathione, 10mM
glycerate-3-phosphate, ImM EDTA (pH8), and 0.1M NAD*, was added to
32500ul of neutralised I P]-inorganic phosphate.
5ul of 4mM GTP and 2ul of the washed enzyme suspension 
were added to initiate the reaction, and the mixture was gently 
mixed and incubated at room temperature for 20 minutes. The 
reaction was terminated by placing the sample on ice.
iii) PEI-cellulose thin layer chromatography
A 10x20cm sheet of PEI-cellulose was pre-run in distilled
water to take most of the yellow soluble material to the top* The
plate was then dried, and marked in pencil into 10x5cm rectangles,
with an origin line 1.5cm from the bottom. These rectangles were
cut out and stored at 4°C prior to use.
lul reaction mixture samples were spotted onto these
plates immediately prior to initiation of the reaction, and
immediately before its termination. The plates were left to dry at
room temperature for 5 minutes, and the placed in a chromatography
tank containing 10ml of 0.75M KH^PO^ buffer (pH3.5). The
buffer was allowed to travel about three-quarters of the way up the
plate (approx. 30 minutes), allowing excellent separation of GTP
from P.; P. runs near the front, and GTP has an R_ in the 
1 1  f
region 0.15-0.20.
The relative amounts of radioactive GTP and P. were
l
determined by developing an autoradiograph of the dried 
PEI-cellulose plate, and cutting out the appropriate areas for 
Cerenkov counting using a wide-open channel setting on an LKB
scintillation counter. From these counts it was possible to
32 32
calculate the %-conversion of S81™1*8 I P]GTP.
32It was also possible to ensure that I P3-labelled
32
inorganic phosphate had actually been converted to gamma[ P]-
labelled GTP by using a charcoal slurry. Here, lul samples were 
removed from the reaction mixture at 0 and 20 minute incubation 
times into 200ul of 50mM NaPO^, pH7. lOOul of this mixture was 
removed into an Eppendorf tube, and 0.5ml of a 5% slurry of Nor it A 
charcoal (in 50mM NaPO., pH7) was added. After vortexing, the 
suspension was centrifuged for 5 minutes at 14,000gav at 4°C.
0.4ml of supernatant was added to 3ml of *Ecoscint* scintillation
/ D»
fluid* and counted in an LKB scintillation counter. Under these 
conditions the charcoal is saturated with unlabelled inorganic 
phosphate* therefore it is possible to separate radioactive GTP from 
radiolabelled inorganic phosphate by specific absorption to the 
charcoal.
The 0 minute reaction mixture sample allows the 
determination of non-specific binding to the charcoal by P..
This 'blank* can then be subtracted from all other samples. Use of 
this relatively quick method enables continuation of the preparation 
to the purification stage without having to wait for the 
PEI-cellulose chromatography quantification to have reached 
completion.
32
iv) Purification of the [ P3GTP
32The [ P]-labelled GTP was purified by anion exchange 
using Dowex 1-X2 (100-200 mesh* Cl form) as the chromedia. The 
resin was washed before use. This entailed suspending 50g of Dowex
resin in 1.5L of 1M NaOH for 30 minutes, and then filtering on a
large Buchner funnel. The resin was washed with 5L of distilled 
water to remove NaOH, and then suspended in 1.5L of 1M HCl for 30 
minutes. The Dowex was then filtered and washed as before.
A 3cm column of this washed resin was then poured in a 
glass Pasteur pipette which had been 'plugged* with some siliconised 
glass wool. After washing the column with 5ml of 1M NaCl* and 10ml
of distilled water, the sample was applied. A further 5ml of water
was then added* followed by 10ml of 0.02M NH^Cl/0.02M HCl to elute 
inorganic phosphate, GMP and GDP. Any ammonium ions were removed 
from the column by washing with 5ml of water, and the GTP was then 
eluted by applying 15 aliquots of 0.25M HCl (0,75ml). These eluted 
fractions were collected in Eppendorf tubes containing 0.25ml of 1M 
Tris (pH9).
Fractions were counted by Cerenkov counting, and the peak
fractions (usually tubes 2-14) were pooled, aliquoted, and stored at
-20°C. Using the Norit A charcoal method outlined previously,
samples of the final GTP were found to be 95% absorbable.
32The specific activity of the [ P]-labelled GTP produced
was calculated by the following equation:-
32
% conversion x mCi [ P) used
= Radioactivity/20nmoles GTP
2.12 Assay of GTPase activity
GTPase activity was measured as described by Houslay et
al. (1986(b)), which is a modification of the original method
described by Cassel and Sellinger (1976).
32
The assay system contained O.luM [ PJGTP, 5mM MgCl^,
lOOmM NaCl, ImM dithiothreitol, O.lmM EGTA, ImM ouabain and ImM
App[NH}p in a buffer of 50mM Tris/HCl, pH7. A regeneration system
of ImM ATP, 5 units of creatine kinase, and 12mM creatine phosphate
32was also present, in order to suppress the transfer of gamma- P 
from GDP to ADP. The final assay volume was lOOul, with drugs 
being added as appropriate. Reactions were initiated by the 
addition of platelet membranes, and after vortexing, the cocktail 
was then incubated for 5 minutes at 30°C. The assay was 
terminated by the addition of 500ul of a 2% slurry of Norit A 
charcoal in 50mM KPO^ buffer, pH7. Samples were then vortexed,
and spun at 14,000gav for 5 minutes.
0.4ml of supernatant was removed from the samples, and 
counted by Cerenkov counting on an LKB scintillation counter using a 
wide-open channel setting.
2.13 SDS-PAGE electrophoresis
Electrophoretic separation of proteins was carried out in 
10% polyacrylamide gel slabs as described by Laemmli (1970).
Firstly, samples were dissolved in a buffer of 0.0625M Tris/HCl, 
pH6.8 containing 2% SDS, 10% (v/v) glycerol, 5% (v/v) 
mercaptoethanol and 0.1% (v/v) bromophenol blue as the tracking 
dye. They were then boiled for 1 minute prior to application, and 
electrophoresis was carried out at room temperature in a 'running 
buffer* of 0.025M Tris/HCl, pH8.3, containing 0.192M glycine and 
0.1% SDS. When the dye front reached the edge of the gel, 
electrophoresis was stopped, and proteins transferred to 
nitrocellulose paper by Western Blotting (Section 2.14).
2.14 Western Blotting
Proteins were transferred from gel to nitrocellulose paper 
using constant current, and 100 volts for 90 minutes in a Bio-Rad 
transblot apparatus. This method is essentially as detailed by 
Huff et al, (1985). Buffer used here is 0.025M Tris with 0.192M
glycine/methanol (4:1 v/v). The nitrocellulose paper was then
incubated at room temperature in 20mM Tris/HCl, pH7.5, containing 
500mM NaCl (i.e. TBS) and 3% dried milk powder. After 90 minute
incubation to block non-specific protein binding, the dried milk 
powder/TBS is removed, and the 'blot* washed thoroughly with 
distilled water. The paper was then incubated overnight in the 
same buffer containing 1% dried milk powder, 0.05% thimerasol, and a 
1:200 dilution of the appropriate antisera.
The antisera used in these studies (Section 3.1) were AS7 
and RV6, which detect alpha-G^, and G-protein beta-subunits 
respectively. Antiserum AS7 was raised in rabbits against a 
synthetic decapeptide (KENLKDCGLF) representing the carboxy-terminus 
of the alpha-subunit of rod transducin. This peptide was
conjugated with keyhole limpet hemocyanin. The resultant anti serum 
was affinity purified and is specific for the alpha-subunits of 
transducin and G^. Transducin does not occur in platelets, RV6 
antiserum was prepared in rabbits using a purified beta-subunit 
polypeptide. This anti serum reacts strongly with all known 
G-protein beta-subunits in platelets.
Next day, the blot was washed with distilled water, 
Tris/HCl with 500mM NaCl, and 0.5ml/L Tween 20, (i.e. TTBS) and 
finally Tris/HCl with 500mM NaCl. Following these washes, the 
paper was incubated with a second antibody (lug of 
peroxidase-conjugated goat, antirabbit immunoglobulin/ml) for 2-3 
hours at room temperature.
After repeated washings (as before), papers were stained 
in lOmM Tris/HCl, pH7.5, 0.025% hydrogen peroxidase, and a small 
volume of 1% orthodianisidine-HCl. Following the appearance of 
protein bands, the colour reaction is stopped by rising with 
distilled water.
2.15 Concentrating protein samples
Where the protein content of samples was too dilute, i.e. 
would require use of large volume of material, these samples were 
made more concentrated using the following procedure.
First, the volume of sample containing the required amount 
of protein was made up to 150ul with distilled water, 6,25ul of a 
2% solution of deoxycholate was then added to solubilise proteins, 
and this was followed by the addition of 0.75ml of distilled 
water, 250ul of a 24% (w/v) solution of trichloroacetic acid was 
then added to precipitate proteins, and samples were spun at 2,500 
rpm on a benchtop microcentrifuge. The supernatant was removed 
from the tubes, and pellets were then resuspended in Tris base (1M) 
to give the volume of sample required.
2.16 Release of G-protein subunits from platelet membranes
Here platelet membranes, prepared as described previously 
(Section 2.4), were incubated in a buffer of 20roM Tris/HCl, pH7.5, 
20mM MgCl^, ImM dithiothreitol and lOOuM EDTA, at 30°C for 10 
minutes. Ligands were added as detailed elsewhere (Section 3.1).
At termination of incubation, 25ug of soyabean trypsin inhibitor was 
added as a soluble carrier protein. Samples were then spun at 20 
psi^ (approx, 126K x. g) for 2 minutes, using a TL100 (30°) rotor in 
a Beckman airfuge. This was to resolve them into supernatant and 
particulate fractions.
The protein in the supernatant fraction was collected by 
deoxycholate/trichloroacetic acid precipitation (Section 2.15), and 
then resolved by SDS-PAGE as described previously (Section 2.13). 
Protein from membrane pellets was solubilised with Laemmli ’loading 
buffer* (Section 2.13) and added directly to the gels.
Immunoblotting of the resolved proteins was as described previously 
(Section 2.14).
Essentially this method is as described by McArdle et al.
(1988).
2.17 Fusion of acidic phospholipid-liposomes with platelet
membranes
Fusion of dioleoylphosphatidic acid liposomes, dioleoyl- 
phosphatidylcholine liposomes, and dioleoylphosphatidylserine 
liposomes was performed using the following procedure, based on the 
method described by Houslay et a^, (1986(c)).
Firstly, a sonicated phospholipid suspension was made.
This involved taking 0.5-4mg of solid phospholipid and dissolving it 
in 0.5ml of chloroform/methanol (2:1 v/v) in an acid-washed glass 
scintillation vial. The solvent was then evaporated off under a 
stream of nitrogen, and 1ml of 50mM-triethanolamine/HCl
80.
(N^-saturated), pH7.4, was added. The vial was sealed with 
parafilm, capped, and shaken for 20 minutes at 8°C. Following 
this, the sample was then sonicated to optical clarity using a bath 
sonicator, kept below 20°C, for 2 hours. The suspension was 
centrifuged at 15,000gav for 1 minute, and this suspension was 
then used to incubate with the platelet membranes.
Pre-incubation of membranes at 8°C for 20 minutes was 
performed prior to addition of the liposomes. After the liposome 
suspension was added to the membranes this mixture was then 
incubated at 8°C for 45 minutes, following which this was used in 
the determination of adenylate cyclase activity.
2.18 Cholera toxin catalysed ribosylation of platelet membranes
(a) Pre-activation of cholera toxin
lOOul of cholera toxin (lmg/ml) was added to lOOul of 40mM 
dithiothreitol. Following mixing, this solution was incubated at 
30°C for 20 minutes. Incubation was terminated by placing the 
sample on ice.
(b) Cholera toxin ribosylation
500ul of ribosylation cocktail (ImM GTP, 2mM NAD+ , 30mM 
thymidine and lOOmM KPO^, pH7.4) was added to the pre-activated 
cholera toxin sample. 300ul of platelet membranes (approx. 2.5mg 
of protein) were then added, mixed, and incubated at 30°C for 10 
minutes. Centrifugation at 14,000g for 15 minutes (4°C) was 
followed by washing of the pellet in 500ul distilled water. This 
procedure was repeated, and the pellet finally resuspended to the 
required volume in lOmM Tris/HCl, pH7.4.
2.19 Pertussis toxin catalysed ribosylation of platelet
membranes
(a) Pre-activation of pertussis toxin
lOOul of pertussis toxin (500ug/ml) was added to lOOul of 
40mM dithiothreitol. Following mixing, this solution was incubated 
at 37°C for 45 minutes. Incubation was terminated by placing the 
sample on ice.
(b) Pertussis toxin ribosylation
500ul of ribosylation cocktail (ImM GTP, 2mM ATP, 2mM
NAD+, 30mM thymidine and lOOmM KPO^, pH7.4) was added to the
pre-activated pertussis toxin sample. 300ul of platelet membranes
(approx. 2.5mg of protein) were then added, mixed, and incubated at
37°C for 30 minutes. Centrifugation at 14,000g for 15
av
minutes (4°C) was followed by washing of the pellet in 500ul 
distilled water. This procedure was repeated, and the pellet 
finally resuspended to the required volume in lOmM Tris/HCl, pH7.4.
CHAPTER 3
PLATELET ADENYLATE CYCLASE AND THE MEMBRANE ENVIRONMENT
General Introduction
This chapter describes the characterisation of the 
platelet adenylate cyclase system with respect to stimulation and 
inhibition by various agents. The effects of manipulating membrane 
fluidity on ligand-regulated enzyme activity is investigated. Such 
modulations in fluidity were achieved by various means, namely 
through the use of charged anaesthetics, neutral anaesthetics, 
acidic phospholipids, and dimethylnitrosamine. However, the bulk 
of this work centres around studies employing the local anaesthetic 
benzyl alcohol.
83.
3.1 The platelet adenylate cyclase system and benzyl alcohol
(i) Introduction
Stimulatory aspects of adenylate cyclase regulation have
been examined in detail in other systems (Ruiz et a l ., 1986; Nelson 
& Seamon, 1985), most notably, rat liver plasma membranes. Here 
such studies have been extended to the human platelet, where 
regulation at the level of each component is examined. This is 
achieved via the use of different ligands:
- activation at the level of the catalytic unit was
 Zj
determined by the use of the diterpene forskolin (10 M), which is 
believed to augment basal adenylate cyclase activity by direct 
interaction with C (see Section 1.3(v)).
- sodium fluoride (15mM) is thought to mimic the terminal 
phosphate moiety and so, in combination with GDP bound in the active 
site of Gg, will stimulate adenylate cyclase. Such activation
via Gg is not the only mode of NaF action; this ligand is also 
capable of attenuating hormone-stimulated adenylate cyclase, as will 
be discussed.
- stimulation at the level of the receptor. Rg, was
examined by two routes: (a) the PGI^/PGE^ prostanoid receptor,
_5
through the use of prostaglandin E^ (2x10 M), and to a lesser
extent through (b) the beta-adrenoceptor, by the use of the
-4beta-agonist isoproterenol (10 M).
In each case, the effect of adding these ligands was 
determined by monitoring cyclic AMP production. By similar means, 
the effect of adding inhibitory ligands was also determined. Much 
less is known about inhibitory aspects of regulation, to the point 
that the actual mechanism of inhibition is unclear, i.e. is it 
direct G^ alpha interaction with the catalytic unit, or is it via 
G. beta-gamma association with G^ alpha? (see Section 1.3 
(iv)). It is this aspect of adenylate cyclase regulation which forms 
the basis of this chapter.
Inhibition was investigated both at the level of the
inhibitory G-protein G. , using low concentrations of the
—8 —6
non-hydrolysable GTP-analogue Gpp(NH)p (10 M or 10 M), and at
the level of the inhibitory alpha^-adrenoceptor, through the use
-4 -6
of adrenaline (10 H) in the presence of propranolol (10 H) to
block beta-adrenoceptor functioning.
As all of the stimulatory/inhibitory effects upon
adenylate cyclase activity are believed to involve the interactions
of distinct components within the platelet membrane, it was decided
to extend the characterisation of this adenylate cyclase system to
include the influence of the membrane environment on its activity.
In this section, the membrane environment has been manipulated
mainly by the use of the local anaesthetic benzyl alcohol (0
-50mM). This neutral compound was previously shown to enhance
fluidity, and augment stimulatory aspects of adenylate cyclase
regulation (Houslay & Gordon, 1983; Dipple & Houslay, 1978). The
effect on benzyl alcohol as regards inhibitory regulation of
adenylate cyclase activity has not been reported. Here we attempt
to determine this effect, and in subsequent chapters, to look at the
effects of other means of manipulating the membrane environment.
< i i > Results
Adenylate cyclase activity was assayed by the method of
Houslay et al,, 1976 and cyclic AMP production was measured as
detailed by Brown et al,, 1972 (see Materials & Methods Section 2,7
and 2,8 respectively).
Any changes in the level of cyclic AMP detected here are
believed to reflect modulations in adenylate cyclase activity, and
not platelet phosphodiesterase (PDE) activity. This is because all
experiments were performed in the presence of the phosphodiesterase
inhibitors theophylline (8mM) and isobutylmethylxanthine (IBMX,
ImM). Such concentrations gave 97.9 + 0;84% and 99.4 + 1.06%
inhibition of phosphodiesterase activity. (n=3 separate
experiments using different membrane preparations).
In examining the stimulation of adenylate cyclase
activity, it was found that activation by the various ligands
employed here exhibited the same trends as observed in other
systems. Figures 15-18 show dose effect curves for ligands which
interact with the catalytic unit, G and R , respectively ands s
illustrate that saturation is obtained. This suggests that, in
each case, a finite number of binding sites exists, whilst the
sigmoidal nature of the curves suggest single-types of binding
site. The ECL^ for activation by these ligands are shown in 
50s
Table 3. It should be noted that NaF was also capable of 
attenuating adenylate cyclase activity: ^or inhibition of
PGE^ is 3,02mM. In all further experiments, saturating 
concentrations of these ligands were used.
A more extensive characterisation of the stimulatory 
aspects of adenylate cyclase regulation is shown in Table 4. Here, 
it is apparent that the ability of these various ligands to 
stimulate adenylate cyclase activity is markedly different, with
PGE1 and forskolin being the most potent activators. This is in 
agreement with other studies (Insel et tQ., 1982).
In order to determine that the activation observed with 
forskolin was indeed due to a direct interaction at the level of the 
catalytic unit, the effect of detergent-solubilisation of adenylate 
cyclase was examined. Following the solubilisation procedure, 
detailed in Materials and Methods Section 2.9, the activities shown 
in Table 5 were obtained. High specific activities observed here 
are due to the fact that experiments were performed in the presence 
of manganese rather than magnesium. From these results it can be 
seen that forskolin is the only ligand able to stimulate the 
solubilised enzyme significantly. This suggests that forskolin 
does not mediate its effects via binding to some other membrane 
component, (i.e. other than the catalytic unit), nor does it 
activate adenylate cyclase by a perturbation of membrane structure.
It should also be noted that another ligand, namely 
adenosine (10 ^M) was able to modulate the activity of the 
solubilised enzyme. In the absence of GTP, adenosine was found to 
inhibit forskolin-stimulated adenylate cyclase activity by 
46.3% + 8.8, for the membrane-bound state. Lubrol-solubilised 
adenylate cyclase was found to be similarly inhibited, i.e.
48.3% + 3.4 inhibition, suggesting that adenosine inhibition is at 
the level of the catalytic unit P-site.
The effect of manipulating the membrane environment 
through the use of benzyl alcohol is reflected in the activity 
profiles shown in Figures 19-23. Concentrations of up to 50mM 
benzyl alcohol were employed, as over this range the anaesthetic has 
been shown to partition into biological membranes. At circa 50mM 
benzyl alcohol, it appears to elicit an increase in bilayer fluidity 
which is equivalent to a temperature rise of approximately 6-8°C
in various model and biological membranes, including human platelets 
(Houslay & Gordon, 1983). Here the effect of the anaesthetic is 
examined at each level of stimulation.
Figure 19 shows that benzyl alcohol enhanced basal 
adenylate cyclase activity, such that 300% activity was observed at 
optimal anaesthetic concentrations i.e. a 3-fold increase in 
activity. An almost identical profile was obtained for 
NaF-activated adenylate cyclase, i.e. at the level of G
s
(Fig.20). However, examining the effects of benzyl alcohol on 
receptor-stimulated adenylate cyclase yielded different profiles 
depending on which hormone was used. Figure 21 shows that where 
beta-adrenoceptor-stimulated activity was observed, through 
isoprenaline-stimulation, a similar profile to that observed 
previously was obtained. On the other hand, activation via the 
PGE^-receptor, did not exhibit such a profile. Here activity was 
enhanced to only approximately 150% of original values (Fig.22). 
Indeed, looking at the effect of benzyl alcohol on the 
fold-stimulation these ligands exerted showed that the anaesthetic 
had little effect on the fold-stimulation (stimulated/basal activity 
ratio) of adenylate cyclase activity elicited by either isoprenaline 
or NaF (Table 6). However, the presence of benzyl alcohol 
decreased the fold-stimulation of adenylate cyclase activity by 
PGE^. Examining the for PGE^-activation showed it to be
altered by the presence of benzyl alcohol; being 0.28 ±  0.09uM in 
the absence of benzyl alcohol, and 0.85 + 0.02uM in the presence of 
benzyl alcohol. (Figures are mean + S.D., for n=3 separate 
experiments using different membrane preparations).
From Figure 23 it can be seen that the profile obtained 
for benzyl alcohol action on forskolin-stimulated adenylate cyclase 
was different from that obtained for all other stimulatory
ligands. Here, increasing concentrations of benzyl alcohol led to 
a progressive inhibition of enzyme activity. When a 
lubrol-solubilised extract of platelet membrane was used, benzyl 
alcohol at concentrations up to 50mM, failed to affect basal 
adenylate cyclase activity (less than 5% change). In contrast, 
forskolin-stimulated soluble adenylate cyclase was still inhibited 
by the anaesthetic; a 31% reduction in activity was observed at 
50mM. Benzyl alcohol exerted little effect on the value for
activation of platelet adenylate cyclase by forskolin, which was 25 
+ 7uM in the absence of benzyl alcohol, and 23 + lOuM in its 
presence. (n=3, separate experiments using different membrane 
preparations). Figure 24 illustrates this point.
The effect of benzyl alcohol on forskolin-stimulated 
adenylate cyclase is thought to reflect a direct action of the local 
anaesthetic. This is because other methods of manipulating 
fluidity, e.g. by increasing temperature, gave rise to a forskolin 
profile which was identical to other stimulatory ligands (compare 
Figs,25,26).
It should be noted that benzyl alcohol, at the 
concentrations used in this study, had no effect on linearity (See 
Figs.27-29).
G^-mediated effects on adenylate cyclase were examined 
under conditions where this inhibitory G-protein was activated 
either directly, through low concentrations of GppNHp, or 
indirectly, via occupancy of the alpha^-adrenoceptor, Thus, in 
one instance, adenylate cyclase was first stimulated by PGB^
(2x10 ^M), and inhibition was then achieved through the 
alpha^-adrenoceptor route by the use of adrenaline (lOOuM) in the
presence of propranolol (lOuM) to block beta-adrenoceptor 
functioning. This resulted in a 79.5 + 1.1% inhibition of activity 
(n=5; results are mean + S.D.). Alternatively, forskolin was used 
to enhance the activity of the catalytic unit, and inhibition was 
elicited by using either adrenaline/propranolol (50.0 + 3.55% 
inhibition), or low concentrations of GppNHp (O.OluM), which 
selectively activate G^ (53,5 + 5.0% inhibition).
When either GppNHp or adrenaline (+ propranolol) was used 
to inhibit forskolin-stimulated adenylate cyclase, then increasing 
benzyl alcohol concentrations had no discernible effect on the 
degree of inhibition elicited (Figs,30,31 respectively). Indeed, 
the for inhibition of forskolin-stimulated adenylate cyclase
by GppNHp was 0,20 ±  0.04uM in the absence of benzyl alcohol, and 
0.28 ±  0.05uM in the presence of 50mM anaesthetic (n=3; results are 
mean + S.D.), In contrast to this however, increasing benzyl 
alcohol concentrations diminished the ability of adrenaline (+ 
propranolol) to inhibit PGE^-stimulated enzyme activity 
(Fig.32). The attenuating effect of benzyl alcohol exhibited an 
IC^q of 12.5 ±  4.2mM (n=6; results are mean + S.D.), At 50mM 
benzyl alcohol, the inhibitory effect of adrenaline (+ propranolol) 
was decreased from a 79% inhibition of activity to approximately 52% 
inhibition of activity. Examining the effect of benzyl alcohol on 
adrenaline-stimulated GTPase activity showed that no detectable 
change in activity could be recorded at concentrations of 
anaesthetic in the range 0-50mM (Fig.33). The was observed
to increase from 57 + 15uM in the absence of benzyl alcohol, to 130 
+ 38uM in its presence (n=4 separate experiments using different 
membrane preparations. Figures are mean + S.D.; results are
significantly different at p<^0.01).
The presence of manganese (in excess of lmM) in an assay
is believed to prevent G. from inhibiting adenylate cyclase
(Hoffmann et al.., 1981). This condition is employed here with
regard to the effect of benzyl alcohol on adrenaline (+ propranolol)
inhibition of PGE^, i.e. to ensure that the observed phenomenon is
due to an effect at the inhibitory G. component. When adenylate
24-cyclase assays were performed in the presence of Mn (5mM) rather 
24-than Mg (5mM), the PGE^-stimulated activity was increased by
some 2.01-fold (Table 7). Here the presence of adrenaline (4-
propranolol) in the assay elicited only a 16 ±  4% inhibition of
PGE^-stimulated activity, compared with 79 ±  5% seen in its
absence (Fig.32). Both of these observations are compatible with a
24-
loss of functional G. . Indeed, when Mn was used in the 
assay, the dose-effect curves for PGE^-stimulated activity to 
benzyl alcohol were very similar, whether or not adrenaline (+ 
propranolol) was present (Fig.34). Such observations not only 
apply to adrenaline-mediated inhibition of PGE^ but can be 
extended to adrenaline- and GppNHp-mediated inhibition of forskolin 
also. In fact, on average, the degree of inhibition elicited by 
these ligands was reduced by 75% + 16.8 (results are mean + S.D., 
for n=8 separate experiments using different membrane preparations) 
by replacing the divalent cation in this manner. Similarly, from 
Table 7 it can be seen that the Mn/Mg ratio for forskolin was 
augmented to a similar extent to that witnessed with PGE^. The 
addition of benzyl alcohol altered the Mn/Mg ratios significantly; 
PGE^ ratio was reduced, whilst that for forskolin-stimulated 
activity was enhanced (see Table 7).
Once again, to be certain that the effects of benzyl 
alcohol on inhibitory aspects of regulation were due to the 
anaesthetic, it was attempted to manipulate the membrane environment
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through increasing temperature by an amount equivalent to that 
change expected to be exerted by benzyl alcohol, i.e. 6-8°C.
Here, no such decrease in the ability of adrenaline to attenuate 
PGE^-stimulated activity was observed (Table 8).
All of the actions of benzyl alcohol were reversible upon 
dilution or washing the membranes to remove this ligand.
It has been proposed that treatment with benzyl alcohol 
may lead to a loss of components of the G. system from the 
membrane. Here the result of imsminoblotting is shown in Figure 
35. No change (less than 8%) occurred in the amount of alpha-G. 
present in platelet membranes treated with 50mM benzyl alcohol in 
the presence or absence of PGE^ and adrenaline (+- propranolol). 
Similarly, no immunoreactive material was found to be released into 
the supernatant fractions of platelet membranes treated with 50mM 
benzyl alcohol. Essentially identical results were found by using 
the anti serum to detect G-protein beta-subunits.
FiKure 15 Forskolin-stimulated activation of adenylate cyclase 
Values are mean + S.D. of a single representative 
experiment employing triplicate observations.
Activity is shown as pmoles of cAMP/min/lOOul assay. 
n=3 separate experiments using different membrane 
preparations.
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FiRure 16 Sodium-fluoride modulation of basal adenylate cyclase
activity
Figures are mean + S.D. of a single representative 
experiment employing triplicate observations.
Activity is shown as pmoles cAMP/min/lOOul assay. 
n=3 separate experiments using different membrane 
preparations.
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FiRure 17 Sodium-fluoride modulation of prostaRlandin-E^
stimulated adenylate cyclase activity 
Figures are mean + S.D. of a single representative 
experiment employing triplicate observations.
Activity is shown as pmoles cAMP/min/lOOul assay. 
n=3 separate experiments using different membrane 
preparations.
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Figure 18 ProstaRlandin-E^-mediated activation of adenylate 
cyclase
Figures are mean + S.D. of a single representative 
experiment employing triplicate observations.
Activity is shown as pmoles cAMP/min/lOOul assay. 
n=3 separate experiments using different membrane 
preparations.
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FiRure 19 Action of benzyl alcohol on basal adenylate cyclase 
activity
Results are means + S.D. for n=6 separate experiments using 
different platelet membrane preparations. Specific activity is 
given in Table 4.
Activity is shown as percentage of that observed in the 
absence of benzyl alcohol (control) i.e. 100%.
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Fifture 20 Action of benzyl alcohol on NaF-stimulated adenylate
cyclase activity 
Results are means + S.D. for n=6 separate experiments using 
different platelet membrane preparations. Specific activity is 
given in Table A .
Activity in the absence of added benzyl alcohol (control) 
is shown as 100%.
Concentration of NaF is 15mM.
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Figure 21 Action of benzyl alcohol on isoprenaline-stimulated
adenylate cyclase activity 
Results are means + S.D. for n=6 separate experiments using 
different platelet membrane preparations. Specific activity is 
given in Table 4. Activity in the absence of added benzyl alcohol 
(control) is shown as 100%.
Concentration of isoprenaline is 10 M.
% 
ad
en
yl
at
e 
cy
cl
as
e 
ac
ti
vi
ty
98.
300
200
100
0 5 04 03 02 01 00
[Benzyl Alcohol] mM
FiRure 22 Action of benzyl alcohol on prostaRlandin-E^- 
stimulated adenylate cyclase activity 
Results are means + S.D. for n=6 separate experiments using 
different platelet membrane preparations. Specific activity is 
given in Table 4. Activity in the absence of added benzyl alcohol 
(control) is shown as 100%.
Concentration of PGE^ is 2x10 ^M.
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Fiaure 23 Action of benzyl alcohol on forskolin-stimulated 
adenylate cyclase activity 
Results are means + S.D. for n=6 separate experiments using 
different platelet membrane preparations. Specific activity is 
given in Table 4. Activity in the absence of added benzyl alcohol 
(control) is shown as 100%.
-4Concentration of forskolm is 10 M.
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Fifture 24 Effect of benzyl alcohol on forskolin dose effect curve
Figures are mean + S.D. of a single representative 
experiment employing triplicate observations.
Activity is shown as pmoles cAMP/min/lOOul assay. 
n=3 separate experiments using different membrane 
preparations.
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FiRure 25 Effect of increasins temperature on forskolin-
stimulated adenylate cyclase activity
Figures are mean + S.D. for n=3 separate experiments
employing different membrane preparations.
Activity is shown as pmoles cAMP/min/lOOul assay. 
Concentration of forskolin is
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Figure 26 Effect of increasing temperature on prostaglandin-
E^-stimulated adenylate cyclase activity
Figures are mean ±  S.D. for n=3 separate experiments
employing different membrane preparations.
Activity is shown as pmole cAMP/min/lOOul assay. 
Concentration of PGET is 2 x 10“5M.
]noO
J./U!Ui/dl/\]VO
 
sioiud
80
0  1   “
10 20 30 40 50
Temperature (°C)
Figure 27 Effect of benzyl alcohol (50mM) on the linearity of 
the adenylate cyclase reaction 
Results are mean + S.D. for n=3 separate experiments using 
different membrane preparations.
Activity is shown as pmoles/min/lOOul assay.
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Figure 28 Effect of benzvl alcohol (50roM) on the linearity of
G^-coupled adenylate cyclase activity 
Results are mean + S.D. for n=3 separate experiments using 
different membrane preparations.
Activity is shown as pmoles/min/lOOul assay.
Concentration of NaF is 15mM.
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Figure 29 Effect of benzyl alcohol (50roM) on the linearity of
R^-G^-coupled adenylate cyclase activity
Results are mean + S.D. for n=3 separate experiments using
different membrane preparations.
Activity is shown as pmoles cAMP/min/lOOul assay. 
Concentration of PGEi is 2 x 10"%.
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Fifture 30 Action of benzyl alcohol on GppNHp-mediated inhibition
of forskolin-stimulated adenylate cyclase activity
Effect of benzyl alcohol is shown on the percentage 
-4inhibition of forskolin (10 M)-stimulated activity elicited by 
low concentrations (10 H) of p[NH]ppG.
Results are means + S.D. for n=6 separate epxeriments using 
different membrane preparations.
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Figure 31 Action of benzyl alcohol on adrenaline
(+ propranolol)-mediated inhibition of
forskolin-stimulated adenylate cyclase activity
Effect of benzyl alcohol is shown on the percentage
-4inhibition of forskolin (10 M)-stimulated activity elicited by
-4 -5
adrenaline (10 M)in the presence of propranolol (10 M).
Results are means + S.D. for n=6 separate experiments using
different membrane preparations.
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Figure 32 Action of benzyl alcohol on adrenaline (4- propranolol)-
mediated inhibition of PGE^-stimulated adenylate 
cyclase activity 
Effect of benzyl alcohol is shown on the percentage
inhibition of PGE^ (2x10 ^M)-stimulated activity elicited by
-4 -5adrenaline (10 M) in the presence of propranolol (10 M),
Results are means + S.D. for n=6 separate experiments using
different membrane preparations.
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Figure 33 Effect of benzyl alcohol on adrenaline-stimulated
GTPase activity in human platelets
Figures are mean + S.D. for n=3 separate experiments using
different membrane preparations.
Adrenaline (10~^M) is in the presence of propranolol
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Fifture 34 Action of benzyl alcohol on adrenaline (4- propranolol)- 
mediated inhibition of PGE^-stimulated adenylate 
cyclase activity, in the presence of manganese 
Effect of benzyl alcohol on the adenylate cyclase activity
( pmol/min/lOOul assay) profiles for PGE^-stimulated activity in
2+  2-j-the presence of either Mg (C^n ) or Mn ( ©,0 ) is shown for
experiments done in either the presence (□,©) or absence ( O,® ) of
-4 -5
adrenaline (10 M) 4- propranolol (10 M).
Results are means + S.D. for n=6 separate experiments using
different membrane preparations.
Concentration of P G E n  is 2 x 10~^M.
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Figure 35 ImmunoblottinR of platelet membranes
After incubation of platelet membranes either with or 
without benzyl alcohol (50mM) under the conditions specified in 
Materials and Methods, Section 2.17, membranes and the supernatant 
fraction were isolated. Immunoblotting of these fractions was 
performed using anti serum RV6 for G-protein beta-subunits and 
antiserum AS7 for alpha-G^ subunits. Data shown is a typical 
experiment of one done three times with different membrane
preparations. In the experiments shown, incubations were done in
-5 -4
the presence of PGE^ (2x10 M), adrenaline (10 M) and
propranolol (10 ”*M).
Abbreviations: P, pellet; SN, supernatant; BA, benzyl
alcohol
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(1) P SN P+BA SN+BA
< ® !a a 1 pha G |
(2) P SN P+BA SN+BA
t) G t3
Table 3 E C ^ 's for li sand-mediated activation of platelet
adenylate cyclase
Ligand Component EC5Q No . of
involved observations
Forskolin C 25.0 + 7.00uM 3
Sodium fluoride Gs 14.80 + 0.50mM 3
PGEi Rs 0.20 ±  0.04uM 3
n= No. of separate experiments using different membrane preparations. 
Errors are S.D, for the given number of observations.
EC^q is the concentration of ligand giving 50% activation.
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Table 5 Comparison of membrane-bound and lubrol-solubilised
adenylate cyclase activities
Specific activities 
Ligand Component Control Solubilised
none (basal) C 193,3 + 11.4 61.5 + 3.6
GTP (10~4M) Gs 213.0 ±  17.0 79.5 ± 12.2
P G E 1 (2x10~5M) Rs 1310.6 ± 65.6 74.7 ± 3.0
forskolin (10“4M) C 3412.5 ± 101.3 1763.8 ± 93.8
Data is from typical experiment : each figure is the mean of 3 
samples + S.D.
No. of separate experiments = 6; all give similar trends. 
Specific activity is expressed as p moles cAMP/mg/min
lib.
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Effect of manRanese (5mM) on PGE^- and 
forskolin-stiroulated adenylate cyclase activities
Mn/MR ratio
Absence of 
Benzyl Alcohol
Table 7
Li Rand 
P G E 1 (2x 10~5H) 
forskolin (10~^M)
Results are shown 
n= No.
2.01 ± 0.66 (6) 
2.48 ±  0.93 (6)
Presence of 50mM 
Benzyl Alcohol
1.44 ±  0.33 (7) 
6.34 ±  2.13 (5)
as mean + S.D.
separate experiments using different membrane preparations.
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Table 8 Effect of temperature on inhibitory ligands
% Inhibition
Inhibitory
Condition
T e m p e r a t u r e  
30°C 35°C 40°C
forskolin 66,7 + 13.1 66.7 + 6.5 46.3 + 3.2
+• low GppNHp (n=4) (n=3) (n=3)
forskolin 68,7 + 3.8 63,5 ±  13.5 66.0 ±  5.3
+ Adrenaline (n=3) (n=4) (n=3)
PGEi 71.7 ±  4.0 77.3 ±  8.9 82.3 ±  8.2
+ Adrenaline (n=3) (n=4) (n=4)
Results shown as mean ±  S.D.
n= No. separate experiments using different membrane preparations
-4 . -6Adrenaline (10 M) is m  the presence of propranolol (10 M)
Concentration of forskolin is 10_4M*
Concentration of PGE-j is 2 x 10--*M.
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(iii) Discussion
It is apparent from this study that the adenylate cyclase 
system of human platelets is ’typical* in a number of respects, 
although some new aspects to regulation of this enzyme will be 
discussed.
Stimulatory ligands were observed as being able to 
activate the enzyme at various levels, namely receptor (PGB^, or 
beta-adrenoceptor), stimulatory G-protein, G^ (NaF) and directly 
at the level of the catalytic unit (forskolin). This is as 
reported for the adenylate cyclase system of other tissues/cells 
(Ruiz et a l ., 1986; Nelson & Seamon, 1985), and exhibits the same 
order of potency; PGE^ and forskolin being the most powerful 
stimulants tested. Once again this was as reported by others 
(Insel et a l ., 1982). The platelet adenylate cyclase enzyme was 
found to retain its activity in the solubilised form, and was able, 
in this state, to be stimulated by forskolin and attenuated by 
adenosine. This provides evidence for the routes by which these 
ligands mediate their effects. For example, forskolin activation 
of adenylate cyclase must be via a direct interaction of the 
diterpene with the catalytic unit. It also provides support for 
the existence of the ’p-site* for adenosine interaction with the 
catalytic unit i.e. adenosine interaction with adenylate cyclase is 
not solely at the level of the receptor.
It was also observed that both NaF and GppNHp exhibited
their characteristic dual regulation of adenylate cyclase, being
able to both stimulate basal activity and inhibit stimulated
activities. This property reflects the different affinities of
G. and G for these ligands. G binding GppNHp with a much 
i s  s
lower affinity than G. (Gawler et al., 1987; Hildebrandt et al.. 
1982), whilst the dual effect of NaF arises due to the fact that in
1 2 0 .
combination with the GDP bound to the G-proteins it mimics the GTP 
in a manner analogous to that observed with GppNHp.
Inhibitory aspects of platelet adenylate cyclase 
regulation are again similar to those reported by others (Morgan, 
1989). Here too, activation was possible at different levels; 
receptor (alpha^-adrenoceptor), inhibitory G-protein, G^
(GppNHp), and directly at the catalytic unit (adenosine). Although 
very little is reported about adenylate cyclase inhibition beyond 
those details, in this chapter the inhibitory arm of regulation will 
be covered in detail.
Having determined that the basic stimulatory and
inhibitory aspects of platelet adenylate cyclase regulation were as
found elsewhere, attempts were then made to examine the effects of
benzyl alcohol on this system. As has been shown in a variety of
membrane systems (Friedlander et al,, 1987; De Foresta et al.,
1987), the activity of adenylate cyclase in the basal and
ligand-stimulated states is enhanced in the presence of this local
anaesthetic. Here it was found that platelet adenylate cyclase is
no exception. The augmentation of activity is seen when monitoring
the basal catalytic unit activity, and also when G^ is stimulated
directly with sodium fluoride, and when stimulated by receptor-G^
coupling invoked by either or ky the beta-adrenoceptor
agonist isoprenaline. In hepatocytes, however, basal adenylate
cyclase activity was relatively insensitive to the action of benzyl
alcohol, whilst the glucagon-stimulated activity (R ) was markedly
s
enhanced (Dipple & Houslay, 1978). Thus benzyl alcohol profoundly 
amplified the ability of glucagon to stimulate the activity of 
adenylate cyclase (i.e. fold stimulation increased). Here, 
however, benzyl alcohol was observed to exert a potent stimulatory 
effect on the basal activity of human platelet adenylate
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cyclase. This may reflect tissue and species differences in either 
the enzyme itself, or its incorporation into the membrane bilayer.
It is presumed that the stimulatory effect of benzyl alcohol was 
related to its ability to decrease membrane order (Insel et al., 
1982; Dipple & Houslay, 1978; Hildebrandt et al., 1982: Gordon et
al., 1980), as no stimulatory effect of benzyl alcohol was observed 
with the detergent-solubilised enzyme. Benzyl alcohol also 
enhanced the degree of sodium fluoride-stimulation of adenylate 
cyclase to a similar extent to that seen for basal activity. This 
suggests that the amplification seen is due to an effect 
predominantly on the catalytic unit of the enzyme, and indicates 
that coupling between G and adenylate cyclase was not influenced
\ S
by the increase in disorder elicited by the anaesthetic. Indeed,
despite mobile collisions between the protein components being
required for this process (Houslay et al., 1980a), it has been shown
(Houslay & Gordon, 1983; Henis et a!L., 1982) that at the
temperatures of assay (30°C) diffusion is not a rate-limiting step
in the reaction, and thus any decrease in membrane order is unlikely
to elicit any significant facilitation of the rate of reaction.
Thus, the membrane environment does not appear to exert any
constraint on the conformational flexibility of G , which is not
s
entirely unexpected, as at least the alpha-subunit of G^ is not an 
integral membrane protein (Gilman, 1984; Houslay, 1984; Birnbaumer 
et al., 1985). As with NaF-stimulation, the presence of benzyl 
alcohol did not augment the net (fold) stimulation of basal 
adenylate cyclase by isoprenaline (Table 6), Thus, the enhanced 
activity seen here may again be due predominantly to an effect on 
the catalytic unit of adenylate cyclase. In contrast, the fold 
increase in stimulation of adenylate cyclase by PGE^ was 
attenuated by the presence of benzyl alcohol (Table 6). Such
experiments imply that there are profound differences in the ability 
of benzyl alcohol to modify the efficiency of coupling of various 
stimulatory receptors to adenylate cyclase. This does not appear 
to be mediated by any change in affinity of the ligands for the 
receptor, but rather, in their potency to couple and activate 
Gg. Although in other experiments benzyl alcohol was seen to 
elicit a change in the PGE^ activation this would not
account for the effects of benzyl alcohol seen here i.e. 
concentration of PGE^ employed is saturating.
Benzyl alcohol, like ethanol and other short-chain 
alcohols (Whetton et al.. , 1983; Robberecht et aJL. , 1983; Huang et 
al., 1982) was seen to inhibit adenylate cyclase when the enzyme was 
activated by the diterpene forskolin (Fig.23). This effect was 
noted as occurring with the forskolin-stimulated lubrol-solubilised 
enzyme also. It has been suggested that such inhibition (Whetton 
et al., 1983; Robberecht et al., 1983) may arise by the alcohol 
competing for the hydrophobic site on adenylate cyclase to which 
forskolin binds. However, in this study it was noted that the 
EC^q value for activation of adenylate cyclase by forskolin was 
not altered by benzyl alcohol. This suggests that benzyl alcohol 
is acting as a non-competitive, rather than competitive, inhibitor 
of forskolin action, and thus interacting at a different site(s) to 
forskolin on the catalytic unit of human platelet adenylate cyclase.
Further evidence that this reduction in 
forksolin-stimulated adenylate cyclase activity is a result of 
properties of the local anaesthetic comes from studies where other 
methods of manipulating membrane fluidity were employed. For 
example, manipulation of temperature by approximately 8°C should 
elicit the same effects as the addition of 50mM benzyl alcohol. In 
fact, it was observed that such temperature manipulation not only
enhanced the activity of the PGE^-stimulated state as would be 
expected, but also enhanced the activity of the forskolin-stimulated 
state. Activation profiles were almost identical (Figs.25,26), 
thereby supporting the proposal that the attenuation of 
forskolin-stimulated activity, seen with benzyl alcohol, was a 
direct reflection of the properties of the local anaesthetic.
G^-mediated effects on adenylate cyclase can be elicited 
and monitored in two distinct ways. Firstly, one can determine any 
direct action on the catalytic unit of adenylate cyclase by 
monitoring action on the forskolin-amplified basal activity. In 
this instance inhibition can be engendered by selectively activating 
G^ with low concentrations of GppNHp, as this G-protein has a much 
higher affinity for GppNHp than does Gg (Gawler et al., 1987; 
Hildebrandt et al., 1982). Direct inhibitory effects on the 
catalytic unit can also be measured by assessing the ability of the 
alpha^-adrenoceptors, which couple to G^, to inhibit the
forskolin-stimulated activity (Jakobs et ajl., 1985; Houslay et al.,
1986a). For both receptor- and GppNHp-mediated inhibitory effects 
on the catalytic unit of adenylate cyclase activity it was observed 
that a complete insensitivity to benzyl alcohol at concentrations up 
to 50mM existed. In contrast to this, the
alpha^-adrenoceptor-mediated inhibition of receptor-stimulated 
adenylate cyclase was attenuated on addition of benzyl alcohol.
This occurred in a saturable fashion, with a maximal attenuation of
approximately 34% being achieved, and was not due to any
interference with the G-protein GTPase activity. It may be that 
this inhibitory effect of benzyl alcohol resulted from its ability 
to modulate the f°r adrenaline-mediated inhibition.
However, this would not appear to be the case here, as it was noted 
that saturating concentrations of adrenaline were used in these
benzyl alcohol experiments. Also, such an explanation would not
explain why adrenaline-mediated inhibition of forskolin was
unaffected by the presence of the anaesthetic. (The
GppNHp-mediated inhibition of adenylate cyclase was unaltered by
benzyl alcohol).
Thus, the alpha^-adrenoceptor-mediated inhibition of
receptor-G -stimulated adenylate cyclase appears to exhibit two 
s
components, one of which is insensitive to benzyl alcohol and the
other which is attenuated by benzyl alcohol.
The attenuating effect of benzyl alcohol was clearly
targetted at a fraction of the inhibitory G^ component. This
could be shown by the experiments performed in the presence of
manganese, rather than magnesium, which serves to uncouple
G.mediated responses (Gilman, 1984; Hoffmann et al., 1981).
Under such conditions, an increase in PGE^-stimulated activity was
observed (as shown by Mn/Mg ratios), owing to a loss of inhibitory
input, i.e. the removal of tonic inhibition. This loss of
functioning G., results in a near obliteration of the 
1
alpha^-mediated inhibition of PGE^-stimulated adenylate cyclase, 
and a response of PGE^-stimulated adenylate cyclase to benzyl 
alcohol which is similar, whether or not adrenaline (■*• propranolol) 
is present to interact with the alpha^-adrenoceptors (see Fig.34).
Having established that the observed effect was indeed a 
result of benzyl alcohol action on a fraction of the inhibitory 
component, the next step was to propose exactly which fraction of 
this component was being affected. Hence, it is proposed that the 
two inhibitory components (see Fig.36) may reflect, (i) a benzyl 
alcohol-insensitive component, which is suggested as reflecting the 
direct inhibitory action of alpha-G^ on the catalytic unit of 
adenylate cyclase, and (2) a benzyl alcohol-sensitive component,
Figure 36 Modulation of G^-roediated inhibition by benzyl
alcohol
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which is suggested may reflect an action on the beta,gamma-subunit-
mediated inhibitory effect of G. on G -dissociation. Thus, ini s
the absence of ligands stimulating G^, only the benzyl 
alcohol-insensitive response may be observed. This is proposed as 
being the case with benzyl alcohol insensitive GppNHp- and 
alpha^-adrenoceptor-mediated inhibition of the 
forskolin-stimulated enzyme state.
At this point, the effect of benzyl alcohol on the Kn/Mg 
ratios for PGE^- and forskolin-stimulated activities should be 
mentioned. As stated previously, the substitution of magnesium 
with manganese resulted in an increase in PGE^-stimulated 
activity. A similar increase was detected with
forskolin-stimulated adenylate cyclase. However, the addition of 
benzyl alcohol to these systems elicited different effects depending 
upon the stimulatory ligand used. With PGE^-stimulated adenylate 
cyclase, the Mn/Mg ratio was reduced in the presence of 50mM benzyl 
alcohol. This is proposed as arising due to the fact that 
magnesium-stimulated activity is enhanced to a larger degree
by benzyl alcohol than is the manganese-stimulated state. From 
this result it may be deduced that part of the method by which 
benzyl alcohol activates adenylate cyclase is by removing tonic 
inhibition. Of course, with the manganese-stimulated state this 
cannot occur, and so the stimulatory effect of benzyl alcohol is 
lessened. With forskolin-stimulated adenylate cyclase the opposite 
is true, i.e. the addition of benzyl alcohol enhanced the Mn/Mg 
ratio. This arises due to the fact that the actual reduction in 
forskolin-stimulated activity elicited by benzyl alcohol, in the 
presence of manganese, is lessened, as specific activities are 
higher in the presence of this cation, relative to those seen with 
magnesium.
1Z/ .
It cannot be defined unequivocally whether the attenuating 
effect of benzyl alcohol on PGE^-stimulated activity is due either 
to enhanced bilayer fluidity, or to a direct action of benzyl 
alcohol itself. However, the ’fluidising* effect of 50mM benzyl 
alcohol can be mimicked by increasing the temperature by some 
6-8°C, as mentioned previously. Here, such an increase in 
temperature did not diminish the potency of adrenaline (+ 
propranolol) to inhibit PGE^-stimulated adenylate cyclase. Nor 
in fact did it alter alpha^-adrenoceptor- or GppNHp-mediated 
inhibition of forskolin-stimulated adenylate cyclase (Table 8).
This suggests that the ability of benzyl alcohol to attenuate the 
inhibitory effect of alpha^-adrenoceptor occupancy on 
PGE^-stimulated activity is by a direct, albeit unknown, action. 
However, it can be stated that such an attenuation of inhibitory 
action was not due to benzyl alcohol causing a loss of components of 
the G. system from the membrane. Immunoblotting studies (Fig.35) 
clearly show that both alpha-G. and G. beta-subunits were not 
displaced by benzyl alcohol under the conditions of the assay.
(iv) Conclusion
In conclusion, it would appear that the adenylate cyclase 
system of human platelet membranes provides a readily available 
model in which to study the dual regulation of this enzymatic 
activity. Whilst it would seem that the platelet enzyme is 
'typical* as regards its ability to be regulated at various levels, 
it would seem that in benzyl alcohol, we have identified an 
'atypical reagent', which may be able to differentiate between the 
regulatory pathways involved in inhibition.
3.2 Effect of charged anaesthetics on platelet adenylate
cyclase activity 
(i) Introduction
It has been proposed that, due to the asymmetry of the 
lipid composition of the plasma membrane, that charged anaesthetics 
are able to preferentially modulate the fluidity of one, or other 
halves of the bilayer (Houslay & Gordon, 1983; Houslay et al., 
1981; Houslay et & 1 ., 1980b), Positively charged drugs are 
suggested to enhance the fluidity of the inner leaflet, whilst 
negatively charged drugs are thought to affect the outer leaflet in 
a similar manner.
Here, the effects of the anionic pentobarbital, and the 
cationic prilocaine, are examined as regards the modulation of 
adenylate cyclase activity through such perturbations.
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(ii) Results
(a) Anionic drugs
Following an initial period of activation, increasing 
concentrations of these negatively charged drugs appeared to 
attenuate both forskolin- and PGE^-stimulated adenylate cyclase 
activity in a dose-dependent manner.
With pentobarbital, low concentrations led to an increase 
in adenylate cyclase activity: forskolin-stimulated activity
(Fig.37) being enhanced by 180% in the presence of 5mM 
pentobarbital, whilst PGE^-stimulated activity (Fig.38) was 
augmented by a much smaller degree, namely 112%. In both cases, 
increasing the concentration of pentobarbital beyond these levels 
led to a loss of adenylate cyclase activity, such that activity was 
effectively abolished at concentrations in excess of 30mM 
(Figs.37,38)
Similarly, with phenobarbital, low concentrations 
augmented adenylate cyclase activity. (n=4 separate experiments 
using different membrane preparations). Here, ImM phenobarbital 
led to 127% and 129% increases in PGE^- and forskolin-stimulated 
activities respectively. Once again, increasing concentrations of 
drug led to a dose-dependent reduction in adenylate cyclase activity. 
When these two anionic compounds were examined with regard 
to their effects on inhibitory aspects of adenylate cyclase 
regulation it was found that pentobarbital at concentrations up to 
lOmM apparently had no effect on the adrenaline (+- propranolol)- 
mediated inhibition of PGE^ (Fig.39). However, adrenaline 
mediated inhibition of forskolin-stimulated activity (Fig.40) was 
slightly reduced by ImM pentobarbital (34.9% reduction), as was the 
GppNHp-mediated inhibition of this state (45.3% reduction) (Fig.41),
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Once again, similar trends were obtained with 
phenobarbital, although not to such marked degrees (n=4 separate 
experiments, using different membrane preparations).
(b) Cationic drugs
Studies with the positively charged drug prilocaine showed 
that increasing concentrations of the anaesthetic led to attenuation 
of both PGE^-(receptor-coupled), and forskolin-(receptor- 
uncoupled)-stimulated adenylate cyclase activities.
It would appear that PGE^-stimulated activity is 
inhibited by concentrations of prilocaine in excess of lOmM 
(Fig.42), Such attenuation of activity appeared to occur in a 
dose-dependent manner, such that at 50mM prilocaine, activity was 
attenuated by 55%, Forskolin-stimulated adenylate cyclase activity 
was affected in a similar manner, although here inhibition occurred 
at lower concentrations than with PGE^, and again activity was 
diminished by increasing concentrations of prilocaine. At 50mM 
prilocaine, forskolin-stimulated activity was reduced by some 76% 
(Fig.43).
Such effects of prilocaine on receptor-coupled and 
-uncoupled activities were mirrored in studies using carbocaine 
(another cationic drug) over the same concentration range; 0 - 50mM. 
(n=3 separate experiments using different membrane preparations). 
Carbocaine induced similar effects to prilocaine with respect to the
action of positively charged drugs on inhibitory aspects of
adenylate cyclase regulation. Here, adrenaline-mediated inhibition 
of PGE^-stimulated adenylate cyclase was found to be slightly 
reduced by low concentrations (<^30mM) of the drug, although 
inhibition was restored by further increases in the concentration of
prilocaine (Fig.44). In contrast to this, the ability of
adrenaline (+ propranolol) to inhibit forskolin-stimulated activity
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was augmented by increasing concentrations of prilocaine. At 50mM 
prilocaine, a 78% increase in the ability of adrenaline to inhibit 
the forskolin-activated state was observed (Fig.45). From Figure 
46, it is apparent that the GppNHp-mediated inhibition of forskolin- 
activated adenylate cyclase was similarly affected, i.e. the 
efficiency of GppNHp to inhibit adenylate cyclase was enhanced by 
prilocaine in a dose-dependent manner. The 38.5% inhibition 
observed in the absence of prilocaine was increased to 
72%-inhibition in the presence of 50mM prilocaine.
Figure 37 The effect of pentobarbital on forskolin-stimulated
adenylate cyclase activity
Values are mean + S.D. of a single representative
experiment employing triplicate determinations,
n=3 separate experiments using different membrane
preparations.
Concentration of forskolin is 10-Z*M.
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Figure 38 Effect of pentobarbital on PGE^-stimulated adenylate
cyclase activity
Values are mean + S.D. of a single representative
experiment employing triplicate determinations.
n=3 separate experiments using different membrane
preparations.
Concentration of PGE^ is 2 x 10~5M.
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Figure 39 Effect of pentobarbital on adrenaline (+ propranolol)- 
mediated inhibition of PGE^-stimulated adenylate 
cyclase activity 
Values are mean + S.D. of a single representative 
experiment employing triplicate determinations.
n=3 separate experiments using different membrane
preparations.
Concentration of PGEi is 2 x 10 ^
Adrenaline (10"4M) is in the presence of 10”5M propranolol
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Figure 40 Effect of pentobarbital on adrenaline (+-
propranolol)-mediated inhibition of 
forskolin-stimulated adenylate cyclase activity 
Values are mean + S.D. of a single representative 
experiment employing triplicate determinations.
n=3 separate experiments using different membrane
preparations.
Concentration of forskolin is 10~^M.
Adrenaline (10“^H) is in the presence of propranolol
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FiRure 41 Effect of pentobarbital on GppNHp-mediated inhibition
of forskolin-stimulated adenylate cyclase activity
Values are mean + S.D. of a single representative
experiment employing triplicate determinations.
n=3 separate experiments using different membrane
preparations.
Concentration of forskolin is lO-^M. ____
Concentration of GppNHp is 10“®M
0 2 4 6 8 10 12
[ P E N T O B A R B I T A L ]  mftl
Figure 42 Effect of prilocaine on PGE^-stimulated adenylate
cyclase activity
Values are mean + S.D. of a single representative
experiment employing triplicate determinations.
n=4 separate experiments using different membrane
preparations.
Concentration of PGEi is 2 x 10~^M.
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Figure 43 Effect of prilocaine on forskolin-stimulated adenylate
cyclase activity
Values are mean ±  S.D. of a single representative
experiment employing triplicate determinations.
n=4 separate experiments using different membrane
preparations.
Concentration of forskolin is 10_^M.
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Figure 44 Effect of prilocaine on adrenaline (^propranolol)-
mediated inhibition of PGE^-stimulated adenylate
cyclase activity
Values are mean + S.D. of a single representative
experiment employing triplicate determinations.
n=4 separate experiments employing different membrane
preparations.
Concentration of PGEi is 2 x 10~-*M, __
Adrenaline (10-4M) is in the presence of 10-5M propranolol
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FiRure 45 Effect of prilocaine on adrenaline (4- propranolol)-
mediated inhibition of forskolin-stimulated adenylate
cyclase activity
Values are mean + S.D. of a single representative
experiment employing triplicate determinations.
n=4 separate experiments using different membrane
preparations.
Concentration of forskolin is 10“4M.----
Adrenaline (10-4M) is in the presence of 10-5M propranolol
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FiRure 46 Effect of prilocaine on GppNHp-mediated inhibition of
forskolin-stimulated adenylate cyclase activity 
Values are mean + S.D. of a single representative 
experiment employing triplicate determinations.
n=4 separate experiments using different membrane 
preparations.
Concentration of forskolin is 10~^M.
 Concentration of GppNHp is 10~8M
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(iii) Discussion
(a) Anionic Drugs
From experiments using the anionic drug pentobarbital, it 
was observed that both receptor-coupled (prostaglandin 
E^-stimulated) and -uncoupled (forskolin-stimulated) adenylate 
cyclase activities were enhanced at low concentrations (ImM) of 
pentobarbital. It is presumed that this reflects an increase in 
fluidity due to the presence of the anaesthetic. However, as 
others have proposed pentobarbital as acting mainly in the external 
half of the membrane (Houslay & Gordon, 1983) it would have been 
expected that receptor-coupled activity (PGE^) (which experiences 
the environment of this leaflet, as well as the inner leaflet), 
would have been enhanced to a much larger degree than the uncoupled, 
forskolin-stimulated state. In fact, in rat liver plasma 
membranes, anionic drugs were observed as having no effect on 
receptor-uncoupled activities (Houslay et a!l., 1981). In 
platelets, it was found that not only was receptor-uncoupled 
activity enhanced by pentobarbital, but it was actually augmented to 
a larger degree than was receptor-coupled adenylate cyclase; 
forskolin-stimulation being enhanced by some 80% over control, with 
PGE^-stimulation being enhanced by only 12% over control.
Although receptor-coupled activity is enhanced by 
pentobarbital in agreement with the rat liver plasma membrane system 
(albeit to a smaller degree - see later), the effect of 
pentobarbital on receptor-uncoupled activity is in total contrast 
with such studies. This suggests that differences exist in the 
sensitivity of platelet- and rat liver-adenylate cyclase to changes 
in fluidity; a fact that was suggested by studies with benzyl 
alcohol (see Section 3.1). Along similar lines, the fact that high 
concentrations of pentobarbital ( ^30mM) can effectively abolish
144.
platelet adenylate cyclase activity, is in contrast to the rat liver 
system, where maximal attenuation of adenylate cyclase activity was 
in the region of 60% at high concentrations of anaesthetic.
This inhibition may result from anaesthetic molecules 
displacing components of the lipid annulus which surrounds integral 
membrane proteins such as cyclase. By this theory, inhibition 
ensues either because the displaced lipid was essential for 
activity, or alternatively, because occupancy of such lipid-obscured 
sites by the anaesthetic allows it to be inhibitory. Such 
inhibition has been observed for both charged (Houslay et a l .,
1981; Houslay et al,, 1980b) and neutral (Houslay & Gordon, 1983) 
anaesthetics (see Section 1.3.(vi)).
Assuming the inhibition observed here with pentobarbital 
does reflect this phenomenon of annular displacement, then it is 
apparent that anionic drugs are able to displace platelet annular 
lipid more readily than rat liver annular lipid. The reasons for 
this are unclear, either reflecting differences in the strength of 
lipid-protein interaction or the affinity of the sites for 
anaesthetic (Houslay & Stanley, 1982).
The small increase in PGE^-stimulated adenylate cyclase 
activity seen with pentobarbital is in contrast to the 170% increase 
in receptor-coupled (glucagon-stimulated) activity seen in rat 
liver. However, this may not be due to differences in the 
sensitivity of platelet and rat liver stimulatory receptors (Rg) 
to pentobarbital, rather it may reflect a specific property of the 
platelet PGE^-receptor. This conclusion arises due to studies 
on the effect of benzyl alcohol on PGE^-stimulated activity (see 
Section 3.1). Here it was observed that PGE^-stimulated 
adenylate cyclase was enhanced to a much lesser degree than other 
ligand-stimulated states, R^-coupled inclusive. It can therefore
only be presumed that pentobarbital would also augment other 
ligand-stimulated states to a larger extent, as seen with forskolin.
Activation of the forskolin-stimulated state by 
pentobarbital in this manner, is in direct contrast to the 
inhibitory effect of benzyl alcohol on this state (see Section 
3.1). This lends support to the proposal that the benzyl 
alcohol-induced inhibition is a direct result of the properties of 
that particular anaesthetic i.e. that the properties of benzyl 
alcohol and pentobarbital are sufficiently different that this 
selective inhibition of forskolin was not observed.
When the effect of pentobarbital was examined with regard 
to the inhibitory aspects of adenylate cyclase regulation, different 
effects were observed depending upon whether the stimulatory state 
being inhibited was receptor-coupled or not, i.e. the effects of 
inhibitory ligands were examined on adenylate cyclase activities 
which were already enhanced, through either prostaglandin E^ 
(receptor-coupled), or forskolin (receptor-uncoupled). Such 
studies showed that adrenaline-mediated inhibition of 
PGE^-stimulated adenylate cyclase was unaltered by the presence of 
the anaesthetic. In contrast to this, both adrenaline- and 
GppNHp-mediated inhibition of the forskolin-stimulated state were 
attenuated at low concentrations of pentobarbital.
If these effects are a result of pentobarbital-induced 
modulations in membrane fluidity, then it may be that such 
modulations alter the efficiency of interaction between the 
components of the adenylate cyclase system. It would therefore 
appear that the interaction in question is at the level of G.-C 
coupling as effects at the level of the receptor (R^) would not 
account for the attenuation of GppNHp-mediated inhibition, i.e. 
involves direct activation of G^. However, the absence of any
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detectable effect of pentobarbital on adrenaline-mediated inhibition 
of PGE^ would appear to invalidate G^-C interaction as being the 
site of anaesthetic action, i.e. any modulation in this site would 
be reflected in adrenaline-inhibition of PGE^ also. It may be 
that the inability to detect any anaesthetic-mediated effect in this 
situation results from the presence of a beta-gamma component to 
inhibition here; adrenaline-mediated inhibition of PGE^ being 
proposed to involve G^ alpha and beta-gamma as discussed in 
Sections 3.1 and 1.3(iv). It is therefore suggested that the 
effect of pentobarbital as regards inhibitory ligands, is to 
modulate the efficiency of the G^-alpha-C interaction. Such 
reduction in the efficiency of this coupling leads to attenuation of 
inhibition. However, this is not observed with PGE^-stimulated 
adenylate cyclase due to the fact that a beta-gamma inhibitory 
component exists to mask this.
Although the effects of pentobarbital with regard to both 
inhibitory- and stimulatory-aspects of adenylate cyclase regulation 
are proposed as being a result of changes in membrane fluidity, it 
is apparent that the expected selective manipulation of fluidity did 
not arise, i.e. no preferential effects of pentobarbital were 
observed on receptor-coupled activities, hence the likelihood of 
selective fluidity modulation can be discounted.
It may be that pentobarbital modulates adenylate cyclase 
activity by a more direct means than enhancing fluidity. For 
example, the possibility cannot be ruled out that pentobarbital is 
acting directly at the coupling interface rather than
modulating its efficiency through membrane fluidity. It may be 
that G^ alpha~C interaction is charge sensitive, or that the 
anaesthetic may disrupt the interaction of the components with 
specific lipids that are required for activity, or indeed
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pentobarbital may affect the species of phospholipid recruited into 
lipid clusters and hence removed from the bulk lipid pool (Houslay 
et al.., 1981). Due to their charge properties, anionic drugs such 
as pentobarbital may be expected to exert a variety of effects on 
integral proteins, such as adenylate cyclase, through perturbing the 
bilayer in ways other than a simple fluidising effect.
(b) Cationic Drugs
When examining the effects of cationic drugs on adenylate 
cyclase activity, it was observed that both receptor-coupled and 
uncoupled activities were attenuated by increasing concentrations of 
prilocaine (Figs.42,43). No stimulation of either activity was
observed. This is in contrast to studies on rat liver plasma 
membranes (Houslay et a^ L., 1980b), where receptor-uncoupled states 
were found to be augmented by low concentrations of prilocaine.
The inhibition of both PGE^- and forskolin-stimulated adenylate 
cyclase activities at concentrations above lOmH, was similar to that 
observed in the rat liver plasma membrane system and may be due to 
annular displacement. This has been observed for both charged and 
neutral anaesthetics. In the rat liver plasma membrane system it 
was observed that high concentrations of prilocaine led to a 
progressive inhibition of activity, whilst e.s.r. studies showed 
bilayer fluidity to be enhanced at such concentrations. As no 
direct interaction of prilocaine with the protein was detected i.e. 
no effect on detergent-solubilised adenylate cyclase, it was 
suggested that the observed inhibition was indeed due to annular 
displacement.
Although it has been shown that prilocaine, at these 
concentrations, is able to enhance membrane fluidity, it may be that 
this charged compound exerts its effects via a more direct 
interaction with the adenylate cyclase system. For example, it may
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be that prilocaine directly interferes with ligand binding; 
although the saturating concentrations of ligands used here tend to 
rule out any detectable changes in the adenylate cyclase activity 
through a shift in ligand-binding.
Adrenaline-mediated inhibition of PGE^-stimulated
adenylate cyclase (Fig.44) was found to be reduced at low
concentrations of the anaesthetic. This may be a result of
prilocaine perturbing coupling interactions. Coupling has been
suggested to occur at the cytosol surface, and to involve acidic
phospholipids, which tend to be localised here. As there is strong
evidence (from n.m.r. studies) for interaction between cationic
anaesthetics and negative phospholipids (Houslay & Gordon, 1983), an
interaction between prilocaine and the acidic phospholipids involved
in coupling might be expected to yield an inhibitory response. The
site of this interaction must be at the level of G, beta/gamma-
G alpha; this conclusion arises because interference at any 
s
other level would be reflected in the activities of other coupling 
states. The return of inhibition to original levels at higher 
concentrations of prilocaine (i.e.^> 30mM) may be due to 
prilocaine-induced increases in fluidity overcoming the effect of 
anaesthetic at the coupling interface.
Any increase in fluidity which prilocaine induces would be 
expected to enhance other activities as well. Adrenaline-mediated 
inhibition of forskolin was enhanced by prilocaine, presumably due 
to such an increase in membrane fluidity. Almost identical results 
were observed with GppNHp-mediated inhibition of forskolin, and 
presumably reflect increased efficiency of G^-C coupling also.
It may be that the enhanced inhibition seen with ligands on 
forskolin-stimulated activity is a result of enhanced fluidity 
augmenting the efficiency of G.-alpha-C coupling. With
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inhibition of PGE^stimulated adenylate cyclase it may be that 
although G^-alpha-C coupling was enhanced, the attenuation of the 
beta/gamma component of inhibition resulted in the effects observed 
here. This attenuation of beta/gamma-inhibition may be a direct 
effect of prilocaine, as discussed earlier.
It is therefore apparent that the incorporation into the 
bilayer of a cationic, hydrophobic molecule such as prilocaine, 
which can also displace membrane-bound calcium, is likely to have 
profound effects on lateral lipid distribution. As a consequence 
of this, the effects observed with prilocaine are not as ’simple* as 
those observed with the neutral, benzyl alcohol.
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(iv) Conclusions
The concentration ranges used here were the same as 
employed in studies on rat liver plasma membranes (Houslay & Gordon, 
1983). From studies done on rat liver plasma membranes and other 
systems, we can assume that similar concentrations of these 
anaesthetics will be able to partition into and perturb platelet 
membranes also. It is likely that prilocaine and pentobarbital 
will be able to act to increase membrane fluidity. However, it is 
apparent that although experiments in other systems suggested that 
charged drugs exhibited a greater tendency to interact with one or 
other halves of the bilayer, and that this was reflected in 
modulations of receptor-coupled or -uncoupled adenylate cyclase 
activities, no such selective effects are observed in human platelet 
membranes.
The question here is whether the observed effects are due 
to modulations in membrane fluidity at all. It would be necessary 
to perform experiments on solubilised adenylate cyclase in order to 
rule out any direct effects of the anaesthetic on the enzyme. 
However, such experiments would still leave the possibility that 
prilocaine and pentobarbital act to interfere with coupling.
In fact, taking the results of these experiments together, it is 
apparent that the G.alpha-C interaction is attenuated by the 
negatively charged pentobarbitol, whilst the positively charged 
prilocaine is able to enhance the efficiency of this coupling 
state. From such observations it can be postulated that the 
interaction of the G,-alpha subunit with the catalytic unit 
involves positive charge to the extent that modulations in this 
charge alter the ability of these two components to interact 
effectively.
Although the exact mechanism by which these anaesthetics 
modulate adenylate cyclase activity is unclear, it has been possible 
to suggest points at which they may affect the adenylate cyclase 
system, and changes in fluidity could indeed explain the majority of 
these effects. From these experiments using charged anaesthetics 
it can be seen that the effects elicited by such drugs (positively 
or negatively charged) are different from those seen with the 
neutral benzyl alcohol.
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3.3 Effect of dimethylnitrosamine on platelet adenylate
cyclase activity 
(i) Introduction
Dimethylnitrosamine is a carcinogenic compound, which has 
previously been used to manipulate the membrane environment of rat 
liver plasma membranes (Whetton et al^ ., 1984). In these studies it 
was found that this compound was capable of reducing the fluidity of 
the membrane, and that this was reflected in a decreased adenylate 
cyclase activity.
Here, the action of dimethylnitrosamine was investigated 
on adenylate cyclase activity in human platelets.
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(i i) Results
From Figure 47 it can be concluded that
-4forskolin-stimulated adenylate cyclase activity (10 M) was 
attenuated by the presence of dimethylnitrosamine. Such 
attenuation occurred in a dose-dependent manner, such that at 50mM 
dimethylnitrosamine, this receptor-uncoupled activity was diminished 
by approximately 30%. Increasing drug concentrations beyond this 
led to still further reductions in adenylate cyclase activity: at
lOOmM dimethylnitrosamine only 43.4% ±3.9 of the original 
forskolin-stimulated adenylate cyclase remained.
Receptor-coupled adenylate cyclase activity was affected 
in an almost identical manner by dimethylnitrosamine. Figure 48 
shows PGE^-stimulated adenylate cyclase to be reduced by 
dimethylnitrosamine; a 40% decrease occurring over the first 
lOmM. At 50mM dimethylnitrosamine a 54% decrease in 
PGE^-stimulated activity is observed.
FiRure 47 Effect of dimethylnitrosamine on forskolin-stimulated
adenylate cyclase activity
Values are mean + S.D. of a single representative
experiment employing triplicate determinations.
n=3 separate experiments using different membrane
preparations.
Concentration of forskolin is lO-^M.
% 
A
C
TI
V
IT
Y
154.
120
100
80
40
20
120100804020
[D im e th y ln i l r o s a m ln e ]  m M
FiRure 48 Effect of dimethylnitrosamine on PGE^-stimulated
adenylate cyclase activity
Values are mean + S.D. of a single representative
experiment employing triplicate observations.
n=3 separate experiments using different membrane
preparations.
Concentration of PGE-^  is 2 x 10
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(iii) Discussion and conclusions
From results shown here it is obvious that 
dimethylnitrosamine affects receptor-coupled and -uncoupled 
adenylate cyclase activities in the same manner. The presence of 
dimethylnitrosamine appears to attenuate these activities in 
platelet membranes in an analogous fashion to that observed in rat 
liver membranes. Hence, it is assumed that such attenuation is a 
result of dimethylnitrosamine inducing rigidity in the membrane as 
this was shown to occur in the studies on rat liver plasma membranes 
(Whetton et al., 1984).
Comparison of PGE^-stimulated adenylate cyclase and
forskolin-stimulated adenylate cyclase at 50mH dimethylnitrosamine,
showed the receptor-coupled and -uncoupled states to exhibit slight
differences in their ability to be attenuated by this drug. At
50mM dimethylnitrosamine, the receptor-coupled activity was reduced
by approximately 54%, whereas the receptor-uncoupled activity was
reduced by only 30%. The reason for this large difference may lie
in the fact that PGE^-mediated stimulation of adenylate cyclase
requires the interaction of a number of components in the membrane,
whereas forskolin stimulates adenylate cyclase by direct interaction
with the catalytic unit. As a result of this difference it may be
that any reduction in bilayer fluidity mediated by
dimethylnitrosamine would lead to reduced efficiency of component
interaction, i.e. R -G -C, such that adenylate cyclase activity
s s
would be diminished. The reduction in forskolin-stimulated 
adenylate cyclase induced by dimethylnitrosamine can be attributed 
solely to reduction in fluidity increasing the physical constraint 
of the bilayer on the catalytic unit. As no mobile collisions are 
required for forskolin-activation, the effect of 
dimethylnitrosamine-induced rigidity is not as marked here.
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In conclusion, it would appear that a decrease in membrane 
fluidity could indeed lead to the observed diminishment of adenylate 
cyclase activity. Hence, this would lend support to fluidity 
modulation of adenylate cyclase, whereby increased fluidity is 
porposed to enhance activity.
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3.4 Effect of acidic phospholipids on platelet adenylate
cyclase activity 
(i) Introduction
Acidic phospholipids such as the negatively charged, 
phosphatidic acid, have been shown to modulate adenylate cyclase 
activity in a number of systems, including rat liver plasma 
membranes (Houslay et al., 1986c), and cultured cell lines (Clark et 
al,, 1980; Murayama & Ui, 1987; Schimmel et a l . , 1980; Proll et 
al., 1985), In each case, it would appear that the presence of 
acidic phospholipids leads to attenuation of adenylate cyclase 
activity, although the precise mechanism by which this occurs is 
unclear.
However, it has been postulated that manipulation of 
membrane phospholipid content may result in changes in membrane 
fluidity (Houslay et al., 1986c) whether or not this leads to the 
reduction in adenylate cyclase activity observed with acidic 
phospholipids is questionable. This possibility will be examined 
here as will the proposals that acidic phospholipids mediate their 
effects via specific phospholipid receptors (Murayama & Ui, 1987), 
or G-proteins (Murayama & Ui, 1987; Schimmel et a l_., 1980; Proll 
et al., 1985)
(i i) Results
From Table 9 it can be seen that the acidic phospholipids, 
phosphatidic acid and phosphatidylserine were able to attenuate 
platelet adenylate cyclase. This inhibition of activity occured at 
all levels of regulation; these negative-charged species were 
capable of attenuating activity which had previously been stimulated 
at the level of the receptor (PGE^; 2 x 10 **M), the stimulatory 
G-protein, G^, (NaF; 15mM), and directly at the level of the 
catalytic unit either basal, or forskolin-stimulated (forskolin; 
10-4M>.
The actual percentage-inhibition mediated by phosphatidic
acid appeared to differ depending on the stimulatory-state of the
enzyme. Forskolin- and PGE^-stimulated activities were inhibited
by 64.5% + 5.4, and 64.9% + 8.2 respectively, with basal and
NaF-stimulated activities inhibited by 32.8% +7.6 and 30.6% +
9.1. However, with phosphatidylserine it would seem that this
species was capable of attenuating the forskolin-stimulated state
(64.7% +4.7) to a greater extent than either the receptor-activated
(PGE,), G -activated (NaF), or basal states, which were all 
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inhibited by 43-48%. The neutral phospholipid,
phosphatidylcholine, exhibited no tendency to inhibit any of these 
cyclase states i.e. either basal or stimulated.
It should be noted that phosphatidic acid was able to 
inhibit adenylate cyclase to a lesser degree if smaller 
concentrations of the phospholipid were employed: approximately
30-35% inhibition of the forskolin- and PGE^-stimulated states was 
observed with concentrations of phosphatidic acid lower than ling. 
Hence, although inhibition by acidic phospholipids is not clearly 
dose-dependent, it can be generalised that lower concentrations of 
phospholipid tend to give lower percentage-inhibitions.
The fold-stimulation exerted by these stimulatory ligands 
was reduced in the presence of phosphatidic acid, and 
phosphatidylserine (Table 10). In agreement with the inhibitions 
detailed in Table 9, it was observed that the fold-stimulation 
exerted by both PGE^ (receptor-mediated activation) and forskolin 
(direct activation at the catalytic unit) was attenuated by 
phosphatidic acid, Phosphatidylserine, whilst reducing the 
fold-stimulation mediated by forskolin (22.8 fold—>8.9 fold), had 
virtually no effect on the stimulation mediated by PGE^. The 
neutral phosphatidylcholine had no detectable effect on either of 
these cyclase activities.
Table 11 illustrates the fact that the presence of 
manganese in the system had no significant effect on the 
phosphatidic acid-induced inhibition of any of these cyclase 
states. It would appear that phosphatidylserine-mediated 
inhibition was similarly unaffected by the presence of 5mM 
manganese; should uncouple G.-C at this concentration.
Other attempts to modify the cyclase system in the 
presence of phosphatidic acid included the addition of benzyl 
alcohol to manipulate membrane fluidity. Table 12 shows that the 
presence of 50mM benzyl alcohol apparently had no significant effect 
on the degree of inhibition elicited by phosphatidic acid.
However, there is apparently an exception to this statement; 
forskolin-stimulated adenylate cyclase did appear to be inhibited to 
a lesser extent by phosphatidic acid if benzyl alcohol was 
present. This reduction from 41.4% + 4,9 to 25.9% + 0,2 
inhibition, may be due to an anomalous effect of benzyl alcohol on 
the forskolin-stimulated state.
It should be noted that the effects of these phospholipids 
were examined regarding inhibitory aspects of adenylate cyclase
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regulation. Table 13 shows that phosphatidylserine mediated 
inhibition of PGE^-activated adenylate cyclase was not additive 
with the adrenaline-mediated inhibition of this state. This is 
true of phosphatidic acid-mediated inhibition also, although here a 
slight degree of co-operativity is apparent.
With adrenaline-mediated inhibition of forskolin, no 
additivity or synergy was seen with either phosphatidic acid or 
phosphatidylserine and adrenaline. On the other hand, a slight 
co-operativity may be observed with both phospholipids and 
GppNHp-mediated inhibition of this forskolin-stimulated state.
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Table 9 Acidic phospholipid-mediated inhibition of platelet
adenylate cyclase 
Results are shown as percentage-inhibitions; mean ±  S.D. 
for n= between 2 and 6 separate experiments as indicated. Each 
experiment used different membrane preparations and employed 
triplicate observations in each case. Amount of acidic PL present 
is 1 - 4mgs
Percentage-inhibition by phospholipids
Ligand
None (basal)
Forskolin
{icr1*^  1
PGEjl
NaF (  l5 rr>M )
P h o s p h o l i p i d
Phosphatidic
Acid
32.8 ±  7.6 
(n=5)
64.5 ±  5.4 
(n=6)
[34.5 ± 5.8) 
(n=3)
64.9 + 8.2 
(n=6)
[31.1 ± 5.4) 
(n=4)
30.6 ± 9.1 
(n=3)
Phosphatidyl­
serine
43.0 ±  5.6 
(n=2)
64.7 ±  4.7 
(n=2)
48.7 ± 4.8 
(n=3)
47.5 ±  3.5 
(n=2)
IbJ
Table 10 Effect of acidic phospholipids on fold stimulations
Results are shown as mean ±  S.D. for n= given number of separate 
experiments. Each experiment employs triplicate observations, and uses 
different membrane preparations.
Stimulatory Fold Stimulation
Ligand Control PA PS PC
PGEX 23.4 + 2.2 16.4 ± 2.3 21.5 ± 1.5 24.1 ±  2.1
(2 x 10“5M) (n=14) (n=7) (n=3) (n=3)
Forskolin 22.8 ±  1.7 16.1 ± 2.7 8.9 ± 4.2 22.2 ±  2.4
(lO-^H) (n=15) (n=8) <n=3) (n=3)
PA = phosphatidic acid 
PS = phosphatidylserine 
PC = phosphatidylcholine
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Table 11 Acidic phospholipid-mediated inhibition of adenylate
cyclase in the presence of manganese 
Results are mean + S.D. for n=3 separate experiments using 
different membrane preparations.
Concentration of manganese present is 5mM.
PercentaRe-inhibition by phospholipid
Lj.gand
None (basal)
Forskolin
<10“4M>
PGEi
(2 x 10_5M>
NaF
<15mM)
Phosphatidic Acid 
MS.
55 + 9 
6 3 + 4
6 6 + 4
6 3 + 4
Mn
6 8 + 3
6 5 + 6
5 5 + 1
65 + 14
Phosphatidyl Serine 
Hr Hn
47
ND
47
45
58
ND
48
60
ND = not determined
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Table 12 Effect of benzyl alcohol on phosphatidic acid-mediated
inhibition of adenylate cyclase 
Results are mean + S.D. for n=3 separate experiments using 
different membrane preparations.
Benzyl alcohol is present at a final concentration of 50mM.
Stimulatory Ligand
None (basal) 
Forskolin (10“^M) 
PGEX (2 x 10~5M) 
NaF (1.5 x 10-2M)
Percentage-inhibition by phosphatidic acid 
Absence of Presence of
Benzyl alcohol
37.2 ± 1.3
41.4 + 4.9
35.7 ± 1.0
39.3 + 3.1
Benzyl aocohol
34.4 ±  2.6
25.9 + 0.2
42.9 ± 0.6
44.3 + 1.9
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Table 13 Effect of acidic phospholipids on ligand-mediated
inhibition of adenylate cyclase 
Results shown are from preliminary experiments.
Percentage inhibition
56 
54
56
57 
72
Forskolin/Adrenaline 25
Forskolin/PS 61
Forskolin/Adrenaline * PS 67
Forskolin/PA 29
Forskolin/Adrenaline + PA 32
Forskolin/GppNHp 43
Forskolin/PS 61
Forskolin/GppNHp + PS 73
Forskolin/PA 29
Forskolin/GppNHp -i- PA 51
PS = phosphatidylserine
PGE^/adrenaline 
PGE1/PS
PGE/Adrenaline -t- PS 
PGE^/PA
PGE^/Adrenaline + PA
PA = phosphatidic acid
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(iii) Discussion
As the membrane bilayer is asymmetric with respect to 
lipid distribution, (acidic phospholipids being found predominantly 
in the cytosol half of the bilayer), it has been suggested that the 
addition of exogenous acidic phospholipids may preferentially 
manipulate this half of the bilayer. Indeed, it has actually been
shown that phosphatidic acid is able to induce a lipid phase
separation (at 16°C) in the inner half of the rat liver plasma
membrane in accordance with this (Houslay et al.., 1986c). It may,
therefore, arise that the activity of integral membrane proteins, 
such as adenylate cyclase, will be affected by such modulations.
From results reported here it would appear that acidic 
phospholipids are indeed capable of modulating adenylate cyclase 
activity in human platelet plasma membranes. Such modulation of 
enzymatic activity has been reported by others (Clark et al., 1980; 
Murayama & Ui, 1987; Schimmel et al., 1980; Proll et al.., 1985), 
although in these studies it was suggested that the ability to 
manipulate adenylate cyclase activity was specific to phosphatidic 
acid, and did not apply to acidic phospholipids in general. In 
human platelets, it would seem that the ability of phosphatidic acid 
to attenuate adenylate cyclase activity is mirrored in studies 
employing phosphatidylserine. Hence, it would appear that this
attenuating effect is common to other acidic phospholipids. The 
fact that the neutral phosphatidylcholine is unable to evoke such an 
inhibitory effect supports this proposal. These trends are in 
agreement with those reported by Houslay et jQ , , 1986c in studies on 
rat liver plasma membranes.
Exactly how these acidic phospholipid species mediate the 
inhibition of platelet adenylate cyclase is unclear. It has been 
suggested that phosphatidic acid inhibits adenylate cyclase by a
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process mediated by G-proteins (Murayama & Ui, 1987; Schimmel et 
al,, 1980; Proll et al., 1985). In fact, in fibroblasts it has 
been reported that not only is phosphatidic acid-mediated inhibition 
GTP-dependent, but such inhibition is attenuated by pertussis 
toxin. This would suggest that G. is the specific G-protein 
involved in this process. However, in the same study, phosphatidic 
acid was found to be incapable of inhibiting adenylate cyclase in 
other cell types (including platelets), and hence it was proposed 
that a direct effect of phosphatidic acid on G. was unlikely.
Instead, it was suggested that inhibition relied on the interaction 
of the G-protein with cell-specific phosphatidic acid receptors 
(Murayama & Ui, 1987). In this study of human platelets, it would 
appear that the addition of exogenous GTP is not required in order 
for acidic phospholipid-mediated inhibition to be observed.
However, it is not possible to discount the fact that a G-protein 
may play a role in mediating these effects. It may be that a 
high-affinity G-protein exists, such that enough GTP is already 
present in the platelet membrane to support this G-protein 
activity. Although not ruling out the involvement of a G-protein, 
the lack of requirement for exogenous GTP does suggest that the 
inhibitory G-protein, G^, is not the mediator of these effects.
This is supported by the fact that replacement of magnesium with 
manganese had no significant effect on the degree of inhibition 
elicited by phosphatidylserine. Had this inhibition been 
G.-mediated, it would have been expected that the addition of 
manganese would uncouple G.-C interactions (Hoffman et al., 1981), 
and that acidic phospholipid-mediated inhibition would be attenuated.
In conflict with this theory of G.-independent 
inhibition, is the apparent lack of additivity between acidic 
phospholipid-mediated inhibition and that known to be mediated by
G, (i.e. alpha^-adrenoceptor and GppNHp-mediated). This would 
1 2
imply that acidic phospholipid-mediated inhibition occurs via the 
same route, i.e. G^. However, the contrasting results of the 
experiments discussed previously would tend to dispel this notion, 
and it may be that the interaction of G^ with the catalytic unit, 
and the method by which acidic phospholipids cause inhibition are 
mutually exclusive. It should, however, be remembered that 
* additivity* experiments were very much preliminary results, and 
would require further characterisation before definite conclusions 
could be deduced from them.
Having eliminated G^ as being the mode by which these 
phospholipid species exerted their inhibitory effects on the 
platelet adenylate cyclase system, other methods were considered. 
Indeed, comparing phosphatidylserine-mediated inhibition of 
receptor-coupled (PGE^-stimulated) and receptor-uncoupled 
(forskolin-stimulated) states suggests that the modulation by 
phospholipid is at the level of a component common to these states, 
namely the catalytic unit. The forskolin-stimulated state is 
particularly sensitive to manipulation of membrane phospholipid 
composition.
Examining phosphatidic acid-mediated inhibition reveals 
the same trends, although here an enhanced effect is seen with 
inhibition of the PGE^-stimulated state also. This may tell us 
something of the nature of the PGE^-receptor interaction with the 
adenylate cyclase system; namely that the presence of phosphatidic 
acid in particular is detrimental to efficient coupling. Perhaps 
phosphatidic acid may be excluded from the coupling interface in 
native membranes, and the addition of exogenous phosphatidic acid 
would therefore lead to inhibition of this state in particular.
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If the interaction of acidic phospholipids in general is 
at the level of the catalytic unit, it may be that activation of 
this component by forskolin leads to a conformational change which 
renders the catalytic unit even more susceptible to inhibition by 
these phospholipid species. This is reflected in the degree of 
inhibition elicited by phospholipids on this state relative to both 
coupled states, and to basal activity (Table 9). As would be 
expected from the fact that the forskolin-stimulated state is 
inhibited to a greater degree than the basal cyclase state, acidic 
phospholipids are able to attenuate the fold-stimulation exerted by 
this ligand (as is phosphatidic acid able to reduce the 
fold-stimulation exerted by PGE^) (Table 10). Such manipulation 
of the ability of ligands to enhance adenylate cyclase is 
important. It may be that acidic phospholipids mediate their 
inhibitory effects by preventing stimulation of adenylate cyclase, 
as well as, or perhaps instead of, directly inhibiting the enzyme.
Whilst it is unlikely that acidic phospholipids act to 
modulate membrane fluidity (Houslay et al., 1986c), the effect of 
benzyl alcohol on the cyclase system was examined in the presence of 
these lipid species. It was thought that the addition of benzyl 
alcohol would influence enzymatic activity in a different manner to 
that observed in native membranes (see Section 3:1). Addition of 
50mM benzyl alcohol was, in fact, found to have no obvious effect on 
the degree of inhibition elicited by either phosphatidic acid or 
phosphatidylserine (Table 12). There is, however, one notable 
exception to this statement; namely phosphatidic acid-mediated 
inhibition of the forskolin-stimulated state, which was apparently 
attenuated by the presence of the local anaesthetic. No obvious 
reason for this effect can be suggested, although it may arise from 
an anomalous effect of benzyl alcohol on the forskolin-stimulated
state, as has been noted elsewhere (Section 3:1). On the other 
hand, it may be that this effect arises from the particular 
susceptibility of this stimulated state to inhibition by the acidic 
phospholipid species (Table 9), i.e. benzyl alcohol may induce a 
change in conformation such that this state is not as sensitive to 
phosphatidic acid. This phosphatidic acid-*insensitive’ state may 
arise due to benzyl alcohol modulation of membrane fluidity, or by a 
more direct prevention of phosphatidic acid interaction with the 
enzyme.
One aspect of acidic-phospholipid inhibition which can be 
deduced from experiments involving benzyl alcohol, is that 
phosphatidic acid-mediated inhibition (of receptor-coupled states) 
does not involve G-protein beta/gamma components which we have 
suggested as being benzyl alcohol-sensitive (Section 3:1). Whilst 
telling us nothing about the involvement of G-protein 
alpha-subunits, these results, in combination with those from 
manganese experiments, as well as the lack of requirement for GTP, 
tend to suggest that a G-protein is not the route by which acidic 
phospholipids inhibit platelet adenylate cyclase.
It has also been proposed that acidic phospholipids 
inhibit rat liver adenylate cyclase by a specific headgroup 
interaction, and that this perturbation is at the level of Gg 
(Houslay et a l ., 1986c). Obviously, whilst such specific headgroup 
interaction cannot be discounted, it would appear that in human 
platelets Gg is not the site of interaction, as the basal and 
G^-coupled states are inhibited to the same extent.
It should be noted that the effects observed here are not 
likely to have arisen through a loss of cholesterol from the 
platelet membranes during the incubation. Liposome incubation was 
under conditions which minimise such loss (short time, low
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temperature, and low concentrations). Also, experiments in rat 
liver plasma membranes showed that the inclusion of cholesterol in 
liposomes, to counteract any cholesterol depletion, had no 
appreciable effect on the degree of inhibition elicited (Houslay et 
al., 1986c). It would, therefore, appear that the observed effects 
of acidic phospholipids are mediated at the level of the catalytic 
unit.
It may be that acidic phospholipids mediate such changes 
in adenylate cyclase activity by virtue of their negative charge.
If this is so, then it might be expected that the negatively charged 
anaesthetic, pentobarbital, would exert similar effects. Comparing 
the results described in this chapter with those obtained in the 
presence of pentobarbital (Section 3.2) does show some 
similarities. For example, both these negative species are able to 
attenuate the activity of the platelet enzyme. This effect must be 
at the level of the catalytic unit in order to explain 
pentobarbital-mediated attenuation of the forskolin-stimulated state 
and phospholipid-mediated inhibition of the basal state. At this 
stage it is not possible to eliminate the possibility that both 
pentobarbital and acidic phospholipids inhibit cyclase by the same 
mechanism. However, when comparing the effect of these negative 
species on inhibitory aspects of enzyme regulation, differences 
arise. It has been proposed that pentobarbital modulates the 
efficiency of the G^-alpha-C interaction, and it is possible that 
this arises by the negative anaesthetic altering the catalytic unit 
such that G.-alpha cannot interact effectively. Hence, it may be 
possible to argue that this conforms to the mechanism whereby 
negatively charged species modulate cyclase activity at the level of 
the catalytic unit. However, upon examining the effects of acidic 
phospholipids on inhibitory aspects of regulation, it becomes
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apparent that these species do not adhere to this theory. Both 
phosphatidic acid and phosphatidylserine were found to have no 
effect on the ability of either adrenaline or GppNHp to inhibit 
adenylate cyclase. This suggests that these phospholipids do not 
modulate the ability of G^alpha to interact with the catalytic 
unit.
Hence, although pentobarbital and acidic phospholipids 
exhibit the same charge characteristics, their effects on the 
inhibitory arm of regulation are quite different. It is therefore 
likely that pentobarbital manipulates this aspect of regulation by 
modulating fluidity (i.e. as opposed to charge sensitivity), whilst 
acidic phospholipids have a more direct effect on the catalytic
unit, which does not extend to modulations in the ability of G.
1
(or G ) to interact with this component, 
s
(iv) Conclusion
Although it has been proposed that the inhibitory effects 
of phosphatidic acid are mediated at the level of the G-protein 
(Murayama & Ui, 1980; Proll et al., 1985), this is apparently not 
the case in human platelet membranes, i.e. neither G. nor Gg 
appear to be involved. It would seem that the ability to attenuate 
adenylate cyclase activity is not restricted to phosphatidic acid, 
but appears to apply to acidic phospholipids in general. It is 
proposed that this inhibition results from an effect at the level of 
the catalytic unit, although the precise mechanism by which this 
attenuation occurs is by no means clear.
CHAPTER 4
INTERACTION OF INSULIN AND THE PLATELET ADENYLATE 
CYCLASE SYSTEM
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4. INTERACTION OF INSULIN AND THE PLATELET ADENYLATE CYCLASE
SYSTEM
4.1 Introduction
Insulin modulation of platelet cyclic AMP levels may occur 
by two routes; either increased phosphodiesterase activity or 
reduced adenylate cyclase activity. Phosphorylation (Pyne & 
Houslay, 1988), involvement of a chemical mediator (Shirong et al. 
(1988)), and interaction of the G-protein system (Heyworth &
Houslay, 1983) have all been proposed as mediating the effects of 
insulin on both these enzymes. However, here we are able to rule 
out insulin modulation of phosphodiesterase activity, as studies are 
performed in the presence of phosphodiesterase inhibitors.
Instead, we will concentrate on the interaction of insulin with the 
adenylate cyclase system, and attempt to determine whether this 
occurs via the processes described above.
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4 .2 Results
Figures 49 and 50 show that PGK^ and forskolin-stimulated
adenylate cyclase activities were inhibited by insulin in an almost
identical manner. IC5o ^or ^ i s  inhibition was approximately
8.3uM for PGE^-stimulated adenylate cyclase (Fig.49) and
approximately lOuM for inhibition of the forskolin-stimulated state
(Fig.50). Examining the effect of insulin on the ability of these
ligands to bind and activate adenylate cyclase showed the f°r
—8
activation by PGE^ to be unaltered by 10 M insulin; being
0.30uM + 0.17 in the absence of insulin and 0.33uM + 0.17 in the 
presence of insulin (n=3 separate experiments using different 
membrane preparations). Forskolin-mediated activation was 
similarly unaltered, exhibiting an EC«^ of 15uM + 7.07 in the 
absence, and 8.5uM + 2.1 in the presence of insulin. Figure 51 
illustrates this point, i.e. that the dose effect curve for these 
ligands (in this case EGE^) was not shifted by the presence of 
insulin.
Attempts were made to manipulate insulin-mediated
inhibition by denaturing the insulin molecule. Heat denaturation,
through boiling the insulin for 5-10 minutes before use, resulted in
complete removal of the ability of insulin to attenuate either
PGE^ or forskolin-stimulated adenylate cyclase, e.g. approximately
34% inhibition seen with non-heat treated insulin was reduced to 0%
with boiled insulin.
The requirement of guanine-nucleotides for insulin-mediated
-4
inhibition was examined using both GTP (10 M) and the
. , —4
non-hydrolysable guanine nucleotide analogue GppNHp (10 M).
Table 14 shows that the presence of GTP had no effect on the 
percentage-inhibition mediated by insulin on either the PGE^ or 
forskolin-stimulated states. Similarly, the presence of the
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non-hydrolysable GppNHp did not influence the percentage-inhibition, 
nor did it alter the f°r insulin-mediated inhibition.
PGE^-stimulated adenylate cyclase was inhibited by insulin with an 
IC<.q of 8uM in the absence of GppNHp, and an IC^q of 9uM in its 
presence. The forskolin-stimulated state was inhibited by insulin
with an of lOuM in both the presence and absence of GppNHp. (
In order to determine if a G-protein was involved in 
insulin-mediated inhibition, maximally inhibitory concentrations of 
ligands were employed in the presence and absence of insulin to see
if additivity could be detected. Table 15 shows that adrenaline-
—4 —6 . . . . .(10 M, plus 10 M propranolol) and msulm-mediated inhibitions
were not additive. However, it may be that a slight co-operativity
exists when considering adrenaline- and insulin-mediated inhibitions
of both the PGE^ and forskolin-stimulated states. In the same
—8
manner, co-operativity may be observed with GppNHp (10 H) and 
insulin-mediated inhibitions of forskolin-stimulated adenylate 
cyclase. It should be noted that in human platelets, insulin was 
observed as being capable of stimulating a GTPase activity;
124.4% ±  11.4 activity being observed in the absence of benzyl 
alcohol. In the presence of 50mM benzyl alcohol no significant 
change in this activity was detected, being 132.8% + 18.8 activity 
(n=3 separate experiments using different membrane preparations).
If the effect of benzyl alcohol was examined with respect 
to insulin-induced inhibition of both receptor-coupled 
(PGE^-stimulated) and -uncoupled (forskolin-stimulated) states, it 
was found that inhibition was insensitive to the presence of the 
anaesthetic in both cases. Figure 52 showed insulin was able to 
inhibit forskolin-stimulated adenylate cyclase by approximately 40% 
over the range of benzyl alcohol concentrations studied; 0-50mM,
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From Figure 53 it can be seen that although insulin-attenuated the 
PGE^-stimulated state to a larger degree (approximately 75% 
inhibition), this too was unaffected by benzyl alcohol. This is in 
contrast to the effects of benzyl alcohol on adrenaline-mediated 
inhibition of these states; adrenaline-mediated inhibition of 
PGE^ being attenuated by the anaesthetic, whilst inhibition of 
forskolin was unaffected (see Section 3.1). Another way in which 
insulin-mediated inhibition differs from adrenaline-mediated 
inhibition is in it sensitivity to manganese. Figure 54 shows that 
whilst replacing macjGesium with manganese (5mM) resulted in a 
74.9% + 7.4 attenuation in the ability of adrenaline to inhibit 
adenylate cyclase, insulin-mediated inhibition showed no significant 
change.
In order to examine the possibilities that insulin may
mediate inhibition of adenylate cyclase by a route other than the
G-protein system, a number of other aspects of inhibition were
considered. As portrayed in Figure 55, the degree of inhibition
elicited by insulin is apparently independent of the time of
incubation. This applies not only to the inhibition of forskolin
as illustrated, but to inhibition of PGE^-stimulated adenylate
cyclase also i.e. 26.2% ±  4,8 at 12 minute incubation, and 32.4% +
5.1 at 24 minutes. Nor apparently was insulin-mediated inhibition
dependent upon the amount of protein present; protein levels
ranging from 5ug to 60ug yielded almost identical levels of
inhibition (Fig.56). This lack of dependence on protein
concentration was observable at other insulin concentrations too
i.e. not only was 10 insulin capable of inhibiting forskolin in
—8
a manner independent of protein levels, but so too was 5 x 10 M 
insulin. Here, with 1.5ug of portein, insulin led to a 35,3% 
reduction in adenylate cyclase activity, and at 30ug of protein, 
this inhibition was observed as 32.4% +4,0 (n=3).
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The replacement of the physiological enzyme substrate ATP, 
with its non-hydrolysable analogue AMP-PNP, apparently had no effect 
on the degree of inhibition elicited by insulin (Table 16). Once 
again this applies to inhibition of both the PGE^- and 
forskolin-stimulated states.
Finally, it should be noted that the insulin-like growth 
factor, IGF-I, was found to inhibit platelet adenylate cyclase. 
Inhibition of both PGE^- and forskolin-stimulated activities was 
observed, being 31.1% and 22.0% respectively. This inhibition 
occurred at approximately the same concentration as insulin-mediated 
inhibition i.e. 10 IGF-I, and 5 x 10 insulin (see Table 
17).
FiRure 49 Insulin dose effect curve for inhibition of PGE^-
stimulated adenylate cyclase activity 
Results are mean + S.D. for n=3 separate experiments using 
different membrane preparations.
Figures are expressed as pmoles cAHP/min/lOOul assay. 
Concentration of PGE^ is 2 x 10“^M.
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Figure 50 Insulin dose effect curve for inhibition of
forskolin-stimulated adenylate cyclase activity 
Results are mean + S.D for n=4 separate experiments using 
different membrane preparations.
Figures are expressed as pmoles cAHP/min/lOOul assay. 
Concentration of forskolin is 10~^M.
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FiRure 51 Effect of insulin (10 M) on PGE^-mediated-
stimulation of adenylate cyclase activity 
Results are mean ±  S.D for n=3 separate experiments using 
different membrane preparations.
Figures are expressed as pmoles cAKP/min/lOOul assay.
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FiRure 52 Effect of benzyl alcohol on insulin-mediated
inhibition of forskolin-stimulated adenylate cyclase 
activity
Results are mean + S.D for a single representative
experiment, employing triplicate observations.
n=3 separate experiments using different membrane
preaprations.
Concentration of forskolin is lO^M.
Insulin is present at a final concentration of l(r8M.
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Figure 53 Effect of benzyl alcohol on insulin-mediated
inhibition of PGE^-stimulated adenylate cyclase 
activity
Results are mean + S.D for a single representative
experiment, employing triplicate determinations.
n=3 separate experiments using different membrane
preparations.
Concentration of PGE^ is 2 x
Insulin is present at a final concentration of 10_8M.
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FiRure 54 Modulation of insulin-mediated inhibition by manRanese
< 5mM)
Results are mean + S.D. for n=3 separate experiments using 
different membrane preparations.
Condition 1 - Insulin inhibition + Mg 
Condition 2 = ” " +• Mn
Condition 3 = Adrenaline inhibition +- Mg 
Condition 4 - " " + Mn
Inhibition is shown as percentage of that observed in the 
2+presence of 5mM Mg (control) i.e. 100%.
185.
Adrenaline+Mn
Adrenaline+Mg
Insulin+Mn
Insulin+Mg
— i 
120
% Inhibition
FiRure 55 Insulin-mediated inhibition of forskolin-stimulated
adenylate cyclase as a function of time 
Results are mean + S.D. for n=3 separate experiments using 
different membrane preparations.
Concentration of forskolin is 10~^M.
Insulin is presentat a final concentration of 10 ^M.
% 
IN
HI
BI
TI
O
N
100
80
60
40
20
0
161410 1286
TIME (minutes)
FiRure 56 Insulin-mediated inhibition of forskolin-stimulated
adenylate cyclase: effect of protein concentration
Results are mean + S.D. for n=4 separate experiments using
different membrane preparations.
Concentration of forskolin is 10“^M._____
Insulin is present at a final concentration of
%
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Table 14 Effect of 10 GTP/GppNHp on insulin-mediated
inhibition of adenylate cvlase 
Results are mean ±  S.D. for n=4 separate experiments using 
different membrane preparations.
Percentage-inhibition
Stimulatory
Ligand
PGB1
(2 x 10“5M)
Forskolin
(10“4M)
[insulin]
10“6M
10“7M
i o~6m
10"7M
Absence of Presence of Presence of
added guanine 10~^M 10"^M
nucleotide GppNHp
61.7 ± 4.8
24.4 ± 9.1
55.9 ± 12.9
28.5 4- 5.2
GTP
64.5 4- 8.2 49.4 4- 3.9
21.9 + 6.8 N.D.
54.6 + 10.0 66.6 4 - 2.0
20.5 4- 0.2 N.D.
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Table 15 Additivity of insulin-mediated inhibition of adenylate
cyclase
Stimulatory
Ligand
P G E 1 (2x10"5M)
Inhibitory
Ligand
Adrenaline (10“^M) 
Insulin (10~^M> 
Adrenaline 4- Insulin
%-inhibition
44.0%
40.0%
57.6%
Forskolin (10~^H) Adrenaline (10~^m ) 41.8%
Insulin (10~6M) 32.2%
Adrenaline 4- Insulin 62.7%
GppNHp (10"8M) 56.7%
GppNHp 4- Insulin 7 7.2%
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Table 16 Insulin-mediated inhibition of adenylate cyclase in
the presence of AMP-PNP 
Figures are mean ± S.D. of n=3 separate experiments using 
different membrane preparations.
Percentage-inhibition
Stimulatory Inhibitory ATP AMP-PNP
Ligand Ligand
PGK^ Adrenaline 69.0 + 4.0 66.9 + 12.9
(2 x 10“5M) (10~4M)
Insulin 25.1 ± 6.1 25.6 ± 5.7
(10“8M)
Insulin 52.8 + 9.6 44.9 + 1.8
<10-6M)
Forskolin Adrenline 66.5 + 9.5 77.6 ± 3.5
(10-^M) (lO'^M)
Insulin 54.8 + 0.6 45.9 ±  0.4
(10“6M)
AMP-PNP is 1.5mM 
ATP is 1.5mM
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Table 17
Stimulatory
Ligand
PGE^ (2 x 10“ 
Forskolin (10
Comparison of insulin- and IGF-I-mediated inhibitions 
of adenylate cyclase activity
Insulin IGF-I
(5xlO"7M) (10“7M>
Percentage inhibition 
M) 31.9% 31.2%
4M) 30.3% 22.0%
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4.3 Pi scussion
In this study, the ability of insulin to mediate inhibition 
of both receptor-coupled (prostaglandin E^-stimulated) and 
receptor-uncoupled (forskolin-stimulated) states was 
characterised. This inhibition is in agreement with studies by 
Heyworth & Houslay (1983) on rat liver plasma membranes; but is in 
contrast to reports by a number of other groups (Falcon et al.,
1988). A recent report by Kahn and Sinha (1990), suggests that at 
physiological concentrations (nM), insulin is able to stimulate 
prostaglandin E^ binding to human platelet membranes, and to lead 
to activation of adenylate cyclase. This report was based on 
studies employing intact platelets, and proposed that the 
insulin-mediated enhancement of prostaglandin E^-stimulated 
adenylate cyclase activity arose from insulin increasing the 
availabiltiy of ’spare’ prostaglandin E^ receptors in the membrane 
bilayers. No effect of insulin was noted on isolated platelet
membranes. Although populations of such ’spare’ receptors may have
occurred in our membrane preparations, the lack of ability to detect 
this activation phase illustrates the complexity of insulin’s 
effects on the platelet adenylate cyclase system. It may be that 
the full mechanism behind insulin’s ability to activate 
PGE^-stimulated adenylate cyclase is more complex than noted by 
Kahn et a l ., and remains unidentified.
The ability to detect insulin-mediated inhibition of
adenylate cyclase is also a matter of conflict, although such
inhibition was routinely detected here. The concentration of
insulin required to mediate this inhibition of platelet adenylate
cyclase (10 ^M) was much greater than that noted to cause
-9inhibition in the rat liver plasma membrane system (10 M)
(Heyworth & Houslay, 1983). The higher levels of insulin required
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to exert inhibition may reflect a difference in the platelet insulin 
receptor relative to those expressed in more conventional target 
tissues (Falcon et al.., 1988).
One reason which has been proposed as contributing to the
conflicting reports on the ability of insulin to attenuate adenylate
cyclase activity is the method of analysis applied. In the
majority of cases where insulin-mediated inhibition was not
detectable, the method by which cyclic AMP was detected involved the
use of a 'trap* of unlabelled cyclic AMP (cf. Salomon assay/CnI 
32I P]-assay). It has been suggested that the presence of this
pool of exogenous cyclic AMP stimulates any cyclic AMP-dependent
protein kinase which may be present in the membranes. The result
of this stimulation is that the kinase phosphorylates the
insulin-receptor to attenuate its functioning: insulin-mediated
inhibition is thereby negated (Houslay, 1990). Indeed,
insulin-mediated inhibition of platelet adenylate cyclase was
undetectable employing the cyclic AMP determination method of
Salomon et al^ . (1974) over a concentration range of 10 ^  to 
-410 M insulin. For this reason, the method employed to assay 
adenylate cyclase here utilised the cyclic AMP binding assay of 
Brown et al.. (Brown et al., 1972) as detailed in Materials and 
Methods, Section 2.8.
As stated previously, both PGE^~ and forskolin-stimulated 
states were inhibited by insulin. The fact that these states were 
inhibited with similar IC^'s would suggest that this 
insulin-mediated inhibition may occur by the same route. Whichever 
route insulin takes to mediate this inhibition is unclear.
However, it does not involve insulin acting to prevent ligand 
binding: EC5q f°r stimulatory ligands is unaltered by the
presence of insulin, as shown in Figure 51,
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As other groups have suggested that insulin inhibits 
adenylate cyclase via interaction with the G-protein system (Gawler 
& Houslay, 1987; Heyworth & Houslay, 1983), various methods were 
employed to see if this was the route of insulin inhibition of the 
platelet adenylate cyclase system. First of all, to ensure that 
the inhibition detected was due to an action of insulin, it was 
decided to denature the insulin molecule, and thereby remove the 
inhibition of adenylate cyclase. Boiling insulin for 5-10 minutes 
before use resulted in heat denaturation, and as expected, this 
species was unable to elicit inhibition of the enzyme. Attempts to 
break the disulphide bonds of the insulin molecule by treatment with 
thiol reagents such as mercaptoethanol, were unsuccessful when 
applied to this system. This is thought to result from the fact 
that thiol reagents have previously been shown to interfere with 
activity of this enzyme. For example, dithiothreitol (DTT) has 
been shown to directly activate rabbit skeletal muscle adenylate 
cyclase. It is presumed that this effect arises due to interaction 
of DTT with an essential sulphdryl moiety in the enzyme (Wright & 
Drummond, 1983).
Having established the the observed inhibition was indeed 
due to insulin, the requirement of GTP/GppNHp was then examined. 
Table 14 shows that these guanine-nucleotides neither modulate the 
ICj.q for insulin-inhibition, nor altered the percentage-inhibition 
mediated by this ligand. This would tend to rule out the 
involvement of a G-protein in the route by which insulin inhibits 
platelet adenylate cyclase. However, it could be that the 
G-protein involved has a high affinity for GTP, such that saturating 
levels of the nucleotides are already present in the membranes i.e. 
before exogenous guanine-nucleotide is added. Other groups have 
reported the involvement of a novel G-protein, which has an
195.
affinity for GTP of K =0.6uM (Gawler & Houslay, 1987) and indeed
m
it was noted that insulin was capable of activating such an activity 
in human platelets (124.4% + 11.4 activity).
Another means by which the involvement of G-proteins can be 
examined is by the use of ligands known to inhibit adenylate cyclase 
via the G-protein system. Here maximally inhibitory concentrations 
of these ligands were employed, and then insulin added to see if 
further inibition could be detected. Any further inhibition 
should, in theory, occur by a route other than G^, as this route 
is already functioning to maximal capacity. In this study on 
platelets, full additivity was not found with insulin and either 
adrenaline, or GppNHp. This would suggest these species must 
inhibit adenylate cyclase by the same route, namely, G. .
However, some co-operativity was observed with insulin and 
adrenaline as well as insulin and GppNHp. This co-operativity 
suggests that insulin is indeed capable of mediating inhibition by a 
route other than G^. Whilst it may be that part of the 
insulin-mediated inhibitory pathway is via G., the results shown 
here illustrate the existence of another route, which can account 
for up to two-thirds of the observed adenylate cyclase inhibition. 
What this other route may be is the subject of investigation here.
Comparison of insulin-mediated inhibition with other 
ligand-mediated inhibitions of adenylate cyclase should suggest a 
route(s) by which insulin acts. Not only did insulin inhibit 
forskolin-stimulated adenylate cyclase to a similar degree to that 
observed with adrenaline and GppNHp, but this inhibition was also 
insensitive to the local anaesthetic benzyl alcohol. This suggests 
that insulin may inhibit cyclase via G^-alpha interaction with the 
catalytic unit. However, insulin-mediated inhibition of 
prostaglandin was also benzyl alcohol-insensitive (and
therefore differed from adrenaline-mediated inhibition of
prostaglandin E^) suggesting that although a G.-alpha component
may be involved in inhibition, a beta/gamma component apparently is
not, i.e. beta/gamma-mediated inhibition is reported as being benzyl
alcohol-sensitive (Section 3.1). If insulin inhibition of
adneylate cyclase is a G^-mediated process, it is unclear why such
inhibition of the prostaglandin E^-stimulated state does not
involve a beta/gamma component. Also, such a condition would raise
the question, what accounts for the difference in
percentage-inhibition mediated by insulin on the forskolin- and
PGE^-stimulated states? Perhaps insulin does inhibit adenylate
cyclase via a G-protein, but not G,. If insulin-mediated
inhibition was through the putative * it may be that
G. alpha-inhibition was analogous to G.alpha-inhibition, being 
m s  1
benzyl alcohol-insensitive, whilst G. beta/gamma mediated 
inhibition was different from G^ beta/gamma, i.e. the latter is 
benzyl alcohol-sensitive and the former is insensitive. Exactly 
why this would be so is unclear, although the beta/gamma ’family’ of 
molecules is being shown to be much more heterologous than 
previously thought (Robishaw et ajl., 1989).
A final attempt to determine directly whether or not G^ 
was involved in the actions of insulin entailed the use of manganese 
in the assay medium. At 5mM, manganese is believed to uncouple 
G. interaction with the catalytic unit, and indeed, 
adrenaline-mediated inhibition was attenuated in accordance with 
this (Fig.54). However, it would appear that the replacement of 
macjnesium with manganese has no effect on insulin-mediated 
inhibition, suggesting the G^-component is not involved in 
insulin-mediated inhibition of adenylate cyclase.
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The possibility that insulin might mediate its effects via 
the production of a chemical mediator was considered next. As it 
has been suggested that these mediators arise from the breakdown of 
inositol glycolipids in the membrane (Houslay, 1986) it might be 
expected that their production would vary with time and with the 
amount of membrane (and therefore substrate) present. Here, 
however, it was found that length of incubation (Fig.55) was not a 
factor in determining the degree of inhibition elicited by 
insulin. This would tend to suggest that the production of a 
mediator probably is not a step in insulin's actions on adenylate 
cyclase. This suggestion receives further support from the 
observation (Fig.56) that the amount of protein present in the assay 
is not a factor either. Again, however, the possibility arises 
that insulin may stimulate a specific phospholipase in a much 
shorter time span than that considered here, and that the efficiency 
of this phospholipase may be such that a very small amount of 
substrate is required, i.e. that insulin produces a highly effective 
mediator in small quantities, over a short time, and that this could 
not be detected by the limitations of these experiments.
Another possible route of insulin-mediated inhibition which 
was considered was the possibility that the insulin-receptor acted 
to phosphorylate some component of the adenylate cyclase system.
This suggestion arises because the insulin-receptor is known to 
exhibit an endogenous tyrosyl kinase activity (Houslay & Siddle,
1989). It may be that insulin stimulates the receptor such that 
this kinase activity is employed either to phosphorylate cyclase 
directly, or to initiate a phosphorylation cascade which results in 
phosphorylation of the enzyme. In either case it may be that 
phosphorylation of occurs such that it attains a more active 
conformation, or, that phosphorylation of Gg or C occurs such that
198.
activation of adenylate cyclase cannot arise. The use of the 
non-hydrolysable AMP-PNP, whilst not distinguishing between these 
possibilities will rule out the involvement of phosphorylation in 
general as the mechanism of insulin-induced inhibition. Indeed, 
experiments here (Table 16) show that insulin-inhibition was equally 
effective in the presence of AMP-PNP as with ATP. This suggests 
that insulin inhibition cannot be via phosphorylation, i.e. the 
terminal phosphate moiety cannot be transferred to some component of 
the adenylate cyclase system.
Finally, the action of insulin-like growth factor I was 
determined on the platelet adenylate cyclase system. It was 
observed (Table 17) that this growth promoting polypeptide was 
capable of inhibiting both receptor-coupled (PGE^-stimulated) and 
receptor-uncoupled (forskolin-stimulated) adenylate cyclase 
activities. This inhibition occurs to approximately the same 
degree as that observed with similar concentrations of insulin, and 
raises the question, are IGF-I and insulin acting through the same 
receptor, and if so, is it the IGF-I or insulin receptor?
It has been reported that IGF-I may simply act as a 
low-affinity insulin analogue and mediate many of its insulin-like 
activities by binding to the insulin receptor. However, it is 
proposed that the IGF-I-mediated inhibition observed here does not 
arise by this route but, rather, that IGF-I acts to attenuate 
platelet adenylate cyclase activity via interaction with its own 
receptor. This proposal arises due to the fact that IGF-I can 
mediate inhibition of adenylate cyclase at concentrations of the 
same order of magnitude as insulin, whilst it has been reported that 
IGF-I is less than 1% as potent as insulin at the insulin receptor 
(Baxter & Williams, 1983). It would therefore appear that insulin 
and IGF-I either bind to their own specific receptors, or both act 
through the IGF-I receptor.
By analogy to the previous argument, it is unlikely that 
insulin acts by binding to the IGF-I receptor. Binding of this 
polypeptide to the IGF-I receptor again occurs with a much lower 
affinity than the binding of the natural substrate. Here the order 
of binding affintiy is IGF-I^IGF-II^Insulin (Hollenberg, 1985) and 
hence binding of insulin at a receptor other than its own would not 
explain the insulin-mediated inhibition of adenylate cyclase 
observed here.
Even though IGF-I and insulin are related both structurally 
and functionally, it would appear from their ability to inhibit 
platelet adenylate cyclase by similar degrees at the same 
concentrations, that each does so by acting as its own specific 
receptor.
4.4 Conclusion
In conclusion, it would appear that insulin is capable of
inhibiting the platelet adenylate cyclase system via an interaction
with its own specific receptors. However, the route by which these
receptors mediate the action of this peptide within the platelet is
unknown. From this study it would appear that no possible route
can be eliminated, although some appear more probable than others.
It would appear that insulin does not cause inhibition via
preventing ligand binding, and so inhibition must arise by a more
direct interaction of insulin with the adenylate cyclase system.
Whether this interaction involves a G-protein is debatable. On one
hand, insulin-mediated inhibition apparently does not require the
presence of exogenous GTP, although insulin was shown to activate a
specific GTPase activity. The possibility that the G-protein in
question may be G^ is remote, as not only does manganese fail to
attenuate this inhibition, but examining the effect of benzyl
alcohol on insulin-mediated inhibition suggests that it occurs by a
different route to the known G.-mediated, adrenaline inhibition.
1
It may be that the G-protein in question is actually * this
would explain the observed GTPase activity, and perhaps also the
apparent lack of requirement for GTP, i.e. enough GTP is already
present in the membranes, as G. has a high affinity for them s
nucleotide. Hence, it may be that at least some of the
insulin-mediated inhibition of platelet adenylate cyclase arises via
the action of G.m s
From the studies with the non-hydrolysable AMP-PNP, it 
would seem unlikely that phosphorylation plays a major role in 
inhibition of the platelet enzyme system. This is in agreement 
with a recent study, where hepatocyte G. alpha was reported as 
being unable to be phosphorylated by insulin treatment of either
Z.U.L .
whole cells or isolated membranes (Pyne et al. , 1989). It was 
suggested that a change in alpha conformation may arise by such 
insulin treatment rather than a stable (covalent) modification, such 
as phosphorylation. It would also appear that the production of a 
mediator-substance is not a major inhibitory route either.
However, caution should be taken not to disregard these 
possibilities, especially with respect to the production of the 
mediator, as it may be that formation of such compounds is not 
detectable within the constraints of detection methods employed here.
Finally, it should be noted that the insulin-like compound 
IGF-I is also capable of attenuating the platelet adenylate cyclase 
system; apparently via its own specific receptors. Again, the 
method of inhibition is unclear.
In summary, insulin-mediated inhibition of adenylate 
cyclase was detected in human platelet membranes. It would appear 
that the route by which this inhibition occurs involves, at least to 
some degree, a G-protein, possibly Gjns* It maY be that 
inhibition results by a combination of routes, or by some route, as 
yet, unidentified, e.g. it has been proposed that other distinct low 
molecular weight subunits may be associated with the insulin 
receptor, and that they may prove to be part of the signal 
generating mechanism.
Indeed the route by which insulin mediates inhibition of 
adenylate cyclase in human platelets appears to differ from that 
which mediates inhibition in hepatocytes. This conclusion arises 
by the following observations, (a) higher concentrations of insulin 
were required to mediate inhibition in platelets, (b) no exogenous 
GTP was required to mediate inhibition of the platelet enzyme, and 
(c) insulin had no effect on the ability of GppNHp to attenuate 
forskolin-stimulated adenylate cyclase, whilst it is reported to
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diminish such inhibition in hepatocytes (Pyne et al., 1989). the 
possibility that platelet insulin-mediated inhibition was different 
from that expressed in hepatocytes was suggested by work from other 
groups; platelet insulin-stimulated GTPase being reported as being 
cholera-toxin sensitive/pertussis toxin insensitive, whilst both 
bacterial toxins were reported to suppress insulin-mediated 
inhibition of hepatocyte adenylate cyclase (Gawler & Houslay 
(1987); Morgan (1989)). The differences in these mechanisms 
remain to be determined, a problem which will be solved when the 
exact mechanism of insulin-mediated inhibition is defined.
CHAPTER 5
G p p N H p - M E D I A T E D  A C T I V A T I O N  O F  T H E  P L A T E L E T  
A D E N Y L A T E  C Y C L A S E  S Y S T E M
5. Gp pNHp -MEDIATED ACTIVATION OF THE PLATELET ADENYLATE
CYCLASE SYSTEM 
5.1 Introduction
Activation of adenylate cyclase at the level of the 
stimulatory guanine nucleotide regulatory protein Gg, is possible 
by a number of means (see Section 1.3(iv)), including the use of 
non-hydrolysable GTP analogues such as GppNHp. In a number of 
systems where such direct activation has been studied, it has been 
noted that hysteresis occurs; a period of slow activation preceding 
a phase of linear activity. Although this effect has been observed 
in rat liver membranes (Iyengar & Birnbaumer, 1981), reconstituted 
cyclase systems (Iyengar, 1981) and human platelet membranes 
(Farndale et ajL* , 1987) amongst others, its exact cause has been a 
matter of debate.
Extensive kinetic studies on GppNHp-mediated activation of
rat liver adenylate cyclase have ruled out a number of possible
causes of this slow activation phase. Amongst these is the
proposal that this period arises due to the slow dissociation of
resident GDP molecules from Gg . The finding that the rate of
activation varies between GTP and its various analogues disproved
the theory that GDP-dissociation is the rate-limiting step (Iyengar
& Birnbaumer, 1981a), as did the observation that NaF-mediated
24-
activation of Gg exhibits hysteresis at low Mg concentrations, 
i.e. NaF exhibited a lag phase in its activation of G^, yet this 
species does not require GDP dissociation (Iyengar, 1981).
Likewise, the theory that the cause of the rate limiting step lay in 
the difference in the susceptibility of the gamma phosphate bond to 
hydrolysis was similarly disproved. Although GppNHp is indeed 
insensitive to terminal phosphatases, that this is not the basis of 
the rate limiting step was confirmed by studies in rat liver plasma
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membranes. Here it was found that hysteresis could be observed in
2+ .
the action of GTP, if the Hg ion concentration was lowered to
below ImM (Iyengar & Birnbaumer, 1981).
The existence of this lag period is in fact, believed to
reflect the conversion of G from an inactive to an active form;s
G inactive-G active (Iyengar & Birnbaumer, 1981; Iyengar, 
s s
1981). The active form produced is believed to reflect a
reversibly activated state, which can undergo further conversion to
give the quasi-irreversible state, i.e.
G active(reversible)— ^G active(irreversible) 
s s
Conversion of G (rev) to G (irrev) is not rate limiting 
s s
and follows first-order kinetics (Farndale et ajl., 1987).
Activation of G^ is therefore thought to involve at least two
steps, and can be summarised as:
G inactive — ^ G active (rev) - - -> G active (irrev) 
s ' s s
The conversion of G from its inactive form to its active
s
form is thought to involve dissociation of the alpha/beta/gamma 
holomer:
Gg alpha/beta/gamma ^G^alpha +- beta/gamma
This equilibrium reaction actually accounts for the
formation of the Gg active (rev) species, which in human platelets
has been proposed to be less effective than G^ (irrev) in
activating the catalytic unit of adenylate cyclase. However, in
other systems such as rat liver, G (rev) and G (irrev) are reported
as being equipotent with regard to their ability to activate C.
Here we attempt to manipulate the equilibrium:
Gs alpha/beta/gamma -• Gs +■ beta/gamma
inactive active
by addition of guanine nucleotides, beta/gamma subunits etc. In
doing so, it is hoped that the lag phase in GppNHp-mediated
activation of adenylate cyclase can be manipulated, i.e. proof that
the conversion of G from its inactive form to its active form is
s
the rate limiting step in GppNHp-mediated activation of the platelet 
adenylate cyclase system.
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5.2 Results
From Figure 57 it can be seen that activation of human 
platelet adenylate cyclase by the non-hydrolysable GTP analogue 
GppNHp occurred following a lag period. Indeed, activation was 
linear with time only after an initial period of slow activation 
lasting approximately 6.4 minutes. However, the actual duration of 
this lag phage varied between membrane preparations and reagent 
batches. The average lag was 5.7 minutes ± 2 . 7  in length, where 
n=17 separate, experiments using different membrane preparations.
The duration of this lag phase was found to be independent 
of the concentration of guanine nucleotide analogue employed 
(Fig.58). GppNHp at concentrations of 0.01, 1.0 and lOOuM, 
elicited a lag phase lasting approximately 3.3. minutes. However, 
although this period of slow activation was unaffected, increasing 
GppNHp concentrations did enhance the steady-state rate of 
activity. Similarly, the actual extent of activation was augmented 
by increasing levels of the nucleotide. This is in agreement with 
studies of adenylate cyclase activation in rat liver membranes 
(Iyengar & Birnbaumer, 1981; Iyengar, 1981).
Previously it has been shown that the activation of G
s
requires the simultaneous presence of guanine nucleotides and 
divalent metal ions (Iyengar & Birnbaumer, 1982). In the presence 
of saturating GppNHp concentrations (lOOuM), the presence of a lag 
phase in the activation of Gg was found to be dependent on the 
concentration of divalent metal ion present (Fig.59). Increasing 
the concentration of magnesium ion from the normal 5mM present in 
the assay, to 25mM, or replacing it with 5mM of manganese ion, 
resulted in a reduction in the lag period. Typically, steady state 
activation occurred following a much shorter length of time, the lag 
being reduced to less than one-quarter of its original duration.
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For example, the lag of 3,6 minutes depicted in Figure 59 in the 
2+
presence of 5mM Mg , could be seen to be reduced to less than 1
2+ 24-
minute with 25mM Mg (0,95 m m ) ,  or 5mM Mn (0.90 mm).
Here, although the actual extent of activation was enhanced by
manipulation of the divalent cation species/concentration, the
steady-state velocity was essentially unaltered; 32.5 with 5mM
Mg^+ and 36.8 with 5mM Mn^*.
It was possible to reduce the duration of this lag phase by
pre-incubating platelet membranes with GppNHp. Figure 60 shows
that a 10 minute pre-incubation in the presence of lOOuM GppNHp/5mM 
24-
Mg resulted in the lag time being reduced from 5.5 minutes to
2.3 minutes. Adenylate cyclase activity was also increased with
pre-incubation time, being typically forty percent higher than that
observed in the absence of such pre-incubation. Steady-state rates
also showed a slight increase with pre-incubation, being 92,8 in the
absence of such treatment, and 118.9 following a 20 minute
pre-incubation.
Further attempts to manipulate the equilibrium between Gg
inactive and G active included examining the effect of the local 
s
anaesthetic benzyl alcohol on GppNHp-treated platelet membranes. 
Addition of benzyl alcohol was found to shorten the length of the 
period of slow activation from 6,3 to 2.1 minutes at 50mM 
anaesthetic and to 1 minute at 80mM anaesthetic (Fig.61). Similar
results were found each time this experiment was performed; in some 
cases, 80mM benzyl alcohol totally abolished the lag phase, i.e. 
activation was linear with time. Assuming this effect of benzyl 
alcohol was due to the ability of the anaesthetic to manipulate 
membrane fluidity (see Section 1.3(vi)), performing the experiment 
at higher temperatures should mimic this effect. Indeed, at 35°C 
the initial lag period seemed to be shorter (3,83 + 0.1 min; n=3
2 0 8 .
separate experiments employing different membrane preparations) and 
lower concentrations of benzyl alcohol were required to abolish this 
phase, i.e. 50mM benzyl alcohol was sufficient to reduce the lag to
zero (Fig.62). At both normal assay temperature (25°C) and at
higher temperatures (35°C) benzyl alcohol led to an increase in 
steady state velocities, and to an increase in the extent of 
adenylate cyclase activation.
Assuming that activation by GppNHp does involve the 
dissociation of the alpha/beta/gamma heterotrimer, the effect of 
adding purified beta/gamma subunits to the equilibrium reaction was 
examined. Figure 63 shows that the presence of these subunits 
appeared to lengthen the duration of the lag phase. It should be 
noted that in some experiments excess beta/gamma had no detectable 
effect on the adenylate cyclase activity measured. Here, however,
the original lag of 4.5 minutes was increased to 6.2 minutes
duration,
The presence of exogenously added beta/gamma subunits also 
reduced the steady-state velocity and led to an overall inhibition 
of adenylate cyclase activity. In fact, at 10 minute incubation 
with beta/gamma, GppNHp-stimulated adenylate cyclase activity could 
be inhibited by up to 95%, This inhibition may be dependent upon 
the concentration of beta/gamma-subunits present, e.g. 94.5% + 3.3 
inhibition observed with 3.72ug*s of the dimer v/as reduced to 77.6% 
inhibition with 0,93ug*s beta/gamma. Addition of benzyl alcohol to 
this system would appear to go some way to overcoming this beta/ 
gamma-mediated inhibition, and to shorten the duration of the 
beta/gamma-lengthened lag phase. This is seen in Figure 64 where 
the original 6.5 minute lag was lengthened to 7.3 minutes by the 
addition of beta/gamma subunits. By adding 50mM benzyl alcohol to 
this system, the lag was reduced to 3.2 minutes. The anaesthetic
did not therefore completely overcome the inhibitory effect of 
beta/gamma, as benzyl alcohol alone could reduce the GppNHp-induced 
lag to 2.7 minutes duration.
Other attempts to manipulate this GppNHp-induced lag were 
made by employing the use of bacterial toxins. Treatment of 
platelet membranes with cholera toxin, which leads to a persistently 
activated Gg state, resulted in a 2.5-3.0 fold augmentation of 
adenylate cyclase activity. The length of the lag phase was also 
reduced; in fact, in some cases actually being abolished 
(Fig.65). A slight increase in steady state velocity was also 
observed under these conditions.
Pertussis-toxin treatment of membranes which 
ADP-ribosylates the inhibitory guanine nucleotide regulatory protein 
G. , also augmented adenylate cyclase activity. The increase in 
enzymic activity seen here was not as great as that observed with 
cholera toxin, being only 1.5-fold (Fig.66). Again, the duration 
of the lag phase was reduced (from 4.4 minutes to 1.8 minutes), but 
was never totally removed; maximal reduction being 59%. 
Pertussis-toxin treatment of platelet membranes had an even smaller 
effect on steady state velocity than did cholera toxin mediated 
ADP-ribosylation.
The addition of high salt concentrations to 
GppNHp-stimulated adenylate cyclase, resulted in an overall 
inhibition of activity. Here there was a decrease in steady state 
velocities, as well as a lengthening of the lag period. This is 
illustrated in Figure 67, where a 1,1 minute lag was increased 
approximately 3-fold, to give a 3,5 minute lag in the presence of 
500mM sodium chloride.
Finally, the effect of adding an inhibitory hormone to the 
system was examined with regard to its effect on the GppNHp-induced
—4 . —6
lag. Addition of 10 M adrenaline < + 10 M propranolol) would
appear to lengthen this lag period (Fig.68). Here a 2.8 minute lag
was increased to 5 minutes duration by the presence of this hormone
which stimulates G. via the inhibitory alpha^-adrenoceptor.
Figure 57 Activation of platelet adenylate cyclase by the
non-hydrolysable guanine nucleotide analogue. GppNHp 
Results are mean ± S.D. of a single representative 
experiment employing triplicate observations. n=17 separate 
experiments using different membrane preparations.
Results are shown as pmoles cAMP/mg protein.
Lag period = 6.4 minutes.
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Figure 58 Effect of varyinK GppNHp concentrations on
activation of adenylate cyclase 
Results are mean + S.D. of a single representative 
experiment employing triplicate determinations. n=3 separate 
experiments using different membrane preparations.
Results are shown as pmoles cAMP/mg protein.
Lag period = 3 . 3  minutes.
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Figure 59 Effect of varying divalent cations on
GppNHp-stimulated adenylate cyclase activity
Results are mean + S.D, of a single representative
experiment employing triplicate determinations, n=3 separate
experiments using different membrane preparations.
Results are shown as pmoles cAHP/mg protein,
2+Lag period = 1 ) 3.6 minutes with 5mM Mg
ii) 0.96 minutes with 25mM Mg^*
2 +m )  0.90 minutes with 5mM Mn
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Figure 60 GppNHp-mediated activation of adenylate cyclase
following* a pre-incubation period 
Results are mean + S.D. of a single representative 
experiment employing triplicate determinations. n=3 separate 
experiments using different membrane preparations.
Results are shown as pmoles cAMP/mg protein.
Lag period = i) 5.5 minutes without pre-incubation
ii) 2.3 minutes with 10 minute 
pre-incubation
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Figure 61 Effect of benzyl alcohol on GppNHp-mediated
stimulation of adenylate cyclase activity (25°C) 
Results are mean + S.D. of a single representative 
experiment employing triplicate determinations. n=14 separate 
experiments using different membrane preparations.
Results are shown as pmoles cAMP/mg protein.
Lag period = i) 6.3 minutes with OmM benzyl alcohol 
ii> 2.1 minutes with 5OmM benzyl alcohol
iii) 1.0 minutes with 80mM benzyl alcohol
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FiRure 62 Effect of benzyl alcohol on GppNHp-mediated
stimulation of adenylate cyclase activity (35°C) 
Results are mean + S.D. of a single representative 
experiment employing triplicate determinations. n=3 separate 
experiments using different membrane preparations.
Results are shown as pmoles cAMP/mg protein.
Lag period = i> 3.8 minutes with OmM benzyl alcohol 
ii) 0 minutes with 5OmM benzyl alcohol
iii) 0 minutes with 80mM benzyl alcohol
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Figure 63 Addition of purified beta/gamma subunits to the 
GppNHp-activated adenylate cyclase system 
Results are mean + S.D. of a single representative 
experiment employing triplicate determinations. n=3 separate 
experiments using different membrane preparations.
Results are shown as pmoles cAMP/lOOul assay volume.
Lag period = i) 4.5 minutes in the absence of beta/gamma 
ii) 6.2 minutes in the presence of beta/gamma
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Figure 64 Modulation of the GppNHp-induced lag by benzyl alcohol
and purified beta/gamma-subunits 
Results are mean + S.D. of a single representative 
experiment employing triplicate determinations. n=2 separate 
experiments using different membrane preparations.
Results are shown as pmoles cAMP/lOOul assay volume.
Lag period = A) 6.5 minutes
B) 7.2 minutes in the presence of beta/gamma
C) 2.7 minutes in the presence of 
beta/gamma and 50mM benzyl alcohol
D) 3.2 minutes in the presence of 50mM 
benzyl alcohol
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Fifture 65 Effect of cholera toxin on GppNHp-mediated stimulation
of adenylate cyclase activity 
Results are mean + S.D. of a single representative 
experiment employing triplicate determinations. n=2 separate 
experiments using different membrane preparations.
Results are shown as pmoles cAMP/mg protein.
Lag period = i) 3.0 minutes before cholera toxin treatment 
ii) 0 minutes after cholera toxin treatment
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Figure 66 Effect of pertussis toxin on GppNHp-mediated
stimulation of adenylate cyclase activity 
Results are mean + S.D. of a single representative 
experiment employing triplicate determinations. n=2 separate 
experiments using different membrane preparations.
Results are shown as pmoles cAMP/mg protein.
Lag period = i) 4.4 minutes before pertussis toxin treatment
ii) 1.8 minutes after pertussis toxin treatment
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FiRure 67 Modulation of GppNHp-stimulated adenylate cyclase
activity by hiRh salt concentrations 
Results are mean + S.D. of a single representative 
experiment employing triplicate determinations, n=4 separate 
experiments using different membrane preparations.
Results are shown as pinoles cAMP/mg protein.
Lag period = i) 1.1 minutes with OmM NaCl
ii) 2.7 minutes with lOOmM NaCl
iii) 3.5 minutes with SOOmM NaCl
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FiRure 68 Modulation of GppNHp-stimulated adenylate cyclase 
activity by adrenaline (+ propranolol)
Results are mean ± S.D. of a single representative 
experiment employing triplicate determinations. n=2 separate 
experiments using different membrane preparations.
Results are shown as pmoles cAMP/mg protein.
Lag period = i) 2.8 minutes in the absence of adrenaline/ 
propranolol
ii) 5.0 minutes in the presence of adrenaline/ 
propranolol
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5.3 Pi scussion
Activation of adenylate cyclase by the non-hydrolysable
guanine nucleotide analogue GppNHp, has previously been shown to
exhibit hysteresis (Iyengar & Birnbaumer, 1981). Here it was
observed that-the platelet adenylate cyclase system is no exception,
exhibiting a lag phase of average duration 5.7 minutes. This is in
agreement with the magnitude of the lag detected by other groups
studying platelet adenylate cyclase (Farndale et al. , 1987).
Manipulating the concentration of guanine nucleotide present
apparently did not affect the lag time, suggesting that the rate
limiting step is independent of the concentration of GppNHp. This
supports the theory that it is the conversion of the nucleotide
bound form of G from its inactive to its active state which 
s
constitutes the rate limiting step. Hence, as long as there is
sufficient nucleotide to activate G , further increases in
s
concentration have no effect on the rate at which this reaction
occurs, i.e.
GppNHp RLS GppNHp
Gsalpha beta/gamma---------— — — Gsalpha + beta/gamma
Independent of 
GppNHp concentration
That the rate limiting step involves dissociation of the
Gg heterotrimer has been suggested by a number of groups,
including Gilman, 1987 who reported binding of the non-hydrolysable
guanine nucleotide analogue GTPyS to be negatively co-operative
with the binding of beta/gamma to G-protein alpha subunits. Thus,
G T P y s  (or GppNHp as used here) promotes G-protein subunit
dissociation. This is supported by studies where activation of
G has been shown to result in a decrease in its size, as assessed 
s
by sucrose density ultracentifugation and gel filtration. Indeed, 
many enzymes that display long-term hysteresis, such as seen here
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with adenylate cyclase, have subunit association or dissociation 
reactions as their rate limiting step (Iyengar & Birnbaumer, 1982).
Although the duration of the rate limiting step was 
unaltered by increasing concentrations of nucleotide, total enzyme 
activity was altered. This is as expected, the final level of 
adenylate cyclase activity having been reported to be dependent upon 
the concentration of nucleotides in a saturable manner (Tolkovsky, 
1986). Similarly, the increase in steady-state velocities which 
was noted here has been recorded with increasing GppNHp 
concentrations in other systems (Iyengar & Birnbaumer, 1981).
Such activation of Gg by guanine nucleotides requires the
2+ 2+ 
simultaneous presence of Mg . Neither GppNHp, nor Mg by
itself will produce an active G^. However, once Gg has been
activated only one of these ligands is required to sustain the
activate state, i.e. Mg^+ (Iyengar & Birnbaumer, 1982). If the 
2 +
Mg concentration is manipulated m  the presence of saturating
levels of GppNHp, it is reported to modify the lag phase. The lag
becoming progressively shorter with increasing concentrations of 
2 +
Hg ion, and concentrations greater than 20mM being reported as
abolishing the lag in rat liver plasma membranes (Iyengar &
Birnbaumer, 1981). In platelets it would appear that this is also
2+- .
the case (Fig,59), not only does altering the Mg ion
concentration modify the lag, but so too does replacing the divalent 
2+cation with Mn . The observed reduction in the duration of the
2+
lag is thought to arise by Me activation of adenylate cyclase
through direct interaction with a cation-binding site on the
G-protein. Effects are independent of the ratio of free ATP to
2 +
KeATP (see Section 1.3(v)), Binding of Me at this G-protein 
site results in the observed decrease in lag time presumably by 
modulating the conversion of Gg (inactive) to G^ (active).
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Exactly how Me^+ modulates this rate limiting step is not entirely
24-
clear. Whilst increasing Mg may be expected to activate more
regulatory components at higher divalent cation concentrations than
at lower concentrations, this would account for the observed
increase in total activity, but not for the variation in the rates
of activation, i.e. the rate limiting step, in the presence of
saturating guanine nucleotide is regulated by Mg^+ ion in terms of
both rate and extent. This is in agreement with studies on rat
24-
liver plasma membrane (Iyengar, 1981). For Me to modulate the
24-
lag phase, it may be that upon binding of Me , the alpha
species changes its conformation, regulating in its dissociation
from the beta/gamma dimer. Higher concentrations of Mg^+ , or
24-
replacmg the cation species with Mn , could encourage this; 
increasing the affinity of Gg alpha for the guanine nucleotide
whilst decreasing its affinity for beta/gamma (Tolkovsky, 1986).
24- . . .
Hence, Mg would shift the equilibrium reaction:
Gg alph a/beta/gamma^p^G^ alpha 4- beta/gamma far to the right
2+
This observed reduction m  lag time seen at high Mg
concentrations is not a result of modulation of inhibitory aspects
24-
of adenylate cyclase regulation (see Section 1.3(vi)). High Mg
is reported to prevent G^ alpha interaction with the catalytic
unit, but not to prevent G^ alpha/beta/gamma dissociation.
Hence, G. beta/gamma would still be available to participate in
the equilibrium reaction of G dissociation. Instead, the effect
s
24-
of Me on the lag phase of G activation is likely to be due to
s
the altered affinity of G^ alpha for guanine nucleotides and G
24- 24-
beta /gamma, However, the attenuation of G. by high Mg /Mn
probably does contribute to the increased final activity observed
under these conditions i.e. removing tonic inhibition by suppressing
24-
the G. alpha inhibitory component. Mg therefore behaves as
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an antihysteretic agent for the stimulation of platelet adenylate
cyclase by GppNHp, by regulating the rate and extent of activation
of G , i.e. the rate limiting step, 
s
If indeed the rate limiting step is the conversion of Gs
inactive, to G^ active by subunit dissociation, then it may be
that altering the membrane environment would influence this
dissociation and hence the lag phase. Benzyl alcohol treatment is
suggested to increase membrane fluidity and to augment stimulatory
aspects of adenylate cyclase regulation (see Section 3.1).
Applying this anaesthetic to studies of Gg activation showed 50mM
benzyl alcohol to have this same effect on GppNHp-mediated
stimulation of platelet adenylate cyclase, i.e. total activity was
enhanced (Fig.61). However, here the duration of the lag phase was
also reduced, suggesting that benzyl alcohol somehow affects the
rate limiting step. As Gg is not an integral membrane protein
its functioning per se is unlikely to be fluidity modulated.
However, it is possible that a more fluid bilayer would modify the
dissociation of holomeric G , as it is linked to the membrane by
s
some unknown means, e.g. via association with an integral protein or 
by lipid linkage. It may be that changing fluidity alters the 
dissociation capability of G^. If Gg alpha/beta/gamma was to 
dissociate more readily in the presence of benzyl alcohol, this 
would indeed explain the shortened lag phase observed here. That 
this is not a direct effect of benzyl alcohol on G is suggested 
by the findings of two subsequent experiments. In the first of 
these, increasing temperature was used to manipulate membrane 
fluidity. A 6-8°C increase in temperature is reported to mimic 
the effect of adding 50mM benzyl alcohol with respect to 
manipulation of membrane fluidity. The observed reduction in the 
length of the lag phase which accompanied this increase in
22/.
temperature suggests that the effect seen with benzyl alcohol is due 
to its ability to modulate membrane fluidity rather than any direct 
effect of the anaesthetic on G . The second experiment which 
lends support to this theory is the addition of purified beta/gamma 
units to the enzyme system. Here the benzyl alcohol-induced 
reduction in lag time was seen to be reversed by beta/gamma - i.e. 
the lag time was increased again. In fact, the addition of these 
subunits could increase the duration of this slow activation phase 
to longer than its original length. This suggests that not only is 
the benzyl alcohol-mediated effect reversible, but that the Gg 
dissociation reaction is the site of modulation, i.e.:
benzyl alcohol
Gs alpha/beta/gamma Gs alpha + beta/gamma
beta/gamma
Benzyl alcohol drives this equilibrium to the right, 
encouraging subunit dissociation and decreasing lag time, whilst the 
addition of beta/gamma drives the reaction to the left and lengthens 
the lag. Indeed, results from Gilman’s laboratory indicate that 
addition of beta-subunits to activated G-proteins results in faster 
deactivation, in agreement with this (Iyengar & Birnbaumer, 1982). 
Although it would appear that the effects of benzyl alcohol and 
beta/gamma do not cancel each other out, this may arise from 
incorrect proportions rather than any permanent effect of these 
ligands on the adenylate cyclase system.
If the rate limiting step for adenylate cyclase activation 
is, as appears, the conversion of Gg from its inactive to its 
active form, then the effect of bacterial toxins is of interest.
The presence of cholera toxin, which ADP-ribosylates G^ alpha, is 
seen to attenuate the lag time in human platelets. Cholera toxin, 
which stabilises Gg alpha-GppNHp dissociated from G beta/gamma, 
would be expected to lead to an increase in total adenylate cyclase
2 2 8 .
activity as observed here, as the enzyme is persistently activated 
under such conditions. However, as cholera toxin modifies G
s
alpha, it would seem that the rate limiting step would be completed 
before cholera toxin-mediated activation occurred, i.e.:
Rate
Gs alpha/beta/gamma ------^Gs alpha + beta/gamma
Limiting
Step Cholera toxin
V
Gg alpha-ADP ribose 
Cholera toxin would therefore be expected to have no effect 
on the lag time. However, by modifying Gg alpha, cholera toxin 
removes this species from the equilibrium reaction, i.e. G
s
alpha-ADP ribose cannot recombine with beta/gamma to give the
inactive G holomer (Gilman, 1987), The result of this is that 
s
the equilibrium reaction is drive to the right as Gg alpha is 
removed, and so we get the observed reduction in lag time until 
activation by GppNHp is linear from time zero, i.e. cholera toxin 
treatment can totally abolish the lag period. Pertussis toxin 
treatment is observed to have a similar effect, reducing the 
duration of the lag in the platelet system, although the means by 
which this arises is slightly different. This treatment should fix
G^ alpha/beta/gamma in the holomeric form as it stabilises the
GPDG^ alpha /beta/gamma complex. If G^ cannot dissociate and 
release beta/gamma subunits, this should remove the possibility that 
G. beta/gamma combines with Gg alpha to extend the lag and so we 
get the .observed reduction in lag time, i.e.
Gg alpha/beta/gamma G^ alpha + beta/gamma
This equilibrium cannot be driven to the left by G. 
beta/gamma and so the dissociation of G^ alpha/beta/gamma to G^ 
alpha is encouraged. However whether it will be actively 
encouraged i.e. to a greater degree than that seen normally, is
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debatable, being dependent upon the extent to which beta/gamma
affected this equilibrium under normal conditions. Under such
conditions it would be expected that G. beta/gamma would play some
role in determining where equilibrium lay in the dissociation of
G , as G. occurs in vast excess relative to G . Hence, the 
s i s
treatment of membranes with pertussis toxin to eliminate this 
beta/gamma input should encourage dissociation of the Gg holomer, 
and so lead to the reduced lag period.
Na ions, at high concentrations, have previously been 
reported as augmenting the inhibition of adenylate cyclase in a 
number of membrane systems, including human platelets (Jakobs et
al,, 1985). The mechanism underlying this inhibition is unclear as
« "J* •it is not obvious as to whether the ability of Na to inhibit
G-protein activation is at the level of guanine nucleotide binding,
or at a reaction distal to this in the activation process.
Here it is seen that at concentrations sufficient to
release peripheral proteins (500mM), NaCl leads to a reduction in
total activity when added to the GppNHp-activated state. This is
in agreement with the observations recorded in the preceding
paragraph. However, it is also noted that NaCl increased the
duration of the lag phase for GppNHp activation of cyclase. In
fact, Figure 67 showed the lag to be extended to as much as three
times its original length in the presence of 500mM Na+ ion, i.e.
from 1.1 minutes to 3.5 minutes. By comparison to the observations
made earlier, this would suggest that Na+ is acting to drive the
equilibrium reaction of G association/dissociation to the left.
s
Na+
Gs alpha/beta/gamma ^-------- Gs alpha + beta/gamma
Hence, the lower activity observed here is due to the reduced
ability of G to form the active G alpha species. Such 
s s
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modulation of the lag phase by NaCl is not unrecorded sodium ions
having been reported to increase the lag phase of GTP-y'S's action on
G in various membrane systems (Jakobs et al., 1985). In this 
s -----
study it is noted that this effect occurs in the action of GppNHp on
platelet adenylate cyclase, and it is suggested that this arises by
Na ion-modulation of Gg subunit dissociation rather than by any
modification of nucleotide binding.
Finally, the effect of a known inhibitory agonist on the
G^ equilibrium was examined. The presence of adrenaline (+
propranolol) was found to extend the lag phase. This is in
contrast to other studies on platelet adenylate cyclase, where the
activation of the enzyme by GppNHp was unaltered by the presence of
adrenaline (Steer & Wood, 1979). However, if adrenaline (+
propranolol) causes inhibition via alpha^-adrenoceptor activation
of G^, then we would expect it to release beta/gamma subunits
whilst promoting G^ dissociation. The indirect result of such
G. dissociation would be that the G equilibrium would be driven l s
in the direction:
G^ alpha + G^ beta/gamma ^Gg alpha/beta/gamma
As this reaction constitutes the rate limiting step, then 
the lag phase would be extended. Indeed this is what was observed 
here, the 2.8 minute lag being extended to 5 minutes duration.
5.4 Conclusions
In platelets, the activation of adenylate cyclase by the
non-hydrolysable guanine nucleotide GppNHp increases with a lag time
of approximately 5.7 minutes and thereafter constant activity
2+
exists. This activation of G is Mg , time, and GppNHps
dependent, and its hysteretic nature is in agreement with other 
membrane systems (Iyengar & Birnbaumer, 1981; Iyengar, 1981).
Activation of Gg by GppNHp is therefore thought to 
involve at least the following steps:
(a) Gs alphaGDP/beta/gamma ------- Gs alphaGPPN^P/beta/gamma
(b) Gs alphaGP P ^ P /beta/gamma Gs alphaGPP^HP+ beta/gamma
(reversible)
(c) Gs alphaGPP^P ______  ^ Gs alphaGPP^P
(reversible) (irreversible)
The dissociation of the nucleotide-bound holomer (step b) 
is believed to constitute the rate-limiting step. The position of 
this equilibrium and hence the duration of the lag phase, can be 
altered by various means, as described within this chapter.
CHAPTER 6 
GENERAL DISCUSSION AND CONCLUSIONS
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CHAPTER 6
GENERAL DISCUSSION AND CONCLUSIONS
From the results presented in the preceding chapters, it is
apparent that the platelet adenylate cyclase system is an enzyme
subject to a variety of complex controls. As defined classically,
the basic system consists of at least five distinct types of
components. These receptors are stimulatory receptors
inhibitory receptors (R^), a catalytic unit (C) and stimulatory
(G^)- and inhibitory (G^)-guanine nucleotide-regulatory
proteins. However, it is possible that considerable heterogeneity
could exist within adenylate cyclase enzymes given the findings that
there are multiple R and R., multiple forms of G (from
s i  s
differential splicing) (Bray et aJL, , 1986), multiple forms of G^
(G., 1,2,3 with G^2 probably mediating inhibition of platelet 
adenylate cyclase (Simonds et al. , 1989; Bushfield et al., 1990)) 
and more than one species of catalytic unit (see e.g. Krupinski et 
al,, 1989).
In the system analysed here I have tried to investigate 
regulation at each of these levels. Regulation at the catalytic 
unit was followed by examining basal adenylate cyclase activity and 
also activity enhanced by the diterpene forskolin (which acts 
directly at the level of the catalytic unit). Gs~c interaction 
was followed by studying enzyme activity in the presence of sodium 
fluoride which mimics the gamma-phosphate of GTP and thus activates 
G^ when GDP is bound. The interaction of stimulatory receptors 
with the enzyme system was studied by the use of either 
prostaglandin-E^ or the beta-adrenergic agonist isoprenaline.
Both these substances activate their own specific receptors in the 
platelet membrane. As well as examining these stimulatory aspects 
of adenylate, cyclase regulation I also tried to gain some insight
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into the mechanisms of cyclase inhibition which is much less well
defined. This study was undertaken by examining the ability of
’G^* to inhibit the activity of either the receptor-coupled
(PGE^-stimulated) or the receptor-uncoupled (forskolin-stimulated)
enzyme. Hence, in one case enzymatic activity would be enhanced by
treatment with forskolin and then G. would be activated either
1
directly (via low concentrations of GppNHp) or indirectly, by the
use of the alpha^-adrenergic. agonist adrenaline (in the presence
of the beta-adrenoceptor antagonist propranolol to block any
possible action of adrenaline on beta-adrenoceptors). This
approach allowed the examination of G^-C interactions and
R^-G^-C interactions respectively. Alternatively, adenylate
cyclase was activated by the use of with inhibition being
elicited via alpha^-adrenoceptors employing adrenaline (plus
propranolol) as before. Under such conditions it was possible to
study inhibition in the presence of receptor (R^J-mediated
stimulatory input. All known components of the enzyme system were
thus involved in such circumstances i.e. R G CG.R,.s s t 1
The outlined approaches forms the basis of the work 
detailed in Chapters 3-5. From these studies it became apparent 
that the platelet adenylate cyclase system exhibited a number of 
similarities with other adenylate cyclase systems (Ruiz et al. ,
1986; Dipple & Houslay, 1978). Interestingly, a number of unusual 
regulatory aspects were observed. In this chapter I will 
concentrate on these latter aspects and speculate as to how and why 
they might have arisen.
In studying the stimulatory control of the human platelet 
enzyme, it was found that this enzyme, in common with that of rat 
liver, adipocytes and red blood cells (Ruiz et aJL., 1986), amongst 
others, could be stimulated directly at the level of the catalytic
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unit, or via G or R . Hence, the diterpene forskolin, at s s
-4similar concentrations (10 H) to that which was effective m  
other tissue systems (Gawler et al^ . , 1987) was observed to be a 
potent activator of the platelet enzyme. In fact, of the compounds 
studied, it was the most potent activator; again in agreement with 
studies on other systems. Similarly, sodium fluoride was observed 
as exerting stimulation (via Gg) of the platelet enzyme at 
concentrations (15mM) and with similar efficiencies (8.2-fold 
increase over basal) to that observed by others (Robberecht et al. , 
1983). The ability of the beta-adrenergic agonist isoprenaline to 
enhance adenylate cyclase activity has also been studied in other 
systems (Jakobs et al., 1978) and, indeed, was noted to augment 
enzyme activity by only 1.2 - 1.5-fold. Once more this was in 
accordance with the effects observed here, i.e. a 1.6-fold increase 
over basal activity. Finally, stimulation of platelet adenylate 
cyclase by PGE^ is believed to occur via occupancy of the 
stimulatory PGE^/PGI^ receptor. The circa 27-fold stimulation 
of activity observed here with 20uM PGE^ suggests that binding to 
functionally active receptors occurs in the platelet membranes.
As well as demonstrating that levels of adenylate cyclase 
activity elicited by these various agonists were similar to those 
previously reported by others, Chapters 3-5, showed that it was 
possible to manipulate such stimulatory control by modulation of the 
membrane environment. The effect of the local anaesthetic benzyl 
alcohol on adenylate cyclase activity has been studied extensively 
in rat liver plasma membranes, where the increased fluidity it 
induces is paralleled by an increase, in stimulation (Houslay & 
Gordon, 1983 (refs, therein)). This effect has been studied to a 
lesser degree in a number of other systems including bovine adrenal 
cortex (de Foresta et al., 1987), macrophages (Cherenkevich et al. , 
1982) and renal epithelial cells (Friedlander et al., 1987). Here
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this was extended to include human platelet membranes, where benzyl
alcohol was observed to enhance stimulatory aspects of regulation at
all levels.
At the catalytic unit, basal adenylate cyclase activity was 
seen to be augmented by the presence of benzyl alcohol. This 
suggested that increasing fluidity, via benzyl alcohol perturbing 
the lipid order of the bilayer, exerted its primary effect on 
adenylate cyclase by releasing the physical constraint of the
bilayer on this enzyme. That is, presumably a higher degree of
conformational flexibility ensued allowing a more biologically 
active conformation to be attained. In contrast to the platelet 
enzyme, the basal adenylate cyclase state as expressed in 
hepatocytes, was found to be relatively insensitive to the action of 
benzyl alcohol (Dipple & Houslay, 1978). This may reflect tissue 
and/or species differences in either the enzyme itself, its 
incorporation into the membrane bilayer, or relate to differences in 
physical properties of the bilayer of these two membranes this 
exerted different degrees of constraint. Indeed, biochemical and 
genetic evidence indicate that there are multiple forms of adenylate 
cyclase (Krupinski et al., 1989) It may be that the platelet and 
hepatocyte enzymes are two different enzymatic species. Similarly, 
the interaction of the enzyme with the membrane bilayer is almost 
certainly different, whether or not the enzymes themselves differ. 
This could arise from the fact that the membrane composition of rat 
hepatocytes and human platelets differ. The finding that a lipid 
phase separation exists in platelets at 37°C but at 28°C in rat 
liver, illustrates this point, as does comparison of the 
cholesterol/phospholipid (C/P) ratios of these membranes. A C/P 
value of 0.5. has been determined for human platelet plasma 
membranes, whilst rat liver membranes exhibit a C/P ratio of 0.71
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(Gordon et al.., 1983). Hence, these membranes may well present 
differing fluidities. In fact, domains of varying fluidity are 
believed to co-exist within the same membrane (Houslay & Stanley,
1982). It is, therefore, reasonable to assume that the platelet 
and hepatocyte enzymes exist in environments of differing 
fluidities. Hence, it would be expected that modulations in 
fluidity would have (slightly) different effects on these two 
species.
Along similar lines, it was noted that the adenylate 
cyclase activity of platelets was attenuated to a greater degree at 
high concentrations of benzyl alcohol, than was the enzyme in rat 
liver plasma membranes. This inhibition at high concentrations of 
benzyl alcohol is believed to be a consequence of the phenomenon of 
annular lipid displacement. Here the lipid species directly 
surrounding the protein are displaced by the benzyl alcohol 
molecules. The displacement of these lipids from the 'shell', or 
annulus, results in inhibition of enzymatic activity either because 
the lipids were essential for activity or because the benzyl alcohol 
molecules are themselves inhibitory (Houslay & Stanley, 1982). 
Whichever mechanism accounts for the observed inhibition, it is 
apparent that the concept of annular displacement depends upon the 
ability of benzyl alcohol to displace the lipid from around the 
catalytic unit of adenylate cyclase. From the attenuation noted 
here it would, therefore, seem that high concentrations of benzyl 
alcohol can displace annular lipid more easily from the platelet 
enzyme that from the rat live*"enzyme. This may arise as a result 
of these two tissues either expressing different adenylate cyclase 
species or the annular lipid composition is sufficiently different 
between the two tissues to account for the observed differences.
Another somewhat unusual aspect of regulation of the
platelet catalytic unit was brought to light in studying the effect
of benzyl alcohol on the forskolin-stimulated activity of this
enzyme. Here it was noted that benzyl alcohol led to a
dose-dependent attenuation of this activity. Whilst this is in
agreement with studies on other adenylate cyclase systems
(Robberecht et ffl,, 1983), a difference arises as to the mechanism
by which this inhibition occurs. The general consensus has been
that inhibition arises by a competitive mechanism; presumably
resulting from the alcohol competing for hydrophobic sites on
adenylate cyclase to which forskolin binds (Whetton et al.., 1983).
However, I noted that dose-effect curves of forskolin-activation of
adenylate cyclase revealed a progressive decrease in the maximal
efficacy of the diterpene with increasing concentrations of benzyl
alcohol. However, there was no parallel shift to the right of log
dose-effect curves in the concentration required for half-maximal
enzyme stimulation, which would have been indicative of competitive
inhibition, i.e. that V was unaltered. Whilst K increased
max m
the result here, i.e. V decreased by K unaltered, suggested
max m
that in platelets, benzyl alcohol attenuated the ability of 
forskolin to simulate adenylate cyclase by a non-competitive 
inhibitory process. It is possible that benzyl alcohol binds to a 
distinct site which alters the conformation of the catalytic unit 
such that the hydrophobic site to which forskolin binds is masked in 
some way. The nature of this site is unknown. Although, given 
the earlier observation that benzyl alcohol can displace annular 
lipid, it may be that this is a phospholipid binding site. It is 
not possible, however, to completely rule out mechanisms whereby 
benzyl alcohol alters protein structure either directly or 
indirectly through affects on membrane fluidity. However, the
finding that forskolin's ability to activate the lubrol-solubilised 
enzyme was still attenuated by benzyl alcohol (Section 3.1) would 
seem to indicate that this ligand may interact directly with the 
protein. The possibility that benzyl alcohol may displace 
essential detergent or detergent-phospholipid complexes from the 
enzyme cannot be discounted as well.
Other aspects of benzyl alcohol-regulation of platelet 
adenylate cyclase which were examined included regulation at the 
level of stimulatory receptors. Whilst it was noted that 
agonist-occupation of the PGE^-receptor led to activation of the 
enzyme, it was proposed that the interaction of this receptor with 
the adenylate, cyclase system may differ from that of other 
stimulatory receptors, notably the beta-adrenoceptors. Studies 
with benzyl alcohol (Section 3.1) showed that the fold-stimulation 
by PGE^ was markedly attenuated by the presence of benzyl alcohol 
(26.7 fold ~ 12.5 fold), whilst that mediated via isoprenaline 
occupancy of the beta-adrenoceptor was unaltered. This apparently 
anomalous regulation of the PGE^-receptor was enhanced by findings 
of previous studies, done in liver, where glucagon-(Rg)-mediated 
stimulation of adenylate cyclase was augmented by benzyl alcohol 
treatment of rat liver plasma membranes. Exactly why the various 
stimulatory receptors should differ in this respect, at least within 
the same, membrane system, is unclear. This may arise as a 
consequence of a receptor requiring specific phospholipid species 
for efficient coupling to the adenylate cyclase system, as has been 
discussed elsewhere (Houslay & Gordon, 1983). Also, studies in 
this system with acidic phospholipids would tend to support the 
proposal that certain phospholipids are more important than others 
in determining the efficiency of component interactions. Such a 
proposal arises from the observation that PGE^-stimulated
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adenylate cyclase activity could be attenuated by the introduction 
of phosphatidic acid into the membrane (Section 3.4). That this is 
not a general phenomenon of membrane disruption is shown by the fact 
that phosphatidylcholine (neutral) had no effect on enzyme 
activity. Nor was it an effect common to all acidic phospholipids, 
as phosphatidylserine was similarly ineffective. Hence, 
phosphatidic acid may, under normal circumstances, be excluded from 
the coupling interface or if it does enter it will exert an 
inhibitory effect, attenuating activity. As proposed earlier, 
benzyl alcohol-induced manipulation of the membrane may remove a 
lipid essential for activity or allow a previously excluded lipid to 
enter the coupling interface. In the case of the prostanoid 
receptor, the manipulation of lipid species may be more potent than 
the benzyl alcohol-induced augmentation of fluidity. Hence, we 
observed inhibition rather than enhanced enzyme activity. 
Alternatively, it could be that the PGE^-receptor and the 
beta-adrenoceptor interact with two different catalytic unit 
subtypes and so the effect of benzyl alcohol might differ.
However, this possibility seems unlikely to account for the observed 
effects given that basal cyclase activity was always seen to be 
enhanced by benzyl alcohol to the same degree. This suggests a 
single population of catalytic unit or at least populations which 
were similarly affected by changes in the membrane environment.
I also examined direct stimulation at the level of the 
guanine nucleotide regulatory protein Gg. In such studies it was 
noted that both sodium fluoride and GppNHp could enhance the 
activity of platelet adenylate cyclase. This is as reported by 
others previously, in both platelets (Insel et al.., 1982) and other 
membrane systems (Iyengar & Birnbaumer, 1981). However, 
stimulation by GppNHp exhibited hysteresis (Chapter 5) whilst that
240.
exerted by sodium fluoride, in my hands, did not. This 'lag' in
GppNHp-mediated activation was found, upon more detailed
24-
investigation, to be time, Mg and guanine-nueleotide 
dependent. As a consequence of detailed manipulation of these 
parameters, amongst others, it was proposed that, in platelets, this 
hysteresis reflected the conversion of Gg from an inactive to an 
active form. This is proposed as being dependent upon subunit 
dissociation, hence -
Gg a l p h a ^ ^ H^beta/gamma--- ^ Gg alphaG^ NI^  + beta/gamma
is proposed as the rate limiting step. Guanine nucleotide binding, 
hydrolysis and dissociation having been ruled out (see Chapter 5 for 
detailed discussion). The addition of benzyl alcohol to this 
system resulted in a reduction in the duration of the lag phase, 
suggesting that increases in fluidity enhance the dissociation of 
the stimulatory G-protein. Presumably this accounts to some degree 
for the enhanced enzyme activity observed with benzyl alcohol on 
other stimulatory conditions, i.e. for R^-mediated stimulation as 
well as NaF-mediated stimulation. It is not suggested that G^ 
functioning per se is fluidity modulated as Gg is not an integral 
membrane protein. Rather, that it is possible that enhanced 
membrane fluidity could modify the dissociation of holomeric Gg, 
albeit indirectly.
Hence, benzyl alcohol may modulate (a) receptor interaction
with adenylate cyclase, at least in the case of PGE^ and/or (b)
G dissociation and/or (c) relieve constraint of the bilayer on 
s
the catalytic unit. Each or all of these effects may contribute to 
the observed alterations in adenylate cyclase activity seen under 
such conditions. Whether or not this effect of benzyl alcohol 
arises purely as a result of its ability to perturb membrane 
fluidity is questionable. However, the lack of stimulatory effect
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on solubilised preparations of the enzyme would tend to rule out any 
direct effect on the protein. Similarly, the ability to mimic many 
of these effects by increasing temperature, e.g. Gg dissociation, 
supports the proposal that events witnessed here arose as a 
consequence of altered membrane fluidity. Nevertheless, upon 
examination of the effects of charged anaesthetics on the platelet 
enzyme, it appears that these compounds had very different effects.
The use of pentobarbital, which is a negatively charged 
compound, showed that both receptor-coupled and uncoupled activities 
were initially enhanced by the presence of the drug, before being 
attenuated by further increases in concentration. Previously it 
had been suggested that such manipulation would preferentially 
enhance the fluidity of the outer leaflet of the bilayer, resulting 
in enhanced activity of the receptor-coupled state only (Houslay et 
al., 1981). That such changes in activity were not observed here, 
may reflect a direct effect of pentobarbital on the enzyme.
Indeed, examination of the inhibitory-regulatory components revealed 
that this may indeed hold true. For, upon such examination, the 
alpha^-adrenoceptor-mediated inhibition of the PGB^-stimulated 
state was found to be unaffected by pentobarbital. In contrast, 
both alpha^-adrenoceptor- and GppNHp-mediated inhibition of the 
forskolin-stimulated state, were found to be attenuated at low 
concentrations of pentobarbital. This suggested that at these 
concentrations pentobarbital was exerting some sort of selective 
effect. By comparing these results and taking into account the 
mechanisms of inhibition underlying these states, it is possible to 
speculate as to the site of * interaction* between the drug and the 
inhibition system. In this case, it is tentatively suggested that 
pentobarbital may act to manipulate G^-alpha interaction with the 
catalytic unit. This effect appeared to be masked in the case of
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alpha^-adrenoceptor-mediated inhibition of the PGE^-stimulated 
state, perhaps as a consequence of the presence of a 
beta/gamma-inhibitory component. However, as pentobarbital is a 
negatively charged compound, it may be that the effect noted here 
resulted from charge rather than as a consequence of the compounds 
ability to perturb membrane fluidity. Hence, G^-alpha may 
require the presence of a positive charge in order to interact 
effectively with the catalytic unit. In examining the effect of 
introducing negatively charged phospholipid species to the membrane, 
it was noted, in preliminary experiments, that adrenaline-mediated 
inhibition of PGE^-stimulated adenylate cyclase was not affected 
by the presence of such acidic phospholipids. Neither was 
adrenaline- or GppNHp-mediated inhibition of the
forskolin-stimulated state. Such findings further complicate the 
role of 'charge* in component coupling, as do the findings from 
experiments done using the cationic drug prilocaine.
In platelets the local anaesthetic prilocaine showed 
different effects from those reported in rat liver plasma membranes 
(Houslay et al., 1980(b)), where this compound altered the activity 
of both receptor-coupled and uncoupled states by inducing a lipid 
phase separation at 16°C in the inner leaflet. It can be 
expected that prilocaine may selectively interact with the lipids of 
the inner leaflet of the membrane resulting in enhanced fluidity.
A corresponding increase in the activity of both the 
receptor-coupled and -uncoupled states would then occur (see Section 
3.2 for discussion of why). However, here it was noticed that both 
these activity states were attenuated in the presence of increasing 
concentrations of prilocaine. Moreover, the ability of adrenaline 
and GppNHp to inhibit these R^-coupled and -uncoupled states were 
differentially affected. Adrenergic-mediated inhibition of the
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PGE^-stimulated enzyme was attenuated at low concentrations of 
prilocaine, although increasing concentrations of the drug did 
appear to restore this inhibitory ability to normal levels. On the 
other hand, adrenergic- and GppNHp-mediated inhibition of the 
forskolin-activated enzyme were enhanced by increasing levels of the 
anaesthetic. This led to the suggestion that G^alpha-C 
interaction may be enhanced by the presence of such positive 
species. This would support the earlier proposal that G.alpha-C 
interaction involves positive charge.
A proposal that gains some support from the recent 
observations that compounds such as mastoparan and the synthetic 
polyamine compound 48/80 are able to interact directly with the 
C-terminal domains of G alpha and lead to alterations in its 
activity (Housli et al. , 1990; Higashijima et al., 1988). This is 
presumed to arise due to a combination of positive charge and 
domains of hydrophobic character, which allow them to interact with 
G Hence, the observation that prilocaine (positive charge)
3 jLpnd
and pentobarbital (negative charge) are able to stimulate and 
inhibit G^-alpha-C interactions respectively may reflect their 
interaction with such domains (see Appendix I for comparison of 
structures).
That enhancement of inhibition was not seen with 
adrenaline/PGE^, in the presence of prilocaine, can only lead to 
the proposal that the presence of the beta/gamma component of the 
inhibition may mask this effect here. Indeed, the reduction in 
inhibition noted here raises the suggestion that G^ beta/gamma 
interaction with G^alpha may be attenuated by prilocaine i.e. that 
the presence of the positively charged anaesthetic is detrimental to 
efficient G^ beta/gamma-G^alpha interaction. Hence, the degree 
of inhibition elicited by adrenaline on PGE^-stimulated adenylate
cyclase was actually reduced rather than augmented. That 
increasing concentrations of prilocaine eventually led to enhanced 
inhibition of this state is of interest.
Benzyl alcohol experiments suggested beta/gamma-mediated 
inhibition to be the minor of the two inhibitory components of 
alpha^-adrenoceptor-mediated inhibition of the PGE^-stimulated 
state. As the concentration of prilocaine increased, the 
contribution of this component and hence its regulation would become 
masked by the anaesthetic enhancing G.-alpha-C-mediated 
inhibition. This would account for the apparent increase in the 
ability of adrenaline to inhibit PGE^-activated adenylate cyclase 
at high concentrations of prilocaine. Whilst such attenuation of 
the G. -beta/gamma-Gsalpha interaction may indeed arise as a 
result of appropriately charged anaesthetic, it may be that this 
particular interaction is fluidity ’hypersensitive*. This would be 
in accordance with the results obtained in the presence of benzyl 
alcohol, a local anaesthetic which displays no net charge. Indeed, 
the ability of charge compounds to manipulate the platelet adenylate 
cyclase system cannot be explained solely on the basis of their 
charge. This follows from the finding that introducing acidic 
phospholipids into the system did not affect G.-mediated 
inhibition. Neither can the effects of these charged anaesthetics 
be explained solely on the basis of their ability to perturb 
membrane fluidity, as the results with receptor-coupled and 
-uncoupled states showed. It would therefore, seem reasonable to 
conclude that pentobarbital and prilocaine act to manipulate the 
platelet adenylate cyclase system via both their ability to perturb 
membrane fluidity and by their charge characteristics.
Examination of the effects of charged lipid species also 
showed that the catalytic unit itself could be inhibited by the
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presence of acidic phospholipids. This is presumed to be via a
direct effect on the enzyme rather than mediated through G-proteins,
as the process was neither GTP-dependent nor altered by the presence 
2+of Mn . It may be that such negatively charged phospholipids 
are normally excluded from the lipid annulus (see earlier 
discussion) but when presented at high concentrations equilibrate in 
and serve to inhibit activity. No such direct effect of acidic 
phospholipids (phosphatidic acid and phosphatidylserine) was 
observed upon the catalytic unit of rat liver adenylate cyclase 
(Houslay et al., 1986c). This again suggests that either the 
annular lipid encasing these two catalytic units are very different
and/or that the two species of adenylate cyclase are themselves
different.
Another ’unusual* aspect of adenylate cyclase regulation 
which was demonstrated during this study, was the ability of insulin 
to attenuate the activity of the platelet enzyme. Whilst this 
observation in itself is by no means novel (Heyworth & Houslay,
1983), it is a matter of some dispute as to whether such inhibition 
occurs as whilst some groups observe it (Hepp, 1971; Heyworth & 
Houslay. 1983), other groups have been unable to record it in
isolated membranes (Pilkis et a l ., 1974; Falcon et al_,, 1988). In
this study inhibition was clearly observed and it appeared to occur 
through a route seemingly different, at least in some respects, from 
that whereby insulin mediates inhibition of hepatocyte adenylate 
cyclase (Pyne & Houslay, 1983; Heyworth & Houslay, 1983).
Insulin mediated attenuation of both receptor-coupled 
(PGE^-stimulated) and -uncoupled (forskolin-stimulated) states was 
achieved. That this was not purely G^-mediated, was suggested by
the lack of requirement for exogenous GTP and confirmed by the lack
2+ , .of attenuation by Mn . This divalent cation having been shown
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to uncouple the selective, G.-mediated inhibition of the catalytic
unit (Hoffman et al. , 1981). Whilst the precise mechanism
underlying insulin-mediated inhibition remains undefined, it may be
that the putative G-protein, G *ng» has some role to play. If
this protein is involved, then experiments with benzyl alcohol
suggest that the beta/gamma subunits expressed with G «ng are not
the same as those expressed with G^alpha. Insulin-mediated
inhibition of forskolin, like that mediated by other inhibitory
ligands, was benzyl alcohol insensitive. Inhibition of the
PGE^-stimulated state was similarly unaffected by the presence of
the local anaesthetic. This latter point is in direct contrast to
adrenaline-mediated inhibition of this same state, which was
attenuated by increasing levels of benzyl alcohol. By comparison
to alpha^-adrenergic inhibition, it is therefore suggested that
insulin-mediated inhibition of the Reactivated state may entail
two components (i) G _ , interaction with C is proposed as being
alpha
benzyl alcohol insensitive, in agreement with the G^alpha-C
interaction observed with adrenaline inhibition of PGE^ and/or
(ii) G beta/gamma interaction with Ggalpha; a benzyl alcohol
insensitive step and therefore different from previous observations
with adrenaline. Alternatively G beta/gamma may play no role in
insulin-mediated inhibition of PGE^. However, the finding that
insulin attenuated the R^-coupled state (75% inhibition) to a
larger" degree than the -uncoupled state (40% inhibition) might
suggest that an inhibitory component other than direct G alpha
interaction with C does exist. Hence, it is likely that G
beta/gamma~Gs alpha mediates insulin inhibition as seen with
alpha^-adrenoceptor inhibition of the R^-coupled state.
Nevertheless, it would appear that the beta/gamma expressed with
*G. ' are different from those expressed with G.alpha. Why 
ins i
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and how they differ is unclear although both beta and gamma subunits 
are now known to exhibit a much higher degree of heterology than was 
first thought (Fong et al. , 1987; Robishaw et al»* 1989).
If a G-protein is involved in mediating inhibitory actions 
of insulin, it is unclear as to whether it is directly linked to the 
insulin receptor or not, i.e. it could occur at some point distal to 
this in the pathway. It is also likely that some other components 
exist in the signalling pathway due to the pleiotropic effects which 
this hormone exerts. Some of these may be linked to the hormone’s 
ability to attenuate adenylate cyclase. In this study it was 
possible to go some way to eliminating the involvement of 
phosphorylation in the inhibition of the platelet enzyme and to 
reducing the likelihood that a chemical mediator was involved (see 
Chapter 4 for discussion). However, no definitive route as to how 
insulin attenuates platelet adenylate cyclase can be suggested and 
so caution should be exercised in disregarding any of the possible 
inhibitory mechanisms discussed above. It is highly probable that 
insulin, upon binding to its receptors, activates a number of 
pathways within the cell. These either alone or in combination 
with others, may thus lead to the attenuation of adenylate cyclase 
activity which was observed here.
The platelet adenylate cyclase enzyme therefore forms a 
highly complex system due to (a) the number of factors involved in 
its regulation and (b) the fact that it is possible to manipulate 
each of the known levels of regulation by modulation of the membrane 
environment. It can only be presumed that other adenylate cyclase 
systems would be regulated in a similar manner. Whether this is 
true or not is open to debate, given the differences between the 
platelet and hepatocyte enzyme systems illustrated here. As well 
as the differences in membrane composition and fluidity, the
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ever-expanding families of the components, i.e. multiple forms of
R , R., G , G. and O, it should also be remembered that 
s 1 s 1
regulatory components in addition to those already identified may 
exist. For example, cytoskeletal elements are candidates for 
supporting roles in the inhibitory regulation of adenylate cyclase 
(Rodbell, 1980). It seems highly probable that the existence of as 
yet unidentified components of the insulin-signalling pathway will 
come to light. Presumably these too may be subject to regulation 
by modulation of the membrane environment.
Not only do platelets provide a valuable system for the 
analysis of the complexities of the adenylate cyclase enzyme, but 
such examination also merits some importance as the level of cyclic 
AMP within the platelet is suggested to be important in determining 
the aggregatory properties of these cells. Indeed, correlation of 
the effects of adrenergic agonists and antagonists on adenylate 
cyclase activity in platelet lysates and on aggregation of the 
intact cells are reported to be very close. For example, adenylate 
cyclase inhibition was only seen in platelets from species in which 
catecholamines induced aggregation (Jakobs et al,, 1978), It 
should be recalled that it is the level of cAMP-dependent 
phosphorylation ensuing from changes in the production of this 
cyclic nucleotide which are believed to be important. However, the 
possibility of manipulating aggregation via altering cyclic AMP 
levels is evident. The observation that increased fluidity 
augmented adenylate cyclase's ability to produce cyclic AMP is 
therefore of much interest. By the previous argument, this could 
lead to attenuated platelet activation and reduced aggregation. 
Indeed, a recent-: study has shown the concentration of benzyl 
alcohol which leads to increased platelet membrane fluidity 
(bovine), also inhibits platelet aggregation (Kitagawa et al.,
1990). In fact, the IC^q for benzyl alcohol mediated inhibition
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of aggregation was 12mM + 1, whilst in the present study the 
for attenuation of alpha^-adrenoceptor inhibition of 
receptor-coupled adenylate cyclase was 12.5mM + 4.2 (see Section 
3.1). This ability of fluidity to modulate cyclic AMP production 
could prove to be of special interest in diabetes given the recent 
observation that such subjects exhibit altered platelet membrane 
fluidity (Winocour et al^ , 1990) as well as pronounced vascular 
disease. Although the precise pathogenesis of such disease remains 
obscure, its importance is well established, with blood platelets 
being known to play a particularly important role in thrombus 
formation. In fact, it has been suggested that retinal infarctions 
and peripheral neuropathy associated with diabetes mellitus arise, 
at least in part, by increased platelet aggregation (Dalsgaad et 
al.. 1982). Hence, elucidation of the biochemical regulatory 
processes controlling platelet aggregation - including synthesis of 
cyclic AMP by adenylate cyclase - may provide a basis for 
understanding how their pathophysiologic or pharmacologic disruption 
can affect platelet-mediated disorders of haemostasis and 
thrombosis. It may be that the manipulation of the membrane 
environment and of adenylate cyclase will prove to be a route to 
better control of platelet functioning (primarily aggregation).
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APPENDIX II CHEMICALS
Supplier
Amersham International 
Amersham, Bucks, 
England U.K.
Chemical
5;8- H-adenosine 3*5* cyclic
phosphate
3
8- H-adenosine 3'5* cyclic
phosphate
32[alpha- P] Adenosine
triphosphate
32P-carrier free
B.D.H. Ltd., 
Poole, Dorset, 
England, U.K.
All other chemical reagents not 
listed here
Bio-Rad
Hemel Hempstead 
Herts, England
Nitrocellulose
Boehringer Mannheim (UK) 
Lewes, East Sussex, 
England, U.K.
App(NH)p
ATP
Creatine kinase
Glyceraldehyde-3-phosphate
dehydrogenase
Glycerate-3-phosphate
Gpp(NH)p
GTP
NAD*
3-phosphoglycerate kinase 
Triethanolamine (HCl)
Tris
Calbiochem
Cambridge, England, U.K.
Forskolin
Eli Lilly & Co. 
Indianapolis, IN, U.S.A.
Insulin (porcine)
National Diagnostics 
Aylesbury, Bucks, 
England, U.K.
Ecoscint
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Supplier 
Porton Products 
Porton Down, Salisbury, 
Wilts, England, U.K.
Scottish Antibody Prod. Unit 
Wishaw, Scotland, U.K.
Sigma Chemical Co.,
Poole, Dorset,
England, U.K.
Chemical 
Pertussis toxin
Goat-antirabbit IgG (peroxidase- 
conjugated)
Adenosine 
Adrenaline 
Alumina 
Benzyl alcohol 
Bovine serum albumin 
Cholera toxin 
Creatine phosphate 
Cyclic AMP 
Deoxycholate 
Dimethylnitrosamine 
Dithiothreitol 
Dowex 50AGWX4 
Dowex AG I-X2 
EGTA
Glutathione
Imidazole
Isobutylmethylxanthine
Isoprenaline
Lubrol-PX
Orthodianisidine (HC1)
Ouabain 
Pentobarbita 
Phosphatidic acid 
Phosphatidylcholine 
Phosphatidylserine 
Prilocaine 
Propranolol 
Prostaglandin E^
Snake venom 
Temed
Theophylline
Thimerasol
Thymidine
Trypsin inhibitor (soyabean) 
Tween 20
ZbV.
Supplier 
Whatman 
Maidstone, 
England, U
Chemical 
DE-50 Cellulose 
Kent, - PEI cellulose plates
K. - Whatman No.54 filter paper
tr; -  ^‘X~
